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ABSTRACT
The po ten tia l ro le  o f embryonic c e lls  in  the IN VITRO 
b io ac tiva tion  o f teratogens was investiga ted , w ith limb bud mesenchyme 
c e lls ,  (LB), and mid brain cells,(C N S), derived from 13 day old ra t 
embryos. The c e lls  were cultu red fo r  5 days and during th is  period 
d iffe re n tia te d  in to  foc i o f chondrocytes (LB) or neurones (CNS). The 
development o f the c e lls  in  cu ltu re  m irrored the IN VIVO development and 
therefore can be used as a teratogen screen.
The presence o f c o n s titu tiv e  forms o f cytochrome P450 isoenzyme 
forms b, c and d (Levin e t .a l .  1978 nomenclature) were detected in  both 
c e ll types a fte r  the 5 day cu ltu re  period by immunocytochemistry. 
Isoenzyme cytochrome P450 b was found to be non-inducib le, whereas 
isoenzymes c and d were found to  be inducib le  by both transplacental 
adm inistra tion o f 3-methylcholanthrene (3MC) and p-naphthoflavone (pNF) 
and by IN VITRO coincubation w ith 3MC and pNF. There was a d iffe rence  
in  the developmental p ro f ile  o f the appearance o f isoenzyme forms b 
and c over the 5 day cu ltu re  period.
Having established the presence o f embryonic cytochrome P450's in  
the cu ltu re  system the ro le  o f metabolism in  the b io a c tiva tio n  o f 
diphenylhydantoin (DPH) was investiga ted . Five approaches were used:
1. Modulation o f cytochrome P450 a c t iv i ty  IN VITRO by coincubation
w ith a va rie ty  o f in h ib ito rs  caused an increase in  DPH to x ic i ty  to
the extent o f 13-82% in  LB and 3-52% in  CNS c e lls .
2. Modulation o f cytochrome P450 a c t iv i ty  IN VITRO by coincubation
with inducers3 only LB c e lls  coincubated w ith 3MC caused a 21%
increase in  DPH to x ic i ty .
Modulation o f cytochrome P450 a c t iv i ty  IN VITRO by transp la cen ta lly  
administered inducers; only LB c e lls  derived from 3MC or pNF 
pretreated dams increased DPH to x ic i ty ,  by 20 and 30% respective ly .
In add ition , only LB c e lls  from pNF pretreated dams had the a b i l i t y  
to  activa te  the pro-teratogen cyclophosphamide (CPA), (CPA is  only 
to x ic  to  LB c e lls  in  the presence o f an external metabolising 
source).
Modulation o f the formation o f the p o te n tia lly  reactive  arene oxide 
intermediate o f DPH showed th a t although the degree o f covalent 
binding could be modulated th is  did not co rre la te  w ith  the 
modulation in  to x ic ity  and i t  was therefore concluded th a t the arene 
oxide intermediate did not play an important ro le  in  DPH 
teratogenesis.
Id e n tif ic a tio n  by HPLC analysis o f DPH metabolites formed by the 
c e lls  IN VITRO. Cells (espec ia lly  LB) were capable o f hydroxyla tion 
and hydantoin ring  cleavage.
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C H A P T E R  1 « I N T R O D U C T I O N
C O N T E N T
1.1 INTRODUCTION
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1.1.1.1 IN VIVO methods
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1.2.1 The tim ing o f the teratogenic in s u lt
1.2.2 Role o f placental tra n s fe r
1.2.3 D irect and in d ire c t action o f teratogens
1.2.4 Factors in fluencing  the expression o f teratogenic in s u lt
1.3 KINETIC PHENOMENA IN PREGNANT ANIMALS
1.3.1 A ltered pharmacokinetics and drug plasma pro te in  binding
during pregnancy
1.3.2 Physiological in te rp la y  between mother and fetus
1.4 ENZYMOLOGY OF TERATOGEN ACTIVATION
1.4.1 Cytochrome P450 -  dependent mixed function oxidases
1.4.2 Phase I I  metabolism
1.4.3, Drug metabolism by the placenta
1.4 .4 . Drug metabolism by the fetus
1.5 BIOACTIVATION OF TERATOGENS
1.5.1 Compounds th a t require b io a c tiva tio n
1.5.2 Compounds th a t may or may not require b io a c tiva tio n
1.5.3 Compounds th a t do not require b io ac tiva tion
1 .6 THESIS OBJECTIVE
1.1 INTRODUCTION
Teratology is  the study o f s tru c tu ra l and functional abnorm alities 
which arise during embryonic development. The word is  derived from 
the Greek "te ra tos" meaning perta in ing  to monsters, and qu ite  c le a r ly  
re fers  to the IN VIVO s itu a tio n . In th is  the s is , reference is  made to  
the term "IN VITRO teratogenesis" and th is  term has no c lea r 
morphological signficance, but ra ther is  used to  id e n tify  an IN VITRO 
end-point w ith possible IN VIVO c o rre la tiv e  s ign ificance .
Drugs or chemicals taken during pregnancy, e ith e r fo r  therapeutic 
purposes or by accident, probably play a re la t iv e ly  minor ro le  in  the 
production o f congenital malformations in  man as compared to genetic 
or environmental facto rs (e .g . in fe c tio n , metabolic imbalances and 
ra d ia tio n ). I t  has been estimated th a t between 4-6% o f b ir th  defects 
in  humans are chemically re la ted (Wilson, 1964, 1973; Bowman and Rand, 
1980). 65-70% o f congenital b ir th  defects is  unknown, so a fa r  higher
percentage o f defects may indeed be drug-re lated (Table 1 .1 ).
Table 1.1 Cause o f Drug-Induced Malformation in  Man
Known genetic transm ission:
Incidence
20%
Chromosomal aberration.* 3-5%
Environmental causes: 
rad ia tions 
in fe c tions
maternal metabolic imbalance 
drugs and environmental chemicals
2-3%
1- 2%
4-6%
1%
Unknown. 65-70%
(adapted from Schardein 1985)
Because 4-6% o f b ir th  defects are a ttr ib u ta b le  to chemicals, we do 
not know whether these drugs would have been considered p o te n tia lly  
teratogenic p r io r  to  consumption. The overwhelming size o f the 
'unknown' category in  the e tio logy  o f b ir th  defects is  somewhat less 
than reassuring and may be a re s u lt o f chemical teratogenesis by 
sp e c ific  agents being so d i f f i c u l t  to es tab lish . Information on drug 
and chemical hazards to the human conceptus is  derived mainly from 
iso la ted  case reports by physicians; only a few are based on 
epidemiological stud ies.
A curren t estimate is  th a t over 2,800 chemicals have been tested 
fo r  teratogenic po ten tia l and about 38% have been proved to be 
teratogenic in  a t lea s t two labora tory species (Schardein 1985) (Table 
1 .2 ).
Table 1.2 Number o f Chemicals Tested fo r  Teratogenic ity
in  Animals^
Tested C learly9 Probably^ Possibly0 Not
P ositive  P ositive  Teratogenic Teratogenic
2,820 180 602 291 1,747
a In two or more species.
b Based on lim ite d  te s tin g  or p o s itive  in  m a jo rity  o f species 
response.
c Equivocal or variab le  reaction , and/or less than obvious response. 
“I” Derived from the data o f Frankos, 1985.
1.1.1 TESTING METHODS FOR TERATOGENICITY
T ra d itio n a lly  the embryo was thought to be protected from to x ic  
in s u lt  by the placenta. In 1915 the f i r s t  evidence (W eller, 1915) 
tha t lead crosses the placenta was obtained from a group o f women 
su ffe ring  from lead-sickness who gave b ir th  to  mentally retarded 
ch ild ren . Subsequently in  1923, a group o f women exposed to  arsenic 
gave b ir th  to  sm aller, less mentally a le r t  babies (U nderh ill and 
Amatruda, 1923). Three fu rth e r s ig n if ic a n t events led to the 
re je c tion  o f the concept o f placental pro tection*
( i )  The 1940 rube lla  epidemic in  A us tra lia  (Gregg, 1941)
( i i )  The 'Minamata disease' caused by methyl mercury (Matsumoto 
e t a l . 1965)
( i i i )  The thalidomide tragedy o f the ea rly  1960's (Lenz, 1961; 
Taussig, 1962)
P rio r to  the thalidomide episode, determination o f the 
reproductive to x ic ity  o f pharmaceutical products was genera lly 
unregulated w ith the p rin c ipa l ob jec tive  o f determining drug 
influences on f e r t i l i t y ,  both in  the male and female. The teratogenic 
action o f thalidomide on the human embryo caused a re -eva luation  o f 
the screening o f drugs fo r  reproductive to x ic i ty .
1.1.1.1 IN VIVO
The aim o f IN VIVO te s t procedures is  to  assess the e ffe c ts  o f 
chemicals on reproduction using common labora tory species as models. 
The guidelines have a number o f common requirements*
( i )  Chemical to be tested fo r  e ffe c t on general reproductive
performance as well as embryo development.
( i i )  Preferred species are the ra t ,  mouse and ra b b it. Other species
may be used when d iffe rences in  metabolism or 
tox ico k ine tics  between the preferred species and man are 
known, or to  c la r i f y  an ambiguous re s u lt.
( i i i )  S u ff ic ie n t numbers o f animals to  perm it s ta t is t ic a l eva luation,
( iv )  The route o f adm in istra tion should p a ra lle l the route by which
man is  to be exposed.
(v) Chemicals administered a t several dose leve ls  (usua lly  th ree ),
(v i)  The lowest dose should produce no observable e ffe c ts  and the
highest dose should be the maximum maternal to le ra te d  dose 
(MTD).
( v i i )  Adequate concurrent contro l groups.
Detailed protocols from various countries and leading regu la tory 
agencies can be found in  the fo llow ing  re ferences:- Schardein, 1976; 
Palmer, 1981; Kelsey, 1982; H.S.C.E. reports , 1982; E.C.M. Guidelines 
on reproductive to x ic ity  te s tin g , 1981.
Chernoff and Kavlock (1982) have proposed an IN VIVO screen ( in  
the mouse) in  which compounds are administered throughout 
organogenesis a t, or near the MTD and the newborn are examined fo r  
number and weight both a t b ir th  and three days a fte r  p a r tu r it io n . The 
ra tiona le  is  tha t prenatal in s u lts  w i l l  manifest the irse lves 
postna ta lly  as reduced v ia b i l i t y  and/or impaired growth. There was a 
good co rre la tio n  w ith known teratogens (100%, 15 out o f 15), but also 
a high incidence o f fa lse  p o s itive  re su lts  w ith  non-teratogens (33%
3 out o f 9). A recent report (Khera, 1984) suggests th a t maternal 
to x ic ity  i t s e l f  may re s u lt in  em bryotoxic ity, and since the Chernoff 
and Kavlock screen uses doses a t or near the MTD th is  could account 
fo r  the high percentage o f fa lse  pos itives  reported. This la t te r  te s t 
is  more expensive and time consuming than the IN VITRO screens 
described below, and is  not necessarily more p re d ic tive .
1 .1 .1 .2  IN VITRO screens fo r  teratogens
In the quest fo r  new, more pharmacologically active  drugs, the 
need fo r  ea rly  hazard assessment in  the screening programme is  
esse n tia l. The answer would be an ideal IN VITRO te s t system th a t 
would be simple, rap id , y ie ld  a large number o f in te rp re ta b le  and 
reproducible re su lts  (g iv ing  few 'fa ls e  negatives' and ‘ fa lse  
p o s it iv e s ')  and re ta in  some relevance to  mechanisms o f teratogenesis. 
IN VITRO teratogen tes ts  have problems th a t are not found w ith other 
IN VITRO to x ic ity  te s ts . F ir s t ly ,  the tox ico lo g ica l ta rg e t is  the 
embryo, a mass o f ra p id ly  d iv id in g  c e lls ,  simultaneously 
d if fe re n t ia t in g  along divergent lin e s . As fa r  as possible the te s t 
should reproduce these aspects o f embryogenesis. Secondly, both 
maternal metabolism o f xenobiotics and fe ta l-p lacen ta l-m a te rna l 
in te rac tions  are usually not present IN VITRO. Since some teratogens 
may require b io ac tiva tio n  to the active  form, the inc lus ion  o f a 
re lia b le  metabolising system or source o f metabolites in  the screen 
would extend the u t i l i t y  o f the te s t procedure. This has been 
achieved as fo llows*
( i )  Use o f serum from whole animals treated w ith the te s t compound 
(Chatot e t a l . 1980; K le in e t a l . 1982; Schmid e t a l . 1982; 
Clapper e t a l . 1983).
( i i )  IN VIVO pretreatment o f the mother w ith inducers o f the drug 
metabolising enzyme systems. For example, limb bud organ 
cu ltu res from mice pre-induced IN UTERO w ith the inducer 
Aroclor 1254 could b ioac tiva te  the proteratogen 
cyclophosphamide whereas non-treated con tro ls  were 
re fra c to ry  (Neubert and B luth, 1981).
( i i i )  The coincubation w ith iso la ted  hepatocytes, contain ing the 
metabolising enzymes (Manson and Simons, 1979; M uller 
e t a l . 1980; Brown and Kram, 1982; Oglesby e t a l . 1984).
( iv )  Coincubation w ith hepatic microsomes, or Sg l iv e r  fra c tio n  
plus cofactors usually from Aroclor 1254-induced male 
rodents or rabb its  (Greenberg, 1982; Wilk e t a l . ,  1980; 
Schmid e t a l . ,  1981; K itch in  e t a l . ,  1981a, 1981b). In 
add ition the fo llow ing  methods are proposed th a t might be 
experimentally useful but which have not y e t been reported 
in  the l i te ra tu re .
(a) IN VITRO co-treatment w ith  inducers given th a t the
embryo c e lls  themselves contain inducib le  forms o f 
the b io ac tiva tio n  enzymes.
(b) Addition o f Sg fra c tio n s  from pregnant females, both
contro l and preinduced.
(c) Incubation o f the te s t compound w ith an Sg fra c tio n
then add ition  o f the f i l t r a t e  to  the IN VITRO te s t 
system.
(d) Addition o f p u r if ie d  enzyme components o f the drug 
metabolising system.
The most sa tis fa c to ry  way o f taking the fe ta l-m a terna l-p lacen ta l 
u n it in to  account is  to dose the mother w ith the te s t compound, p r io r  
to removing the embryos fo r  cu ltu re  (Kochaar, 1975; Beaudoin and 
Lowell-F isher, 1981, F l in t  e t a l . ,  1984). This would then co n s titu te  
a combined IN VIVO/IN VITRO approach.
The d if fe re n t types o f IN VITRO teratogenic screens th a t have been 
described are summarized in  Table 1.3 and the IN VIVO to  IN VITRO 
co rre la tio n  o f tes ts  w ith reported teratogens and non-teratogens are 
summarised in  Table 1.4. The most e ffe c tiv e  screens (from Table 3) 
measure several q u an tifia b le  end points and have some degree o f 
complexity i .e .  they model IN VIVO mammalian embryogenesis as c lose ly  
as possible. From Table 1.4 , the most e ffe c tiv e  screens have a high 
percentage o f IN VIVO to IN VITRO co rre la tio n  (a t le a s t 90-95%), 
e x h ib it low incidences fo r  both fa lse  negatives and fa lse  pos itives  
and have been tested on s u ff ic ie n t number o f teratogens and non­
teratogens to  be meaningful.
Several reviews o f te s tin g  e x is t ,  covering the advantages, 
disadvantages and experimental techniques o f a ll the major categories 
o f IN VITRO screens (Clayton, 1980; Shepard e t a l . 1983; Kimmel e t a l . 
1982; P ra tt e t a l . 1980; Freese, 1982; Neubert, 1982; F l in t ,  1980; 
Kochaar, 1980; Barrach and Neubert, 1980). In general i t  appears th a t 
IN VITRO screens lack a re lia b le  drug m e tabo lis ing /ac tiva ting  system.
I t  has been suggested (Kimmel e t a l . 1981) th a t Sg hepatic fra c tio n s  
from Aroclor 1254 induced male Sprague-Dawley ra ts  should be included
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in  IN VITRO tests  to standardise the a c tiva tio n  system. Recently, the 
concensus workshop on IN VITRO te ra to g e n ic ity  tes tin g  recommended tha t 
te s t va lid a tio n  would be fa c i l i ta te d  by te s tin g  specified xenobiotics 
w ith  defined te ra to g e n ic ity  (Smith e t a l . 1983) and l is te d  47 
compounds intended to serve as a basis fo r  IN VITRO screens in  the 
hope o f id e n tify in g  systems which w i l l  con tribu te  to  a more e ffe c tiv e  
te s t programme.
The micromass ce ll cu ltu re  system uses 13 day old ra t embryo limb 
bud (LB) and mid-brain c e lls  (CNS) representative o f 2 c r i t ic a l  
tissues in  the developing embryo (F l in t  e t a l . 1985; F l in t ,  1981; 
G ir lin g  and F l in t ,  1984). This is  a well va lida ted screen w ith  95% 
p re d ic ta b il ity  w ith known teratogens y ie ld in g  few fa lse  pos itives  or 
fa lse  negatives (Table 1 .4 ). This system is  ne ither too complex nor 
too simple to  e ith e r perform or va lid a te . I have used th is  cu ltu re  
system to investiga te  the po ten tia l metabolic c a p a b ilit ie s  o f ra t 
embryo c e lls ,  and the p o s s ib il ity  o f modulating the to x ic i ty  o f 
diphenylhydantoin (DPH).
1.1.2 DEVELOPMENT IN VIVO VS IN VITRO
A comparison w il l  be made o f the d if fe re n t ia t io n  in  the micromass 
cu ltu res w ith the d if fe re n tia t io n  in  the embryo in  v ivo .
Limb bud: The development o f the limb skeleton s ta rts  w ith the
formation o f the mesodermal structures (somite, somatopleure). From 
here c e lls  migrate in to  the limb bud (m igration) and increase in  
number (p ro life ra t io n ) .  Cells in  the core o f the limb mesenchyme 
condense to form pre-ca rtilag inous blastemata (day 14/15 gestation in
the ra t ) ,  and la te r  secrete ca rtila g inous  m atrix to form the typ ica l 
ca rtilag ino us  limb skeleton. Late in  fe ta l l i f e  the ca rtila g e  
skeleton is  replaced w ith bone. The s e n s it iv ity  o f these d if fe re n t 
steps to teratogens varies g re a tly . Blastema formation and the onset 
o f c a rtila g e  d if fe re n t ia t io n  especia lly  can be disturbed by 
teratogenic substances (Merker, 1977). The most appropriate IN VITRO 
tests  fo r  teratogenic hazard towards the skeleton w i l l  thus be those 
in  which blastema formation and d if fe re n t ia t io n  occur.
Micromass c e ll cu ltu re  is  a system in  which iso la ted  limb bud 
c e lls  IN VITRO y ie ld  blastema c e lls ,  other mesenchymal c e l ls ,  myoblast 
c e lls  and myotubes ( F l in t ,  1981; Merker e t a l . 1980). Dense packing 
in  the blastema and the occurrence o f numerous gap junctions are a 
p rerequ is ite  fo r  d if fe re n t ia t io n . A lte ra tio ns  in  the c e ll density , 
membrane or contact behaviour lead to disturbances in skeletogenesis. 
Pertubation o f these processes which are known to occur in  the 
IN VITRO micromass cu ltu re  is  considered to be a sens itive  in d ica tio n  
o f teratogenic hazard.
In conclusion the IN VITRO micromass cu ltu re  o ffe rs  a re lia b le  and 
accurate re fle c tio n  o f IN VIVO skeletogenesis.
Midbrain/Mesencephalon:-  At day 13 o f gestation in  the ra t the 
neural tube in  the head has closed (both a t the a n te rio r and p o s te rio r 
end), and three brain vesicles have formed: the prosencephalon, the
mesencephalon and the rhombencephalon. The fa te  o f each o f these is  
as fo llow s* the prosencephalon divides in to  the telencephalon 
(cerebral hemispheres) and the diencephalon (tha lam i, po s te rio r lobe 
o f p itu a to ry  gland, pineal body and op tic  lobes ) s  the mesencephalon
(m idbra in); the rhombencephalon which divides in to  the mylencephalon 
(medulla oblongata) and the metencephalon (pons and cerebellum).
At the time o f closure the neural tube consists o f a s ing le  layer 
o f neuroep ithe lia l c e lls  (the germinal c e lls )  which give r is e  to 
neuroblasts or more co rre c tly  immature neurones. In the micromass 
c e ll cu ltu re  un d iffe ren tia ted  neuroep ithe lia l c e lls  from the 
mesencephalon are disaggregated and cu ltu red , in  small d iscre te  
is lands. Cells th a t are destined to  d if fe re n tia te  as neurones 
a c tu a lly  segregate from the other c e lls  in  the is land and aggregate 
together in  small clumps (F l in t ,  1983). Other c e lls  f la t te n  and 
attach to the substrate and resemble typ ica l fib ro b la s ts  throughout 
the cu ltu re  period. The clumps o f preneurone c e lls  spread out forming 
large ir re g u la r fo c i.  Cells in  the fo c i d if fe re n tia te  as a pure 
population o f neurones id e n t if ia b le  by sp e c ific  incorporation o f 
lab e lled  y-aminobutyric acid incorporation or by la b e llin g  w ith  a 
monoclonal antibody to  neuronal GQ-ganglioside. The ganglioside is  
not found on the c e ll surface a t the s ta r t  o f the cu ltu re  period but 
emerges during the 5 days o f cu ltu re . S im ila r ly  the antigen is  not 
present in  the embryonic mesencephalon IN VIVO a t day 13 post coitum, 
only emerging la te r  in  the d iffe re n tia te d  m idbrain. There appears to  
be a DE NOVO synthesis which is  pa ra lle le d  IN VIVO and IN VITRO.
The formation o f neurones, binding o f neural c e ll p ro jec tions 
(neurites) in to  nerve-like  s tructures (confirmed by e lectron 
microscopy) the synthesis o f neural c e ll antigen and H^-y-aminobutyric 
acid uptake studies confirm th a t the micromass c e ll cu ltu re  system is  
an exce llen t model fo r  IN VIVO neuronal d if fe re n t ia t io n  (F l in t ,  1983), 
and th a t while c e lls  are d if fe re n t ia t in g  they are sens itive  to  the 
teratogenic in s u lt .
1.2. KEY FACTORS INVOLVED IN TERATOGENESIS
1.2.1 TIMING OF THE TERATOGENIC INSULT
An important feature o f chemically-induced teratogenesis is  the 
tim ing o f treatment. During the pre-im plantation period, the 
conceptus is  generally re s is ta n t to  the production o f congenital 
malformations, although wastage due to  em bryo le tha lity may occur. 
Following im plantation and during organogenesis, the embryo is  
extremely susceptible to  the teratogenic e ffe c ts  o f chemicals. As 
each organ system is  progressively d iffe re n tia te d  (Table 1.5) i t  
becomes less susceptible so th a t teratogenic in s u lt  by the same 
chemical a t d if fe re n t stages o f organogenesis can produce e n tire ly  
d if fe re n t re s u lts . In the post-organogenesis fe ta l stage o f 
development, to x ic ity  can take the form o f growth in h ib it io n  leading 
to fe ta l death or impaired postnatal development. Teratogenesis 
i t s e l f  is  thus in e x tr ic a b ly  linked w ith c e ll and tissue 
d if fe re n t ia t io n . The length o f organogenesis re la tiv e  to  the period 
o f gestation varies between species (Figure 1 .1 ). The commonly used 
labora tory animals (mouse, ra t and ra b b it)  spend 38-48% o f th e ir  to ta l 
gestational time in  organogenesis, and the human only 13%. However, 
because o f the long gestation time in  the human (35 days compared to  
8-13 days in  the rodent), th is  species is  a t r is k  longer.
1.2.2 ROLE OF PLACENTAL TRANSFER
Disposition in  the embryo o f a number o f drugs and chemicals may 
be almost completely blocked by the placental s tructures ea rly  in  
gestation (Denker, 1976). I t  is  not completely understood whether the 
placenta acts as a to ta l b a rr ie r a t th is  stage or whether i t  allows 
xenobiotic tra ns fe r in  trace amounts (Denker, 1982). In la te
gestation several drugs appear to cross the placenta and accumulate in  
sp e c ific  organs o f the fetus? examples are diphenylhydantoin in  fe ta l 
myocardium, l iv e r  and kidney (Waddell and M irk in , 1972) d ie thy l - 
s t i lb e s tro l in  the reproductive tra c t  (M ille r  e t a l . 1982) and 
diazepam in the l iv e r  and small in te s tin e  ( Ig a ri e t a l.  1982). The 
accumulation s p e c if ic ity  may be due to  ( i )  the a b i l i t y  o f the organ 
to metabolise the xenobiotic or ( i i )  the a f f in i t y  o f th a t tissue/organ 
fo r  the xenobio tic.
Table 1.5 Comparison o f Developmental Events in  Man
and Experimental Animals*
I DEVELOPMENTAL EVENT
1 SPECIES GESTATIONAL AGE 
1
1 MAN | RAT I MOUSE I 
1 1 1 1
(DAYS) I 
RABBIT |
1 Implantation
1
1 6-7 5-6
1 I 
1 5-6 | 1 | 6 1
I F ir s t  somite 1 18-21 I 10
1 1 
1 7 II i 8 !
1 Right and l e f t  heart primordia 1 21 
1
9.5
1 1 
1 7 I 
j j
8.5 I
I L ive r d iverticu lum 1 26 11 1 8.5 I 1 | 9.5 |
1 A nte rio r neuropore closed I 24-25 10.5
1 1 
1 9 I 9.5 I
1 A nte rio r limb bud 1 27-28 10.5 1 9.3 1 10.5 |
1 Posterior limb bud 1 29-30 
1
11.2 1 10.3 I 11 1
I TOTAL GESTATIONAL TIME
T
I 267 
1
22
1 1 
1 19 I 
1 1
32 I
* data taken from Schardein, 1985.
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Figure 1.1 Mean Gestational Time and Relative C r it ic a l 
Periods o f Organogenesis in  Experimental 
Animals and Man
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The numbers re fe r to the percentage o f the gestation period spent in  
the sens itive  phase o f organogenesis.
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There appears to be three mechanisms whereby chemicals are 
transfe rred  across the placenta (Waddell and Marlowe, 1981j Krauer 
e t a l . 1980) namely*
( i ) Passive tra ns fe r e.g. drugs, in fe c tio us  agents and fa t ty  acids 
( i i )  C arrie r mediated tra n s fe r e .g . glucose 
( i i i )  Active tra ns fe r e.g. methyl mercury and iron
The m a jo rity  o f chemicals seem to be passively transfe rred  across 
the placenta w ith l ip id  soluble molecules crossing much more re a d ily  
than hydroph ilic  molecules (Freese, 1982; Waddell and Marlowe, 1981; 
Krauer e t a l . 1980; Goodman e t a l . 1982; Dvorchik, 1982). The extent 
o f passage o f hydroph ilic  molecules is  s trong ly dependent on the size 
and structure  o f the molecules as well as on the species and 
gestational stage (Mihaly and Morgan, 1984).
1.2.3 DIRECT AND INDIRECT ACTION OF TERATOGENS
Very l i t t l e  work has been d irected towards determining the actual 
mechanisms o f teratogenesis. However, fo r  the compounds studied to  
date the biochemical mechanisms o f teratogenesis may be divided in to  
two categories (add itiona l inform ation may be found in  Juchau, 1981 
and Beckerman and Brent, 1984).
( i )  D irec t Acting* i .e .  those compounds (parent compound, reactive  
intermediate or m etabo lite ), tha t in h ib i t  synthesis and/or 
accumulation o f essential c e llu la r  components or bind d ire c t ly
to c e llu la r  components thereby a lte r in g  function or s truc tu re  
o f embryonic tissue (Table 1 .6 ).
( i i )  In d ire c t Acting* i . e .  those compounds whose to x ic  e ffe c t on 
the maternal/embryo u n it as a whole (ra the r than the embryo 
alone) lead to  teratogenesis (Table 1 .7 ).
K 2 .4  FACTORS INFLUENCING THE EXPRESSION OF TERATOGENIC INSULT
The expression o f a teratogenic e ffe c t is  influenced by several 
fac to rs , inc lud ing genetic, hormonal (sex) and interspecies 
d ifferences in  metabolic c a p a b ility .
( i )  Genetic: The Ah locus is  a c lu s te r o f genes thought to  be the 
centre o f the genetic regu la tion  o f some o f the cytochrome P450 
mediated mono-oxygenases (Nebert and Jensen, 1979; Denker and 
P ra tt, 1981) one o f the enzyme systems responsible fo r  
xenobiotic metabolism. Benzo(a)pyrene is  metabolised by 
cytochrome P450 mono-oxygenases under the contro l o f the Ah 
locus and the degree o f responsiveness/suscep tib ility  to  both 
teratogenesis and enzyme induction d if fe rs  in  two mice s tra in s  
(C57/BL6 = responsive s tra in , AKR = non responsive s tra in )
(Shum e t a l . 1979; Legreverand e t a l . 1984). Responsive mice 
were found to have 50 times more hepatic cy toso lic  receptor 
(a prote in c o n tro llin g  induction) than the non-responsive 
s tra in , (Galloway, e t al 1980). Teratogens th a t show a 
co rre la tio n  between s tra in  s e n s it iv ity  and increased Ah 
receptors in  mice include 2, 3, 7, 8 -te trach lorod ibenzo-p-
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d ioxin  (TCDD) (Denker and P ra tt, 1981; Nebert, 1980; Pinsky and 
Digeorge, 1965; McDevitt e t a l . 1981) g lucocortico ids 
(Kasanagi, 1983; Je linek and Peterka, 1983; Wee and Zimmerman, 
1983; Kochaar and Lai son, 1977) diphenylhydantoin (S u lik  e t a l . 
1980; P ra tt, 1983; Fazel and S u lik , 1980; A tlas e t a l . 1980; 
Hansen and Hodes, 1982, 1983) and acetazolamide (Hirsch e t a l . 
1983; Hackman and Hurley, 1983; B iddle, 1975). The sex o f the 
animal also has an in fluence on s u s c e p tib ility  to  
teratogenesis. Methyl mercury is  an established teratogen in  
the mouse and decreases hepatic mono-oxygenase a c t iv i ty  in  the 
male o ffsp rin g  only (Robbins e t a l . 1978). In con tras t, 
acetazolamide-induced te ra to g e n ic ity  seems to a ffe c t a greater 
percentage o f female mice o ffsp rin g  (S cott, e t a l . 1972). 
S im ila rly  the synthetic oestrogen, d ie th y ls t i lb e s t ro l, 
the rap eu tica lly  used between 1950-1970 in  order to  prevent 
threatened miscarriage during the f i r s t  tr im e s te r, caused human 
female o ff-s p rin g  to  develop vaginal adenocarcinomas (Herbst e t 
a l.  1971) during sexual maturation (14-22 year o ld s ). In 
ad d ition , male o ffsp rin g  s im ila r ly  exposed p re -n a ta lly , have 
been reported to have reduced sperm counts and a high incidence 
o f s t e r i l i t y  (G ill e t a l . 1976).
Hormonal: In general, the actions o f a va rie ty  o f drugs are
more pronounced and p e rs is t longer in  female ra ts  than in  males 
(Kato, 1974, Fueur, 1979, Kato and Kamataki, 1982, Gustafsson 
e t a l . 1980). One consequence o f th is  is  th a t to x ic  e ffe c ts  o f 
drugs may be more pronounced in  pregnant females. One o f the 
con tribu ting  fac to rs  to  th is  phenomenon is  thought to  be the
a c t iv i ty  o f microsomal drug metabolising enzymes, con tro lled  by 
s te ro id  hormones acting d ire c t ly  or in d ire c t ly  on the hepatic 
drug metabolising system.
In view o f the apparent de fic iency o f such enzyme systems in  
the embryo, fe tus , neonate and perinate (Juchau, 1981; Kato e t 
a l . 1962; Pelkonen, 1980; Neubert e t a l . 1978; G il le t te  and 
S tr ip , 1975; Waddell and Marlowe, 1976, Pelkonen, 1977; S ne ll, 
1982; Kimmel and Buelke-Sam, 1981; F i l le r  and Lew, 1981; 
P a c ific i e t a l . 1983) the ro le  o f the drug metabolising enzymes 
in  teratogenesis a t the ea rly  stage o f organogenesis is  a t 
present unclear.
( i i i )  Species d iffe rences in  metabolism: Table 1.8 shows the
in te r-species va ria tions  between the minimum teratogenic doses 
o f some selected compounds. There are c lea r d iffe rences fo r  
example, between the mouse and ra t .  The mouse appears more 
sensitive  to  the teratogenic e ffe c ts  o f diazepam,
2,5 diami notoluene, ca ffe ine , diphenylhydantoin and a s p ir in .
In con tras t, the ra t  is  more sens itive  to  the e ffe c ts  o f L- 
dopa. The interspecies va ria tion s  are probably not due to 
d ifferences in  p lacentation but may well be due to  d iffe rences 
in  e ith e r xenobiotic biotransform ation or pharmacokinetics.
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1.3. KINETIC PHENOMENA IN PREGNANT ANIMALS
1.3.1 ALTERED PHARMACOKINETICS AND DRUG PLASMA PROTEIN BINDING DURING
PREGNANCY
Pregnancy Increases the clearance o f drugs whose excretion is  
predominently renal and re la ted to c re a tin in e  clearance, but fa i ls  to  
change the clearance o f oral drugs th a t are extensive ly metabolised by 
the l iv e r ,  i .e .  have a high hepatic ex trac tion  ra t io  (Dvorchik, 1982). 
Processes which a ffe c t the k in e tic s  o f renal clearance (renal plasma 
flow  and glomerular f i l t r a t io n  ra te ) are usually increased during 
pregnancy (Dean e t a l . 1980). The apparent volume o f d is tr ib u t io n  is  
also a lte red due to increased plasma volume. Drug d is tr ib u tio n  and 
e lim ina tion  is  changed by an increase in  body fa t  and a decrease in  
the concentration o f plasma pro te ins. The net re s u lt is  a tendency 
towards prolonged drug h a l f - l i f e  (Boobis and Lewis, 1982). Absorption 
o f drugs is  also a ffected . In add ition , delayed ga s tric  emptying has 
been noted during pregnancy (approximately twice as long as compared 
to non-pregnant women) and reduced ga s tric  m o t i l i ty  can lead to  
prolonged d is in teg ra tion  o f some tab le ted drugs (Krauer e t a l . 1980).
Most drugs are p a r t ia l ly  bound to  plasma p ro te ins, predominantly 
albumin. The albumin concentration fa l ls  in  the f i r s t  4 months o f 
pregnancy which reduces the binding capacity o f a given volume o f 
plasma, but since the plasma volume increases during pregnancy the 
to ta l mass o f albumin e ffe c t iv e ly  remains constant. For h igh ly  bound 
drugs, the hypoalbuminaemia o f pregnancy w i l l  produce a lower to ta l 
plasma concentration, associated w ith a decrease o f the bound drug 
fra c tio n  and corresponding increase o f the free drug fra c tio n  in  the 
plasma (Stock e t a l . 1980; A llen and Greenblatt, 1981). In con tras t
to  albumin, most g lobu lin  fra c tio n s  r is e  during pregnancy. The to ta l 
e ffe c t o f changing patterns o f plasma proteins and o f physio logical 
competitors fo r  th e ir  binding s ites  is  complex and varies from 
compound to  compound (Krauer e t a l . 1980). Accordingly, a lte red 
pharmacokinetics during pregnancy is  a well documented area in  both 
humans and labora tory animals (Dean e t a l . 1980; Ramsay, e t a l . 1980; 
Lovecchio e t a l . 1981; Levy, 1981; Combes e t a l . 1963; Perucca and 
Crema, 1982; Cummings, 1983).
In humans there is  l i t t l e  evidence o f changes in  drug m etabolite 
p ro file s  during pregnancy, or l iv e r  size/weight changes (Combes e t a l.  
1963). However, the l iv e r  o f the pregnant ra t has been reported to 
increase by up to  40% o f the normal weight and i t  has been suggested 
th a t th is  increase is  an adaptive response to  accommodate 
hydroxylation o f the r is in g  tid e  o f sex hormones (Symons e t a l . 1982). 
In te re s tin g ly , the same group also noted a decrease ( 5 3 - 7 3 % )  in  
cytochrome P450-mediated reactions accompanied by l iv e r  weight changes 
p r io r  to  p a rtu r it io n  (Symons e t a l . 1982).
1.3.2 PHYSIOLOGICAL INTERPLAY BETWEEN MOTHER AND FETUS
There appears to be four general pharmacokinetic models which 
represent the plasma drug concentrations in  mother and fe tus fo llo w ing  
a s ing le oral dose to  the mother (Waddell and Marlowe, 1981). The 
f i r s t  model (Figure 1.2 , Type 1) is  applied to  compounds th a t fre e ly  
cross the placenta and d is tr ib u te  ra p id ly  in  a s ing le compartment in  
the fe tus . The compound must obey ce rta in  c r i te r ia  in  order fo r  the 
concentration p ro f i le  in  the m aternal/ p la c e n ta l/fe ta l u n it to  fo llo w  
f i r s t  order k in e tic s  in c lud ing *-
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(1) No p re fe ren tia l binding to  e ith e r fe ta l or maternal plasma 
pro te i ns
(2) D is tr ib u tio n  must be unaffected by pH gradients
(3) Fetal plasma concentration is  s l ig h t ly  higher than maternal a t 
equ ilib rium
A concentration gradient must e x is t i f  the only route o f 
e lim ina tion  is  passage back across the placenta fo r  appropriate 
metabolism and/or excre tion . An example o f a drug fo llow ing  th is  
pattern is  carbamazepine.
The second type o f p ro f i le  (Figure 1 .2 , Type 2) requires a 
detectable in te rva l in  which fe ta l/m aterna l plasma concentration 
are in  eq u ilib rium . A fte r th is  po in t the fe ta l concentration is  
always higher because tra n s fe r o f the non-polar metabolites across the 
placenta back to  the mother is  low. This type o f k in e tic s  is  a re s u lt 
o f a large fe ta l compartment which may be a re s u lt o f e ith e r fe ta l 
plasma binding or a pH gradient trapping the non-polar e n t it ie s .  
Compounds th a t fo llo w  th is  k in e tic  p ro f i le  include loca l anaesthetics 
and asp irin  (Kimmel and Young, 1980).
In the th ird  type (Figure 1.2, Type 3) fe ta l metabolism occurs 
and po lar metabolites accumulate on the fe ta l side, crea ting  a 
concentration gradient. These may, however, undergo minor e lim in a tion  
in to  the amniotic f lu id  and pass back across the placenta by 
p inocytosis. Compounds o f th is  type include diazepam and oxazepam 
(A llen and Greenblatt, 1981 j Ridd e t a l . 1983, Bakke and Haram, 1982, 
Idanpaan-Heikkila e t a l . 1971).
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The fou rth  type o f k in e tic s  (Figure 1.2 Type 4) ex is ts  when a 
very polar parent drug is  unable to  cross the placenta, and is  
therefore excluded from the embryo, fo r  example quaternary ammonium 
s a lts .
I t  should be noted th a t these fou r types o f k in e tic s  and drug 
tra n s fe r between the mother and fetus are idea lised s itu a tio n s . In 
re a li ty  i t  is  more probable th a t a hybrid type o f pharmacokinetic 
p ro f i le  ex is ts  and tha t there is  some accumulation and/or metabolism 
in  the fe ta l compartment o f the parent drug and i t s  m etabolites.
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1.4 ENZYMOLOGY OF TERATOGEN ACTIVATION
Studies o f the in te ra c tio n  o f chemicals w ith b io log ica l systems 
have shown th a t in  many cases, the parent compound is  not the chemical 
species responsible fo r  the observed to x ic  e ffe c ts . Rather, the 
parent compound is  biotransformed, i . e ,  converted to a to x ic  reactive  
intermediate or m etabolite . These reactions (metabolism or 
biotransform ation) have been studied in  maternal hepatic tissue  and in  
tissues o f importance to teratogenesis, inc lud ing the placenta and 
fe ta l l iv e r .
1.4.1 CYTOCHROME P450
Enzymes cata lyz ing ox ida tion , reduction and hyd ro ly tic  reactions 
o f chemicals are those most frequently  im plicated in  the b io a c tiva tio n  
o f teratogens, and they are c o lle c t iv e ly  re fe rred  to  as "Phase 1" or 
"Functiona lisa tion" reactions. The most important o f these enzymes 
appears to  be the microsomal mono-oxygenases which have been s trong ly  
im plicated in  b io a c tiva tio n  mechanisms. The haemoprotein cytochrome 
P450, functions as an oxygenase fo r  both xenobiotics and endogenous 
substrates (Schenkman and Gibson, 1982). L ite ra l ly  hundreds o f drugs 
and chemicals can bind to  (Schenkman e t a l . 1981) and be metabolised 
by th is  enzyme system (Gibson and Skett, 1986) which therefore 
occupies a centra l pos ition  in  pharmacology and tox ico logy.
Exposure o f experimental animals or humans to  a wide va rie ty  o f 
chemicals can re s u lt in  increased rates o f biotransform ation catalysed 
by microsomal cytochrome P450. Such increases in  rates appear in  p a rt 
a ttr ib u ta b le  to  enzyme induction (p a r t ic u la r ly  cytochrome P450) as 
manifested by increased DE NOVO synthesis o f enzyme p ro te in . I t
appears tha t there are a t le a s t two main categories o f inducers 
(Conney e t a l . I960; Gelboin and Blackburn, 1964) and th a t these 
induce d if fe re n t groups o f cytochrome P450 isozymes. The prototype o f 
one category ( 'phenobarbitone-type inducers*) is  phenobarbitone, 
(Conney, 1967) and 3-methylcholanthrene (3MC) is  representative o f the 
second c lass. Chemicals in  the la t te r  group include other po lycyc lic  
aromatic hydrocarbons, halogenated d iox ins , flavones (such as p- 
naphthoflavone) and polyhalogenated hydrocarbons. Recently a th ird  
category o f inducer has been described, the prototype being 
hypolipidemic agents such as c lo f ib ra te  (Gibson e t a l . 1982; Tamburini 
e t a l . 1984). Other classes o f inducers are being increas ing ly  
recognised. I t  is  also important to  note th a t cytochrome P450 
induction is  generally associated w ith the synthesis o f a p a rtic u la r  
m u ltip le  form(s) (o r isoenzyme) o f the haemoprotein.
There are a number o f in h ib ito rs  which can in te rfe re  w ith 
mono-oxygenase function by a va r ie ty  o f mechanisms (N e tte r, 1979; 
A lston, 1981; Hal pe rt and Neal, 1981). For example, metyrapone binds 
to  the haem iron  o f cytochrome P450, or in  i t s  v ic in i ty  and so reduces 
the binding o f oxygen (N ette r, 1979). Other in h ib ito rs  commonly used 
as too ls  to  investiga te  cytochrome P450-dependent metabolism include 
SKF525A (N ette r, 1979), e l l ip t ic in e  (Delaforge e t a l . 1980, Lesca 
e t a l . 1980), c im etid ine (Bell e t a l . 1983; Henry e t a l . 1980) 
a-naphthoflavone (Wiebel e t a l . 1971) and piperonyl butoxide (A lston , 
1981; Hal pe rt and Neal, 1981).
1.4.2 PHASE I I  METABOLISM
D eto x ifica tion  o f chemicals contain ing aromatic rings by 
oxidation proceeds v ia  a h igh ly reactive  n uc leoph ilic , arene oxide
intermediate (Jerina and Daly, 1974) and may re s u lt in the formation 
o f phenols. These arene oxides can also be enzym atically hydrated to  
unreactive dihydrodio ls by epoxide hydrolase or conjugated w ith  
g lu ta th ione , by g lu ta th ione-S -transferase, to e sse n tia lly  unreactive 
species (Oesch, 1982). The presence o f these enzymes has also been 
established in  the human fe ta l l iv e r  (Peng e t a l . 1984; P a c if ic i e t 
a l . 1983). Other 'phase I I '  enzymes include glucuronyl transfe rase , 
sulphotransferase and acyl transferase, however, these are e ith e r 
present a t very low leve ls  or not detectable in  both human and rodent 
fe ta l tissue (Juchau, 1981).
1.4.3 DRUG METABOLISM BY THE PLACENTA
Most o f the drug biotransform ation reactions present in  the l iv e r  
have also been reported in  the placenta (Juchau, 1980). Examples are 
cytochrome P450 dependent reactions (Pelkonen and K ark i, 1975), 
g lucuronidation, sulphation, g lu ta th ione conjugation, epoxide 
hydratase, catechol-0-m ethylation and monoamine oxidase (Juchau,
1980). Human placental cytochrome P450 concentration is  approximately 
20% o f th a t found in  maternal l iv e r  (Connelly and Bridges, 1980;
Burke and Orrenius, 1979). The placental m itochondrial cytochrome 
P450 concentration is  several times greater than in  the microsomal 
fra c tio n  (Meigs and Ryan, 1968).
There is  some evidence fo r  the m u ltip le  forms o f cytochrome P450 
in  the placenta (Meigs and Ryan, 1968; Zachariah and Juchau, 1977; 
Zachariah e t a l . 1976). Placental cytochrome P450 appears to  be 
inducib le only by 3MC-type inducers (Juchau, 1980). The aryl 
hydrocarbon hydroxylase system ( i .e .  the po lycyc lic  hydrocarbon
metabolising system) in  the placenta appears to have a n a tu ra lly  high 
basal a c t iv ity  compared to  other oxidation reactions (Juchau and 
Zachariah, 1975) and is  h igh ly induc ib le , especia lly  by benzo(a)pyrene 
or c ig a re tte  smoking (Zachariah and Juchau, 1977; Zachariah e t a l . 
1976; Juchau e t a l . 1973; Juchau e t a l.  1980b). However, de tox ica tion  
o f the benzo(a)pyrene metabolites by Phase I I  g lu tath ione conjugation 
does not appear to be s im ila r ly  induced (Manchester and Jacoby, 1982). 
The main ro le  o f placental cytochrome P450 appears to be in  
cholesterol side chain cleavage and biosynthesis o f oestrogens from 
Cl9 endogenous stero ids (Juchau, 1980; Connelly and Bridges, 1980; 
Meigs and Ryan, 1968; Zachariah and Juchau, 1977)
1.4 .4 METABOLISM BY THE FETUS
Although the fe ta l l iv e r  o f primates possesses a well-developed 
complex o f xenobiotic metabolising enzymes (a lb e it  less active  than 
the a d u lt) , the fe ta l l iv e rs  o f many labora tory animals ( r a t ,  mouse, 
guinea p ig , ra b b it and hamster) are apparently d e fic ie n t in  the 
microsomal cytochrome P450 system. There is  a la te  development o f the 
smooth endoplasmic reticulum  (Remmer and Merker, 1963).
Non-human primates and humans d i f fe r  from the common labora to ry 
animals w ith respect to  the early  appearance o f the hepatic smooth 
endoplasmic reticulum  and e a r lie r  development o f cytochrome P450 
isoenzymes p ro file s  (Neubert e t a l . 1978a; Pelkonen, 1980). Studies 
on the stumptail monkey (Dvorchik and Hartman, 1982) and marmoset 
(Neubert e t a l . 1978b) have shown xenobiotic metabolising capacity 
a t m id-gestation comparable w ith the human fe ta l capacity a t the same 
stage o f gestation (Dvorchik and Hartman, 1982). Human fe ta l
microsomes as early  as the 13th week o f gestation have the c a p a b ility  
o f metabolising diazepam (Ackermann and R ichter, 1977; Nau e t a l . 
1979).
Laboratory animals, w ith few exc}ptions, have a low capacity to  
oxid ise drugs and fore ign chemicals u n t il a fte r  b ir th ,  whereupon th is  
capacity increases u n t il ad u lt leve ls  have been achieved. Oxidative 
enzymes are f i r s t  detectable in  the l iv e r  close to b ir th ,  and ad u lt 
leve ls  are a tta ined a fte r  a few days (as in  the guinea p ig) or a few 
weeks (as in  the ra t ) .  There also appears to be a sex d iffe rence  in  
time o f attainment o f adu lt leve ls  in  the ra t ;  the female requires 30 
days and the male 40 days (G il le t te  and S tr ip , 1975).
For a more comprehensive analysis o f the above aspect o f 
developmental pharmacology than is  possible here, the numerous reviews 
and a r t ic le s  on the subject should be consulted (Juchau, 1981; 
Pelkonen, 1980; Kimmel and Buelke-Sam, 1981; Juchau e t a l . 1980;
Ja ffe , 1983; Parkhie e t a l . 1982; Neubert e t a l . 1978b).
IN VITRO studies w ith cu ltu red fe ta l ra t heptocytes have shown 
th a t th e ir  a b i l i t y  to metabolise ce rta in  xenobiotics only appeared 
a fte r  day 18 o f gestation (Yeoh e t a l.  1983; W orre ll, 1984). Other 
studies w ith cu ltu red mouse embryos (during ea rly  development) have 
ind icated tha t the onset o f p o lycyc lic  aromatic hydrocarbon a c tiv a tio n  
coincides w ith  b lastocyst formation ( F i l le r  and Lew, 1981) and th a t by 
day 12 o f gestation, benzo(a)pyrene hydroxylation is  e a s ily  detectable 
(Galloway e t a l . 1980). Following IN VIVO pretreatment o f the 
mothers, or IN VITRO exposure to inducers, induction o f the 
microsomal oxidases o f ra t fe ta l hepatocytes can be demonstrated 
(W orell, 1984; C reste il e t a l . 1984; Mizokami e t a l . 1982). Mouse
limb bud organ cu ltu res fo r  example can ac tiva te  the proteratogen 
cyclophosphamide fo llow ing  3 days o f Aroclor induction IN UTERO 
(Neubert and B luth, 1981) whereas contro l cu ltu res require an 
a c tiva tin g  source.
Mizokami e t a l . (1982) found th a t pretreatment o f the mother 
w ith  3-MC induced a phenobarbitone type o f cytochrome P450 in  fe ta l 
l iv e r  and not the cytochrome P448 type. However other workers have 
reported tha t exposure o f the mother to 3MC, Aroclor and (3- 
naphthoflavone resu lted in  expression o f the cytochrome P448 
isoenzyme(s) in  ra t fe ta l l iv e r  (Sunouchi e t a l . 1983). Recent work on 
whole ra t  embryos in  cu ltu re  (Faustman-Watts e t a l . 1984) has shown 
th a t p r io r  IN UTERO exposure to  3MC permitted b io a c tiva tio n  o f 2- 
acetylaminofluorene but not cyclophosphamide. Phenobarbitone 
induction had no e ffe c t. Studies presented la te r  in  the thes is  have 
shown th a t IN UTERO exposure to  p-naphthoflavone and subsequent 
micromass cu ltu re  o f limb bud c e lls  (F l in t  e t a l.  1984; F l in t ,  1981; 
F l in t  and Orton, 1985) resu lted in  the ac tiva tio n  o f cyclophosphamide 
but th a t 3MC, phenobarbitone and hypolipidemic agents were w ithout 
e ffe c t. As human embryo/fetal tissue mono-oxygenase a c t iv i ty  is  
comparatively higher than tha t observed in  common labora tory species 
and does not appear to  be coupled w ith  a correspondingly high leve l o f 
the Phase I I ,  detoxication enzyme system (Juchau, 1981) th is  may be 
important to  chemical teratogenesis and therefore a cause fo r  concern.
1.5 BIOACTIVATION OF TERATOGENS
1.5.1 COMPOUNDS THAT REQUIRE BIOACTIVATION
1.5.1.1 Cyclophosphamide
The b io ac tiva tio n  o f cylophosphamide (CPA) has been most 
extensively studied. Foley e t a l . (1961) f i r s t  demonstrated th a t CPA 
required hepatic a c tiva tio n  before (growth) in h ib it io n  o f tumour c e ll 
growth could be observed, and i t  is  now widely accepted th a t CPA- 
induced teratogenesis involves metabolic a c tiv a tio n . The maternal 
l iv e r  is  the s ite  o f b io ac tiva tio n  (Greenaway e t a l.  1982; Hales,
1981, 1982) v ia  the cytochrome P450 dependent mono-oxygenases (Manson 
and Simons, 1979; K itch in  e t a l . 1981; Fantel e t a l.  1979; Manson and 
Smith. 1977; Manson, 1981; Torkelson e t a l . 1974) (Figure 1 .3 ). This 
has been fu rth e r confirmed by IN VIVO and IN VITRO studies w ith  
inducers and in h ib ito rs  o f cytochrome P450-mediated metabolism (Table 
1 .9 ).
IN VIVO stud ies: In the ra t ,  phenobarbitone pretreatment o f the
pregnant female increased CPA te ra to g e n ic ity ; pretreatment w ith  
p-naphthoflavone however, had e ith e r no e ffe c t or decreased the 
te ra to g e n ic ity  (Hales, 1981). In the mouse, phenobarbitone again 
increased te ra to g e n ic ity  and SKF525A decreased the response; in  these 
animals, phenobarbitone decreased and SKF525A increased the fra c tio n  
o f unchanged drug in  maternal plasma and the embryo (Gibson and 
Becker, 1968, 1971) ind ica ting  tha t a CPA metabolite is  the u ltim a te  
teratogen. In con tras t, acute or chronic adm in istra tion o f A roclor 
1254 (a po lychlorinated biphenyl m ixture) attenuated CPA 
em bryotoxicity and te ra to g e n ic ity ; the k in e tic s  and placental tra n s fe r 
o f to ta l ra d io a c tiv ity  was unaffected by Aroclor 1254 fo llo w in g  l^ c -  
CPA adm inistra tion (Welsch 1985).
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IN VITRO studies* Incubation o f whole ra t embryos IN VITRO w ith 
CPA had no e ffe c t on em bryotoxicity or te ra to g e n ic ity  (Fantel e t a l . 
1979; Mirkes, 1985) but a 5 hour exposure in  the cu ltu re  medium w ith  a 
metabolising system (S9-mix) is  s u ff ic ie n t to  e l i c i t  the teratogenic 
e ffe c t (Mirkes e t a l . 1983). The embryotoxic and teratogenic e ffe c t 
o f CPA was increased in  ra t embryo cu ltu red w ith l iv e r  S9 fra c tio n  
from phenobarbitone (Juchau e t a l . 1985) or Aroclor 1254 pretreated 
ra ts  (Faustman-Watts e t a l . 1984). p-naphthoflavone or 
3-methylcholanthrene pretreatment had no e ffe c t (Juchau e t a l . 1985; 
Faustman-Watts e t a l . 1984). In te re s tin g ly , i t  was not possible to  
induce malformations in  embryos tra nsp lacen ta lly  pretreated w ith 
phenobarbitone (o r 3 methylcholanthrene) and then exposed to CPA 
IN VITRO (Juchau e t a l . 1985, Brown e t a l . 1986). However 
P-naphthoflavone was active  (Brown e t a l . 1986).
The major reactive  metabolites o f CPA are acro le in  and 
phosphoramide mustard (Figure 1 .3 ). Phosphoramide mustard is  a potent 
a lk y la tin g  agent (Hales, 1981) and is  presumed to be the u ltim a te  
teratogen (Mirkes e t a l . 1981; Nau e t a l . 1982. IN VIVO, ac ro le in , 
has been reported to  be embryolethal but not teratogenic (Hales, 1982; 
Schmid e t a l . 1981). However, abnorm alities are observed in  whole ra t  
embryos exposed to acro le in  in  serum free medium (Mirkes e t a l . 1984) 
suggesting tha t i t s  extensive binding to prote in  may play an im portant 
ro le  in  reducing the teratogenic e ffe c t IN VIVO. Co-adm inistration o f 
CPA w ith th io l compounds IN VIVO to ra ts  causes a decrease in  
te ra to g en ic ity  whereas co-adm in istration w ith a th io l deple ting agent 
causes an increase in  teratogenic e ffe c ts  (Hales, 1981b). 4-
hydroperoxy CPA, which decomposes to  phosphoramide mustard and 
acro le in  (Hales 1982; Mirkes e t a l . 1984) causes dysmorphogenesis
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in mouse limb-bud cu ltu res (Barrach e t a l.  1978) s im ila r to tha t 
observed w ith CPA IN VIVO. Thiol agents were w ithout e ffe c t vn v i t r o  
(Brown e t a l . 1986).
1.5 .1 .2  Acetyl aminofluorene
IN VITRO studies? 2-acetyl aminofluorene (2AAF) was i n i t i a l l y  
found to be teratogenic to whole ra t embryos IN VITRO only in  the 
presence o f a S9 mix from Aroclor or 3-methylcholanthrene treated ra ts  
(Faustman-Watts e t a l . 1983). A m etabolite o f 2AAF (N-hydroxy AAF), 
was found to  be d ire c t ly  teratogenic to  whole embryo cu ltu re  IN VITRO 
(Faustman-Watts e t a l.  1983) g iv ing the prosencephalic defects 
observed w ith 2AAF fo llow ing  IN VITRO a c tiv a tio n . Rat embryos 
transp lacen ta lly  exposed to  3-methylcholanthrene and subsequently 
treated during cu ltu re  w ith 2AAF ( in  the absence o f S9 mix) showed 
increases in  malformation incidence; transplacental exposure to 
phenobarbitone had no e ffe c t (Juchau e t a l.  1985). Oxidative 
metabolites o f 2AAF were detected during incubation o f 2AAF w ith  
day 10 ra t embryos transp lacen ta lly  exposed to  3-methylcholanthrene 
(Juchau e t a l . 1985).
1 .5 .1 .3  Benzhydrylpiperazine Derivatives
The benzhydrylpiperazine an tih is tam in ic  drugs, c h lo rc y c liz in e , 
c y c liz in e , bucyc liz ine , m ecliz ine, hydroxyzine and no rcyc liz ine  are 
teratogenic in  ra ts  and mice (King, 1963; King e t a l . 1965, 1966). 
Cytochrome P450 mediated N-dealkylation o f ch lo rcyc liz in e  and 
m eclizine forms a common m etabolite , no rch lo rcyc liz ine  (Narrod e t a l . 
1965). In the ra t ,  the incidence o f c le f t  palate induced by 
c h lo rc y c liz in e , but not n o rch lo rcyc liz in e , was reduced by SKF525A 
adm in is tra tion . This response was associated w ith an increased fe ta l
concentration o f ch lo rcyc line  (6-12 fo ld ) and a decrease in  
no rch lo rcyc liz in e , in d ica tin g  th a t no rch lo rcyc liz ine  is  the u ltim a te  
teratogen (Posner e t a l . 1967).
1 .5 .1 .4  Benzo(a)Pyrene
When benzo(a)pyrene is  administered in  the d ie t to  susceptible 
s tra in s  o f mice, the frequency o f malformations is  greater in  those 
embryos o f the Ah^/Ah^ than the Ahb/Ahd genotype (Legreverand e t a l . 
1984, Nebert, 1980). Ahd and Ahb re fe r to  the dominant or recessive 
a lle le  respective ly encoding a cy to so lic  receptor th a t regulates the 
expression o f cytochrome P448. The greater s u s c e p tib ility  o f Ahd/Ahd 
embryos is  associated w ith a higher leve l o f to x ic  m etabolites o f 
benzopyrene (1 ,6 - and 3,6-quinones) suggesting th a t the parent 
compound is  not the teratogenic species.
1 .5 .1 .5  Rifampin
Rifampin, an a n t ib io t ic ,  causes embryo growth re ta rda tion  
IN VITRO but no increase in  neural tube defects. The add ition  o f a 
l iv e r  microsomal preparation and cofactors to  ra t embryos cu ltu red  in  
the presence o f rifam pin resulted in  increased numbers o f neural tube 
defects which could be re la ted to the abnormalities observed in  
fetuses exposed IN UTERO (Greenaway and Fante l, 1983). These re su lts  
ind ica te  th a t an un iden tified  m etabolite , probably produced by a 
cytochrome P450-mediated reaction , is  the u ltim ate  teratogen.
1.5 .1.6  Procarbazine
Procarbazine is  not teratogenic to  whole cu ltu red ra t  embryos 
IN VITRO unless the serum from pretreated animals or an S9 mix is  
added to  the cu ltu re  medium (Schmid e t a l . 1983).
1.5.2 COMPOUNDS THAT MAY OR MAY NOT REQUIRE BIOACTIVATION
1.5.2.1 Al d r i n
IN VIVO studies? L ite ra tu re  reports ind ica te  th a t both a ld r in  
and i t s  major m etabolite d ie !d r in  are teratogenic but induce d if fe re n t 
malformations (Joy, 1977; Brandt and Hogman, 1980). Studies on the 
teratogenic e ffe c ts  o f a ld r in  and i t s  major metabolites a t equimolar 
doses did not e lucidate whether or not the parent compound was the 
more teratogenic e n tity  (Ottolenghi e t a l . 1973).
IN VITRO stud ies: A ld rin  (F l in t  e t a l . 1984) and d ie ld r in  (F l in t
and Orton, 1985) in h ib it  d if fe re n t ia t io n  o f ra t embryo LB and CNS 
c e lls  in  the absence o f a metabolising system.
1.5 .2 .2  D ie th y ls t ilb e s tro l
IN VIVO stud ies: D ie th y ls t ilb e s tro l (DES) is  a transplacenta l
carcinogen and teratogen. The e ffe c t o f th is  compound appears to  be 
dependent on the amount o f unchanged drug reaching the fe tus 
(S likke r e t a l.  1983; M ille r  e t a l.  1982) although i t  has been 
recently  reported th a t a m etabolite may be the active  species.
(B a lling  e t a l . 1985; G o ttsch ilich  and M etzler, 1984; Maydl and 
M etzler, 1984).
1.5 .2.3 Thaii domi de
The main transform ation o f thalidomide in  the body is  generally 
considered to be spontaneous non-enzymic hydrolysis (Schumacher e t a l . 
1968, 1970). However in  a va rie ty  o f experimental animals, the 
turnover rates in  plasma and muscle tissue and are su rp ris in g ly  
constant, whereas the rates in  the l iv e r  vary considerably.
IN VITRO stud ies: D iffe re n tia tio n  o f ra t limb bud c e lls ,
cu ltu red a t low density was in h ib ite d  by thalidomide in  the absence o f 
a metabolising system (F lin t  e t a l . 1985). Metabolism has been shown 
however to  play a ro le  in  thalidomide c y to to x ic ity . Gordon e t a l . 
(1981) reported tha t only microsomes from a thalidomide sen s itive  
species were capable o f producing to x ic  metabolites (arene oxide) in  
an IN VITRO lymphocyte system. Braun e t a l . (1979, 1982) measured 
adhesion o f mouse ovarian ascites tumour c e lls  and showed th a t 
thalidomide to x ic ity  requires a c tiva tio n  by hepatic microsomes, an 
NADPH-generating system and molecular oxygen, but tha t th is  a c tiv a tio n  
was not species s p e c ific .
1 .5 .2 .4  Pi phenylhydantoi n
Diphenylhydantoin (DPH) is  used in  the treatment o f epilepsy 
despite a syndrome o f drug re la ted teratogenic e ffec ts  described in  
humans (Hansen, 1975; Hansen and Smith, 1976; Hansen e t a l . 1975). A 
dichotomy ex is ts  between the b e lie f th a t DPH i t s e l f  (F inne ll and 
D ilb e r t i ,  1983; Harbison and Becker, 1970, 1971, 1974; Wells e t a l . 
1982; Brown e t a l . 1982, Brown e t a l . 1986) or a m etabo lica lly  derived 
arene oxide intermediate is  the u ltim a te  teratogen (Harbison e t a l . 
1977; Chow and Fischer, 1982; Lu and Miwa, 1980; Martz e t a l.  1977;
Claesen e t a l . 1982, M ilton e t a l . 1985, Pantarotto e t a l . 1982, Wells
ficlAbULIU r ATE Ofr DIPHENYLHYDANTOIN IN VIVO IN THE RAT
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e t a l . 1980, 1983$ Spielberg e t a l . 1981). The metabolic p ro f i le  o f
DPH IN VIVO in the ra t is  represented in  Figure 1.4.
a. Evidence tha t an arene oxide intermediate o f DPH metabolism 
is  the u ltim ate  teratogen.
1. In common w ith other aromatic hydroxylations i t  has been
proposed th a t the hydroxylation o f DPH to p. hydroxy.
DPH observed in  ra t and man, proceeds v ia  an arene oxide
intermediate (Wells e t a l . 1980; Speilberg e t a l . 1981). 
IN VITRO studies have shown th a t an ox ida tive  m etabolite 
o f DPH ( i .e .  NADPH/O2 dependent) ir re v e rs ib ly  binds to  
ra t l iv e r  microsomes; binding could be increased by co­
incubation w ith trich loropropene oxide, an epoxide 
hydratase in h ib ito r ,  and reduced by g lu ta th ione (Martz e t 
a l . 1977; Pantarotto e t a l . 1982; Wells e t a l.  1980) 
suggestive o f formation o f a reactive  arene oxide.
S im ila r find ings were reported using a human leucocyte 
system (Spielberg e t a l . 1981).
2. There is  a co rre la tio n  between the teratogenic e ffe c t 
and amount o f cova lently  bound material in  the 
gestational tissue o f the mouse fo llow ing  adm in is tra tion  
o f T4c-DPH. Coadministration o f trich loropropene oxide 
and DPH doubled the incidence o f c le f t  palate and the 
extent o f covalent binding (Martz e t a l . 1977). This 
experiment cannot be regarded as conclusive as the 
d ihydrodiol metabolite was detected in  maternal f lu id  
samples ind ica tin g  in e ffe c tiv e  in h ib it io n  o f epoxide 
hydratase.
Evidence th a t DPH is  teratogenic per se.
1. Studies on the teratogenic response induced by the major 
metabolites a t equimolar doses in  mouse show th a t the 
maximum response o f any o f the metabolites was only 10% 
o f th a t caused by DPH i t s e l f  (Harbison and Becker, 1974). 
However th is  evidence is  not conclusive as the 
dihydrodiol m etabolite (or the arene oxide interm ediate) 
have not been tested.
2. DPH is  d ire c t ly  in h ib ito ry  in  the micromass c e ll cu ltu re  
system (F lin t  and Orton, 1985) and d ire c t ly  teratogenic 
to  whole mouse embryos (Bruckner e t a l . 1983).
3. DPH to x ic ity  IN VITRO was increased by between 13-80% 
above contro l leve ls  by co-incubation w ith a v a r ie ty  o f 
cytochrome P450 in h ib ito rs  (Brown e t a l . 1986).
4. DPH te ra to g e n ic ity  was increased over 3 -fo ld  in  A/J mice 
fed a p u r if ie d  d ie t compared to standard rodent chow.
This d iffe rence is  associated w ith an increased 
concentration o f DPH in  maternal blood (McClain and Rohrs 
1985).
5. SKF 525A pretreatment increased DPH te ra to g e n ic ity  in  the 
mouse. In th is  experiment, in h ib it io n  o f DPH metabolism 
was indicated by a raised concentration o f DPH and a 
lowered concentration o f p. hydroxy. DPH in  maternal 
plasma, but parent and m etabolite concentrations in  
(whole) fetuses were however unaffected. In con tras t, 
phenobarbitone treatment decreased DPH te ra to g e n ic ity  and 
th is  was associated w ith lowered concentration o f DPH and 
raised concentration o f p. hydroxy. DPH in  the fe tus 
(Harbison and Becker, 1970).
Other theories as to  the u ltim ate teratogenic 
species o f DPH include a DPH-protein complex/modified 
serum prote in (Clapper e t a l . 1985, 1983) or the catechol 
m etabolite (B ill in g s  and Fischer, 19855 B ill in g s  e t a l . 
1985).
1.5 .2 .5  Chlorambucil
Chlorambucil is  a b ifunc tiona l a lk y la tin g  agent (Murphy, 1959) 
and is  teratogenic when added d ire c t ly  to cu ltu res o f whole ra t  
embryos (Mirkes and Greenaway, 1982). The addition o f an S9 mix 
enhances the e ffe c t,  although cytochrome P450 was shown not to be 
involved by se lec tive  in h ib ito r  studies (Mirkes and Greenaway, 1982). 
I t  has been postulated tha t chlorambucil and/or i t s  phenylacetic acid 
m etabolite are responsible fo r  the teratogenic e ffe c ts .
1 .5 .2 .6 Adri amyci n
Adriamycin is  a g lycos id ic  anthracycline a n t ib io t ic  commonly used 
in  the treatment o f a va rie ty  o f tumours. The compound is  teratogenic 
in  the ra t (Thompson e t a l . 1978) but not in  the ra b b it.
Embryotoxicity was observed when cu ltu red ra t embryos were d ire c t ly  
exposed to  adriamycin. The response was enhanced when cu ltu res were 
incubated w ith l iv e r  S9 fra c tio ns  prepared from ra ts  p re-trea ted w ith 
3 methylcholanthrene or A roclor 1254; the add ition  o f S9 from contro l 
or phenobarbitione treated ra ts had no e ffe c t (Fantel e t a l.  1985).
The data suggests adriamycin is  m etabo lica lly  ac tiva ted , although the 
fa ilu re  o f carbon monoxide to in h ib it  the response w ith an S9 fra c tio n  
from 3-methylcholanthrene pretreated animals argues against the 
involvement o f a cytochrome P450-dependent oxygenation.
.3 COMPOUNDS NOT REQUIRING BIOACTIVATION
D irect acting teratogens include*
1 . the metals which form prote in  complexes tha t d ire c t ly  
in te rfe re  w ith c e ll p ro life ra t io n  and organogenesis (M otte t, 
1981).
2. Androgens, oestrogens and other stero ids which bind to  
cy toso lic  receptors and are translocated as complexes in to  
the nucleus where the complex binds to chromatin and 
u ltim a te ly  d isrupts prote in  biosynthesis (Muther e t a l . 1982; 
P ra tt, 1983; Kochaar and Larssan, 1977; Je linek and Peterka, 
1983; Nebert and Jensen, 1979; Denker and P ra tt, 1981; Juchau 
and Fante l, 1981).
3. D-oxo-norleucine which is  thought to act through a receptor 
(P ra tt, 1983).
4. Vitamin A which is  more teratogenic than any o f i t s  
metabolites (Kochaar, 1976; Newall and Edwards, 1981). When 
vitam in A was given a t both teratogenic and non-teratogenic 
doses, the amount o f re tin o l-b in d in g  prote in  trans fe rred  to  
mice fetuses was found to  be d ire c t ly  proportional to  the 
maternal dose o f vitam in A (Kochaar, 1976) s trong ly  
suggesting b io a c tiva tio n  is  not involved.
5. Ethylenethiourea is  teratogenic both o ra lly  and 
subcutaneously in  both ra ts  and hamsters (Khera and Iverson, 
1981; Khera e t a l . 1983; Khera, 1984). In both species, 
metabolic modulation studies showed th a t phenobarbitone 
pretreatment IN VIVO had no e ffe c t on the te ra to g e n ic ity  
whereas SKF525A increased the incidence o f the malformations. 
The increased te ra to g e n ic ity  w ith SKF525A suggests the parent 
compound is  the u ltim a te  teratogen.
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6 . S a lic y lic  acid but not i t s  pu ta tive  metabolites causes 
dysmorphogenesis in  cu ltu red ra t  embryos (Greenaway e t a l . 
1982, 1984). In the same series o f experiments, pre­
incubation o f s a l ic y l ic  acid w ith a va rie ty  o f 
biotransform ing systems fa ile d  to generate a more to x ic  
metabol i te .
7. Cytochalasin D is  d ire c t ly  embryotoxic in  the ra t  embryo 
cu ltu re  system but the e ffe c t is  g rea tly  reduced by 
incubation w ith an Aroclor 1254 pretreated ra t  l iv e r  enzyme 
preparation (Fantel e t a l.  1981), presumably due to  
metabolism o f the active  parent compound.
8 . Ethanol but not i t s  p r in c ip le  m etabolite , acetaldehyde, 
causes fe ta l malformations in  an IN VIVO mouse model 
(Samojlik e t a l . 1969). Furthermore co-treatment w ith  the 
alcohol dehydrogenase in h ib ito r ,  4-methylpyrazole, causes an 
increase in  malformations (Samojlik e t a l.  1969). 
Malformations in  the cu ltu red ra t  embryo are found on d ire c t 
exposure to ethanol, confirm ing th a t the alcohol is  the 
u ltim ate  teratogen (Brown e t a l . 1979; Wynter e t a l . 1984).
9. Acetazolamide is  probably a d ire c t acting teratogen as both 
in tra -am n io tic  or in tra -u te r in e  in je c tio n  o f the compound 
gives r is e  to the typ ica l pattern o f limb abnorm alities 
observed in  the mouse fo llow ing  oral adm in istra tion (S co tt, 
1970; Storch and Layton, 1973).
10. Caffeine is  a d ire c t acting teratogen as co-adm in is tra tion  
w ith p-naphthoflavone to cytochrome P450 inducib le  and non­
inducib le s tra ins  o f mice showed th a t increased drug 
metabolism was concomitant w ith  a decrease in ca ffe ine  
te ra to g e n ic ity  (York e t a l . 1985).
Other Compounds: There remain a group o f compounds which are
teratogenic because o f th e ir  e ffe c ts  on the mother or the 
extra-embryonic tissues ra ther than the embryo i t s e l f .  One 
example is  mi rex which causes a s ig n if ic a n t decrease in  blood 
flow  to the uterus and placenta and th is  is  re la ted  to  i t s  
em bryotoxicity (Buelke-Sam e t a l . 1983). Trypan blue which 
does not cross in to  the embryo (Wilson e t a l . 1959) in h ib its  
v iscera l yo lk  sac lysosomal enzymes, e ffe c t iv e ly  s ta rv ing  the 
embryo o f essential nu trien ts  (Beck and Lloyd, 1966).
The teratogenic a c t iv ity  o f a t lea s t 15 compounds can be 
accounted fo r  by maternal to x ic i ty  caused a t doses where 
te ra to g e n ic ity  was observed (Khera, 1984; Khera, 1985;
Kavlock e t a l . 1985). When these compounds ( in s u lin ,  
tolbutam ide, 6-ami nonicotinamide, morphine sulphate, dinoseb, 
z in c -1 , 10-phenanthroline complex, maytansine, v in c r is t in e , 
nickel ch lo ride , indo le -3 -ace tic  acid , d i- ( 2 -e thy lhexy l) -  
phthalate, phencyclid ine, 2-nitro-p-phenylenediam ine, 
ethylene glycol monomethyl ether and N -phthaloyl-L-glutam ic 
acid) were administered a t non m aternally to x ic  doses, no 
te ra to g en ic ity  was observed.
1.6 . THESIS OBJECTIVE
A rapid and accurate (> 90% p re d ic ta b il i ty  w ith known teratogens) 
teratogen screen has been achieved using cu ltu res o f d if fe re n t ia t in g  
limb bud mesenchyme (LB) and m id-brain c e lls  (CNS) from 13 day post­
conception ra t embryos (F l in t  and Orton, 1984; F l in t  e t a l . 1985).
For th is  p ro je c t I have used these cu ltu res to examine the po ten tia l 
metabolic c a p a b ility  o f ra t embryo c e lls  and the ro le  o f metabolism in  
the IN VITRO teratogenic a c t iv i ty  o f diphenylhydantoin (DPH), a well 
documented and well metabolised (IN VIVO) teratogen.
Five approaches were used:-
( i )  modulation o f cytochrome P450 a c t iv i ty  IN VITRO by co­
incubation w ith a va rie ty  o f in h ib ito rs  a t concentrations 
th a t were non-cyto toxic.
( i i )  induction o f cytochrome P450 a c t iv i ty  by p r io r  
transplacental exposure.
( i i i )  modulation o f the leve l o f the pu ta tive  epoxide m etabo lite .
( i v ) immuno-cytochemical s ta in ing  o f the c e lls  w ith both 
monoclonal and polyclonal cytochrome P450 antibod ies.
(v) id e n t if ic a t io n  o f the metabolites formed by the c e lls  
themselves IN VITRO.
The ob jective  o f my thesis is  to  show th a t ra t embryo c e lls  
IN VITRO have a metabolic ca p a b ility  and th a t e ith e r th is  inherent or 
drug induced capacity plays an important ro le  in  chemical 
teratogenesis.
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2.1 MATERIALS
2.1.1 COMPOUNDS
Test compounds o f the highest p u r ity  commercially ava ilab le  were 
used. Diphenylhydantoin, e l l ip t ic in e ,  g lu ta th ione , saccharin, 
c im etid ine , sodium s a lic y la te , inosine, 3-methylcholanthrene, 
phenobarbitone and p-naphthoflavone were obtained from Sigma Chemical 
Company, Poole, Dorset. U.K. Benzimidazole, metyrapone and 
a-naphthoflavone were obtained from Fluka, Flurochem, Glossop, 
Derbyshire. U.K. m.hydroxy. DPH, p. hydroxy. DPH, trich loropropene 
oxide, 5-p-methyl phenyl-5 phenyl hydantoin, 5-p-hydroxyphenyl-5-p- 
to ly lhydan to in  and 5-phenyl-5-hydroxyhydantoin were obtained from 
A ldrich  Chemical Company, G illingham, Dorset, U.K. N -acety l-L- 
cysteine was obtained from B.D.H. Chemicals L td ., Speke, L ive rpoo l, 
U.K. Cyclophosphamide was obtained from Koch-Light Laboratories 
Colnbrook, Bucks, U.K. 5 -cyc lobu ty l, 5-phenylhydantoin was obtained 
from Lancaster Synthesis L td ., White Lund, Morecambe, U.K. 5, 
cyclohexyl, 5-phenylhydantoin, 5-cyclopentyl -5-phenylhydantoin, 
5,5-dicyclopropylhydantoin and 5-cyclopropyl-5 phenyl hydantoin were 
obtained from I.C .N . Pharmaceuticals Inc L ife  Sciences Group, 
P lainview, New York. U.S.A. 5 - [r in g -2 -^ 4C]-phenobarbitone was obtained 
from the Radiochemical Centre, Amersham, Bucks, U.K. 5 ,5 -[4 -^ 4C]- 
diphenylhydantoin and 3 - [6 - l4C]-methylcholanthrene were obtained from 
New England Nuclear, Du Pont (UK) Ltd, Southampton, U.K. SKF525A was 
a g i f t  from Smith K line and French Labs Ltd , Welwyn Garden C ity ,
Herts, U.K. R an itid ine hydrochloride was a g i f t  from the Glaxo 
Research Group, Ware, Herts, UK. Diphenylhydantoic acid , hydantoin,
5-5 dimethylhydantoin, 5-phenylhydantoin, 5,5. p-d ich lorod iphenyl- 
hydantoin, 5-p-hydroxyphenylhydantoin, 5-methylhydantoin, 5-methyl-5 - 
p-chlorophenylhydantoin , 5-ami no-5 phenylhydantoin, 5 -e th y l-5 
phenylhydantoin, 5-phenyl-p-aminohydantoin, 5-phenyl-p- 
chlorohydantoin, 5-hydroxy-5-methylhydantoin, 5-p.m- 
dichiorophenylhydantoin, 5-o-hydroxyphenylhydantoin, 5-ethanoic acid 
hydantoin, 5-5 diphenyl-p-dihydroxyhydantoin and 5 phenyl-5 - 
hydroxyhydantoin were synthesised a t ICI Pharmaceuticals D iv is io n . 
Culture media and sera were obtained from Gibco B io cu lt, Pa is ley, 
Scotland.
2.1.2 ANTIBODIES
Pre-immune goat sera and horseradish peroxidase lab e lled  a n t i-  
species IgG antibodies were obtained from Miles S c ie n t if ic ,  Slough, 
Bucks., England. The cytochrome P450 antibodies were g i f ts  from 
Dr G G Gibson, Biochemistry Department, U n ivers ity  o f Surrey, England, 
Dr C R Wolf, Department o f Molecular Pharmacology and Drug Metabolism, 
I.C .R .F ., Western General H osp ita l, Edinburgh, Scotland and 
Professor D Davies and Dr A Boobis, Royal Postgraduate Medical School, 
Hammersmith Hospital London/CTL, M acclesfie ld . The types o f 
antibodies are described in  Table: 2.1.
TABLE 2 .1 .
ORIGINS OF CYTOCHROME P450 ANTIBODIES
I NAME AND TYPE OF ANTIBODY (Ab) TISSUE SOURCE 
OF ANTIGEN
SPECIES IN I 
WHICH Ab I 
WAS RAISED |
1 Surrey P450 (form alised as 
1 Levin form 'b ' ) * ,  polyclonal
Phenobarbitone 
induced Wistar 
ra t l iv e r
ra b b it I
1 W olf's PB3 (form alised as 
1 Levin form 'b ') * ,  polyclonal
ra b b it I
1 W olf's PB] (form alised as 
1 Waxman 'P B ]') polyclonal
Phenobarbitone 
induced Sprague- 
Dawley ra t l iv e r
1 W olf's PB2 
1 polyclonal
1 W olf's /MC] (form alised 
1 as Levin form 'd ') *  polyclonal 3-methylcholanthrene 
induced Sprague-
ra b b it I
1 W olf's /MC2 (form alised 
1 as Levin form 'e ') *  polyclonal
Dawley ra t l iv e r
1 CTL/Hammersmith 3 :4 :2 , 
1 Monoclonal
p-naphthoflavone 
mouse spleen
mouse I
1 Surrey P452, po lyc lona l** C lo fib ra te  induced 
W istar ra t l iv e r  P452
sheep I
* -  Ryan e t. a l . (1982) and Wolf e t. a l . (1984)
**  -  Gibson e t. a l . (1982)
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2.2 METHODS
2.2.1 CULTURE TECHNIQUE 
Animals
S u ffic ie n t v irg in  A lderley Park a lb ino ra ts  were mated to  provide 
s ix  successful pregnancies per experiment. Conception was determined 
by the vaginal smear technique. The pregnant animals were maintained 
u n t il the 13th day a fte r  noting a p o s itive  vaginal smear. The animals 
weigh 250-350 g on th is  day.
Euthanasia
Animals were sa c rifice d  by exposure to  CO2 .
Equipment fo r  aseptic removal o f the uterus
S te rilis e d  b lun t and sharp ended scissors.
Pair o f forceps.
4" s te r i le  glass or p la s tic  p e tr i dishes.
Method
The dead animal was immersed in  a bath o f d ilu te d  Savlon* 
(approximately 10 ml concentrate in  500 ml water) p r io r  to  d issec tion . 
The animal was la id  on a clean surface covered w ith absorbant paper and 
an in c is ion  made w ith b lun t scissors through the body w a ll, but not 
entering the peritoneum. The hole was expanded by re tra c tio n . A
* Savlon is  a trademark, the property o f Imperial Chemical Industries  
PLC.
fu rth e r in c is ion  was made in  the peritoneum using sharp scissors 
and forceps. The uterus was then located in  the lower abdomen and 
removed using scissors and forceps w ith as l i t t l e  adherent fa t  as 
possib le. I t  was then transfe rred  ra p id ly  to a dry s te r i le  p e tr i 
dish.
Embryo dissection equipment
Laminar flow  cabinet.
Zoom stereo d issecting microscope w ith transm itted and inc iden t 
illu m in a tio n .
1 p a ir o f MC19 Pascheff W olff m icro-scissors. (M icrodissection 
equipment: Moria-Dugast, P a ris ).
1 MCI7 d r i l le d  spatula.
2 pa irs o f sharpened Mo 5 Watchmakers forceps.
4" glass or p e tr i dishes.
Solutions
E a rl's  Balanced S a lt Solution (Eagles m odifica tion  - EBBS).
50% V/V horse serum and EBSS (HS-EBSS).
A ll so lu tions were s te r i le  and used w ith in  twelve months or otherwise 
discarded.
fS S S S BS^
CMF : 20 mins /3 7 °  C 
1% Trypsin in CMF (v/v) :  
20 mins /  37 ° C
2 hours
Figure 2.1 Micromass cu ltu re  technique
A ll procedures were undertaken in  a lam inar flow  cab inet, the surfaces
o f which were s te r ilis e d  by wiping down w ith  tissues soaked in  70% 
a lcohol. U teri were washed through three changes o f EBSS in  p e tr i 
dishes. The fo llow ing  procedures took place using the d issecting  
microscope a t x6 m agnifica tion . Each conceptus consis ting  o f the 
embryo plus extra-embryonic membrane was removed to  EBSS by tea ring  a 
small hole in  the wall o f the uterus w ith  Watchmakers forceps. A fte r 
a l l  the conceptuses were removed from a uterus, the remaining tissue
was discarded. Conceptuses pooled from a l l  s ix  animals were
transfe rred using the d r il le d  spatula to fresh HS/EBSS in  a p e tr i d ish . 
HS/EBSS was warmed in  a water bath, to  approximately 37°C. Extra- 
embryonic membranes were removed w ith watchmakers forceps and 
discarded. The embryos were co llec ted  to  one side o f the p e tr i d ish . 
Approximately 1 0 - 1 2  embryos are found per uterus. At th is  stage o f
development, embryos have 34 -  36 somites. Small embryos having 
less than 34 somites and large embryos having more than 36 somites 
were re jec ted . The mesencephalon and fo re -lim b bud were removed 
from the acceptable embryos using m icrodissection scissors and 
watchmakers forceps. See Figure 2.1.
Processing o f tissues p r io r  to  cu ltu re  o f disaggregated c e lls  
equipment
S te r ile  glass Pasteur p ipe ttes .
S te r ile  glass p ipettes w ith 0.7 mm t ip  diameter, produced by 
drawing conventional pasteur p ipettes in  a bunsen flame.
Test tube rack.
S te r ile  capped p la s tic  te s t tubes, conical bottom.
S te r ile  universal containers.
S te r ile  disposable 10 ml syringes w ith  removable plungers.
S te r ile  sta in less steel Swinney f i l t e r  holders (Mi11ip o re ) w ith 10 urn 
mesh nylon f i l t e r  (Simon) in  place.
Modified Fuchs-Rosenthal Haemocytometer.
Benchtop cen trifuge  (capable o f 1000 rpm).
Solutions
Calcium and magnesium-free E a rl's  Balanced S a lt Solution (CMF- 
Gibco). 1 % so lu tion  o f tryp s in  (D ifco , 1:250) prepared by s t i r r in g  fo r  
30 - 60 minutes in  CMF and then f i l t e r in g  through a mi 11 ex GS 0.2 urn 
pore f i l t e r .  Hams F12 cu ltu re  medium w ith supplements o f 10% fe ta l 
c a lf  serum, L-glutamine (584.6 mg/1), p e n ic i l l in  (106 iu per l i t r e )
and streptomycin (100 mg/1). A ll so lu tions were used w ith in  twelve 
months.
Method
Tissues were transfe rred  by Pasteur p ipe tte  to  separately lab e lled  
te s t tubes. The HS/EBSS was aspirated o f f  w ith a Pasteur p ip e tte  and 
tissues washed three times w ith  CMF. About 15 ml o f CMF was kept in  a 
s te r i le  universal container fo r  th is  purpose. The tubes were incubated 
fo r  20 minutes a t 37°C. Trypsin so lu tion  was followed by a b r ie f  wash 
in  CMF which was immediately replaced by 1.3 ml o f the complete Ham's 
medium (CM). Tissue fragments were then disaggregated in to  th e ir  
component c e lls  by repeated asp ira tions through the 0.7 mm in te rn a l t ip  
diameter Pasteur p ipe tte  (15 -  20 tim es). Care was taken not to  make a 
fro th . The re su ltin g  c e ll suspension was then poured in to  a 10 ml 
disposable syringe w ith a Swinney f i l t e r  holder attached. Replacing 
the plunger forces the suspension though the 10 urn mesh nylon f i l t e r  
and in to  a fresh te s t tube. A suspension o f s ing le c e lls  was thus 
obtained. 1ml o f th is  suspension was transfe rred to  a fresh te s t tube. 
The small amount o f remaining suspension was d ilu te d  1:9 w ith  CM and 
counted w ith the Fuchs-Rosenthal Haemocytometer.
The estimated c e ll concentration was used to  ca lcu la te  the amount 
o f medium required to produce in  the case o f m idbrain, 5 x 10^ c e lls  
per ml, and in  the case o f lim b, 2 x 10? c e lls  per ml. I f  these f in a l 
concentrations can only be acheived in  volumes o f less than 1 ml 
cu ltu re  medium, the 1 ml o f suspended c e lls  was then cen trifuged a t 
1000 rpm fo r f iv e  minutes, the supernatant removed and the c e lls  re -
suspended in  the calculated volume o f fresh medium. Otherwise, excess 
fresh medium was added to  the o r ig in a l 1 ml to  give the appropriate 
f in a l c e ll concentration.
Culture preparation equipment
Eppendorf "M u ltipe tte " 4780.
Eppendorf "Combitips" (s te r il is e d )  (500 ul s ize ).
Falcon Primaria (3801) s te r i le  p la s tic  p e tr i dishes (35 mm diam eter).
Method
The c e ll suspension was drawn up in to  a 500 ul "Combitip" f i t t e d  to  
the "M u ltipe tte " and delivered in  10 ul a liquo ts  to  35 mm s te r i le  
p la s tic  disposable p e tr i dishes.
Cells were allowed to  s e tt le  fo r  two hours a t 37°C, forming 
c irc u la r  ce ll islands (6-8 mm) the cu ltu re  dishes f i l l e d  to  a f in a l 
volume o f 2 ml w ith  CM and other supplements described below. Five (10 
u l ) a liquo ts  o f midbrain and a t le a s t three (10 u l) a liquo ts  o f limb 
c e ll suspension were delivered to  each dish. (See Figure 2 .1 .)
S u ffic ie n t dishes were prepared fo r  assessment o f a concentration 
response curve fo r  the tested compound, (usua lly  7 dishes fo r  each c e ll 
type).
One midbrain and one limb bud dish receive veh ic le contro l and each 
concentration o f the compound in  2 ml cu ltu re  medium. The medium was 
not changed fo r  the fo llow ing  f iv e  days o f cu ltu re . Culture conditions 
were 37°C, 5% C02* 95% a ir  and 100% re la tiv e  hum idity.
Formulation o f stock so lu tions o f te s t compounds
Compound or in h ib ito rs  were formulated in i t i a l l y  as a concentrated 
stock so lu tion  in  e ith e r dimethyl sulphoxide (DNISO), ethanol (EtOH) or 
E arle 's  Balanced S a lt so lu tion  (EBSS) according to  s o lu b i l i ty .  The 
f in a l concentration o f these vehicles in  cu ltu re  medium were* DMSO,
0.5% V/V and 1.0% V/V EtOH or EBSS to  35 mm p e tr i dishes (Falcon) 
containing 2 ml o f cu ltu re  medium followed by a g ita tio n . I f  the 
compound was inso lub le  ( i .e .  p re c ip ita te s  out) the concentrated stock 
was d ilu te d  u n t il s o lu b il i ty  in  cu ltu re  medium was achieved. A series 
o f d ilu tio n s  o f the stock so lu tions were then prepared to  give the 
desired f in a l concentration range in  cu ltu re  medium.
Culture medium was brought to  37°c and gassed w ith 5% C02, 95% a ir  
in  s te r i le  beakers in  a flow  CO2 Incubator (Flow Laboratories, Irv in e , 
Scotland). S u ff ic ie n t medium and beakers were made ready to  include 
the range o f concentrations o f compound plus a beaker in  a s te r i le  
laminar flow cabinet and medium was s t ir re d  on a magnetic s t i r r e r .
F ixa tion and s ta in ing  o f cu ltu res a fte r  5 days o f incubation
1. Midbrain cu ltu res
Medium was removed from cu ltu re  dishes by asp ira tion  and replaced 
w ith about 1 ml o f 10% formaldehyde so lu tion  per d ish. F ixa tive  was 
removed w ith running tap water a fte r  a minimum o f twenty minutes 
f ix a t io n . Cells were then stained fo r  one to  three minutes w ith  
haematoxylin followed by washing under w ith tap water. A ll the 
cu ltu res were a ir  dried .
2. Limb cu ltu res
A fte r asp ira tion  o f the medium, cu ltu res were fixed  w ith 10% 
formaldehyde containing 1% ce ty lpyrid in ium  ch lo ride  fo r  a minimum o f
twenty minutes. Cultures were then l e f t  fo r  1 hour in  3% ace tic  acid
and stained w ith 1% a lc ian blue in  0.1 N hydrochloric acid (pH 1.0) 
fo r  a minimum o f two hours. A fte r washing w ith tap water, the 
cu ltu res were a ir  dried .
Measurement o f c e ll d if fe re n t ia t io n  w ith an automated colony
counter
Equipment
Image analyser. AMS 40-10. (A na ly tica l Measuring Systems L td ., 
Saffron Walden, Essex, UK.).
Method
Operation o f the colony counter was described in  the manual 
supplied by the manufacturer. Each c e ll is land was positioned
under the lens o f the te le v is io n  camera so th a t i t s  image was
presented on the TV monitor. The colony counter was then set to count 
the number o f foc i o f darkly s ta in ing  c e lls  which correspond in  
midbrain cu ltu res to neurones and in  limb cu ltu res to chondrocytes. 
These d iffe re n tia te d  c e ll types were not present in  the in i t i a l  c e ll 
suspension prepared from the embryo but have d iffe re n tia te d  in  cu ltu re  
( F l in t ,  1983; F l in t  and Orton, 1984), thus p a ra llin g  the IN VIVO 
development p ro f i le .
By counting the number o f darkly s ta in ing  fo c i,  an estimate was 
made o f the to ta l population o f c e lls  which have d iffe re n tia te d
during the period o f cu ltu re  (F l in t  e t a l , 1984).
Analysis o f resu lts
The mean and standard deviation o f the number o f d iffe re n tia te d  
foc i per ce ll is land was calcu la ted fo r  con tro ls  and each 
concentration o f compound. Results were p lo tted  and the concentration 
(IC50) o f compound in h ib it in g  d if fe re n t ia t io n  by 50% o f contro l leve l 
was calcu la ted by in te rp o la tio n , or w ith the in h ib ito rs , the maximum 
concentration a t which no e ffe c t on d if fe re n t ia t io n  was observed 
(N.C.C.). A ll data analyses comparing treatment groups w ith th e ir  
concurrent con tro ls  were performed using Student's t - te s t .
Coincubation w ith in h ib ito rs
Once the N.C.C. leve ls  were determined, in h ib ito rs  and te s t 
compound were coincubated over the 5 day cu ltu re  period in  the same 
dish. The volumes o f veh ic le were appropria te ly  a lte red  to compensate 
fo r  two compounds in  the same dish.
2 .2 .2 . TERATOLOGY STUDY
Aider!ey Park s tra in  alb ino female ra ts  (200-250g) were mated and 
the f i r s t  day o f the appearance o f a vaginal plug taken as day 1 o f 
pregnancy. Dams were randomised in to  three groups o f ten and maternal 
weight gain throughout pregnancy monitored. The dosing regimen was as 
fo llow s; Group I - Tween 80 (so lvent ve h ic le ), Group I I  -  150 mg/kg 
DPH in  Tween 80, Group I I I  -  300 mg/kg DPH in  Tween 80 (dosing
solu tions fo r  Groups I I  and I I I  v/ere b a ll-m ilie d  fo r  24 hours before 
dosing commenced). Dosing was by oral gavage a t a volume o f 10 ml/kg 
days 10-15 (in c lu s ive ) o f gestation. The maternal weight gain during 
th is  dosing period was calcu la ted separately from the to ta l maternal 
weight gain during gestation and c lin ic a l observations were made 
throughout pregnancy. Animals were sa c rif ice d  on day 20 o f gestation 
(one day p r io r  to term) and each uterus was scored fo r  number o f l iv e  
fetuses, resorp tions, im plantation s ite s , corpora lu tea and pre­
im plantation losses. Other parameters measured were the ra t io  o f male 
to  female o ff-s p r in g , l i t t e r  mean and fe ta l body and placenta weight, 
empty uterus weight and amniotic f lu id  per fe tus . C lin ica l 
observations o f the dams were made throughout gestation and necropsy 
observations made fo r  each dam a t the term ination o f the study.
2.2.3 PLACENTAL TRANSFER OF RADIOLABELLED COMPOUNDS 
14c -  DPH
24 pregnant female Aider!ey Park s tra in  ra ts  (250-350g) were 
in jec ted  i .p .  w ith 100 mg/kg DPH (in  Tween 80) contain ing 5.26% W/V 
l^c-DPH according to  i t s  weight. The dosing so lu tion  was b a ll-m ilie d  
fo r  24 hours p r io r  to in je c tio n  (ne ithe r pH nor composition was 
a lte red  during th is  preparation).
The dams were in jec ted  a t 3 pm on day 12 o f gestation so th a t 18 
hours a fte r  the in je c tio n  the dams were 13.5 days pregnant ( th is  
protocol is  in  accordance w ith the IN VIVO/IN VITRO method o f F l in t  
e t. a l.  1984). Groups o f three animals were sac rifice d  a t 
^ , 1 , 2 ,3 ,4 ,5 ,6 , and 18 hours post in je c tio n  and blood samples from each
dam were taken and plasma samples prepared. The number, dry weight 
and prote in  content o f embryos per uterus were recorded.
Pooled, dry embryos from each uterus were oxidised in  a Packard 
tr i- c a rb  sample ox id ise r model 3375 and 14 CO2 co llec ted  in to  12 ml 
optisorb s c in t i l la t io n  f lu id .  The ra d io a c tiv ity  in  these samples and 
100 pi a liquo ts  o f maternal plasma was then determined on an 
Intertechnique S.L.30 liq u id  s c in t i l la t io n  counter. The pg/ml bound 
DPH to  maternal plasma and ng/mg pro te in  bound DPH in embryos was 
calculated by comparison o f the ra d io a c tiv ity  in  the samples to  a 
reference sample o f known weight o f 14c.DPH.
14c-Phenobarbi tone
The inducing dosing regimen was followed as per section 2 .2 .4 . 
0.1% PB in  drink ing water was supplied ad lib itu m  and supplemented 
w ith 14c~pb so th a t each dam received over a 10 day period 
(gestational days 4-13) 0.75 pCi/day. Maternal plasma and oxid ised 
embryo samples were prepared as described e a r lie r  and the 
concentration o f bound 14c-PB calcu la ted against a reference sample 
(as fo r 14c-DPH.).
14c-3-Methylcholanthrene
The dosing regimen in  section 2 .2 .4 . was fo llowed, each dam 
received 3.3 pCi/day 14c-3MC in a 25 mg/kg, i .p .  in je c tio n  on 
gestational days 10, 11 and 12. Samples o f maternal plasma and 
oxidised embryos were prepared as previously described and the 
concentration o f bound 3MC calcu la ted against a reference sample (as 
fo r  DPH).
2 .2 .4 . TRANSPLACENTAL INDUCTION OF FETAL CYTOCHROME P450
The maternal dosing regimens fo r  transplacental induction o f 
embryo c e lls  were as fo llo w s :-
1) p-naphthoflavone, 35 mg/kg in  arachis o i l ,  dosing volume 5 
ml/kg given in tra -p e r ito n e a lly  on days 10, 11, 12 gesta tion .
2) 3-methylcholanthrene, 25 mg/kg in  arachis o i l ,  dosing volume 5
ml/kg given in tra -p e r ito n e a lly  on days 10, 11, 12 gesta tion .
3) Sodium phenobarbitone given a t 0.1% (w/v) in  the d rink ing  water 
ad lib itu m  on days 4 -13 o f gestation.
2 .2 .5 . IMMUNOCYTOCHEMICAL STAINING TECHNIQUE FOR CYTOCHROME P450
The method used to  id e n tify  the presence and isoenzymes o f 
cytochrome P450s was the peroxidase anti-peroxidase (PAP) method 
adapted from Wolf e t. a l . (1984).
Method
A ir  dried cryosat sections o f whole embryos a t gestational day 18 
or ce ll cu ltu res o f LB and CNS grown on s te r i le  p e tr i dishes were 
washed three times fo r  5 minutes in  excess 0.15 M sa line conta in ing 
0.05M, phosphate bu ffe r pH 7.2. Samples were then dehydrated by 
passage through graded aqueous methanol (v /v ) (50%, 75%, 95%) and the 
endogenous peroxidases in h ib ite d  by treatment w ith 0 .01% hydrogen 
peroxide in  95% aqueous methanol fo r  20 minutes. Samples were then 
rehydrated by passage through graded methanol (95%, 75%, 50%) and 
washed again in  PBS followed by PBS supplemented w ith 1% bovine serum 
albumin (BSA) and then incubated in  non-immune goat serum (d ilu te d
1*30 w ith PB,1% BSA) in  order to  saturate the antigen binding s ite s . 
Samples were then incubated w ith the P450 antibodies or pre-immune 
sera fo r  24 hrs a t 4°C followed by treatment w ith horseradish 
peroxidase labe lled  a n t i-  species IgG (a t 1*20 d ilu t io n  in  PBS, 1%
BSA) fo r  20 minutes a t room temperature. Unreacted antibodies were 
washed o f f  by three successive washings fo r  5 minutes each in  PBS, 1% 
BSA., and a fou rth  wash in  0.05M T ris  b u ffe r pH 7.6. Peroxidase 
a c t iv ity  was revealed by incubation fo r  20 minutes w ith 3,3 
diami nobenzidine 0.05M pH 7.6 and 0.01% H2O2 . A fte r washing in  T r is  
b u ffe r, samples were counterstained w ith haematoxylin, dehydrated and 
mounted under cover s lip s .
Control incubations were performed by su b s titu tio n  o f the f i r s t  
anti-serum w ith pre-immune goat serum.
Figure 2.2 shows the peroxidase/anti peroxidase immunocytochemical 
s ta in ing  technique schem atically.
2 .2 .5 . IMMUNOLOGICAL ASSAY FOR EMBRYO CYTOCHROME P450 BY WESTERN BLOT
E lectrophoretic B lo ttin g  Procedure 
This method is  an adaptation o f Towbin e t. a l . (1979) and is  
cu rren tly  used a t Dr C.R.Wolf's lab (Im perial Cancer Research Fund, 
Edinburgh), where th is  work was ca rried  out.
Protein estimations (Lowry e t. a l . 1951) were carried  out on ra t  
LB and CNS c e lls  a fte r  the 5 day cu ltu re  period. The cu ltu res were 
obtained from e ith e r untreated or p-naphthoflavone - induced dams.
1 mg prote in  samples d ilu te d  1*1 w ith  'b o ilin g  mix' (10% stacking ge l, 
2% sodium dodecyl sulphate, 5% p-mercaptoethanol, 10% glycero l and
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0.005% bromophenol blue (W/V)), were subjected to e lectrophoresis.
The conditions fo r  electrophoresis were as fo llo w s*- Separating gel = 
9% polyacrylamide, separating gel = 4.5% polyacrylamide, e lectrode 
bu ffe r = 25 mM TMS 0.192 mM glycine/20% (V/V) methanol a t pH 8.3.
Gels were run a t 20 mA/gel when the dye fro n t was in  the stacking ge l, 
and a t 30 mA/gel when in  the separating ge l. The proteins were then 
transfe rred  to  n itro c e llu lo s e  sheets as fo llow s. A sheet o f 
n itro c e llu lo s e  (0.45 pm pore size in  r o l l  form, Mi 11ip o re ) was b r ie f ly  
wetted w ith water and la id  on a scouring pad (Scotch B r ite ) which was 
supported by a s t i f f  p la s tic  g r id . The gel to  be b lo tte d  was put on 
the n itro c e llu lo s e  sheet and care taken to  remove a ll a ir  bubbles. A 
second pad and p la s tic  g rid  were added and the 'sandwich' s lo tte d  in to  
the b lo tt in g  apparatus w ith the n itro c e llu lo s e  sheet nearest the 
anode. The e le c tro b lo t apparatus was f i l l e d  w ith bu ffe r (20 mM 
disodium phosphate 20% (V/V) methanol) and attached to  a power pack 
source o f 0.25A overnight.
S taining fo r  Protein
The b lo t was stained w ith ami do black (0.1% in  45% methanol/10% 
acetic  acid) and destained w ith 90% methanol/2% acetic  acid to  ensure 
complete tra ns fe r o f prote in  to  the n itro c e llu lo s e  sheet.
Immunological Detection o f Proteins on N itroce llu lose
The e lectrophore tic  b lo ts  were soaked in  3% bovine serum albumin 
in  sa line (0.9% NaCl, lOmM TRIS-HC1, pH 7.9) fo r  1-2 hours a t room 
temperature to saturate additiona l p ro te in  binding s ite s . The b lo ts  
were then rinsed in  sa line before incubation w ith the cytochrome
P450 antibodies (see tab le  2.1 fo r  legends), appropria te ly d ilu te d  
w ith buffered sa line . The sheets were then washed in  sa line  (about 4 
changes during 1 hour) and incubated fo r  1 hour w ith 125j_tabeled 
pro te in  A (0.1 pCi/ml buffered sa line ) and washed u n til the rinses 
showed no ra d io a c tiv ity . The sheets were then incubated w ith the 
second (in d ica to r) antibody d irected against the immunoglobulins from 
the f i r s t  an ti serum (anti-species IgG horseradish peroxidase labe led ). 
F in a lly  the substrate, (3% 4-ch loro-l-naphtho l in  methanol, T r is  
buffered sa line and H2O2 a t a ra t io  o f Is 6 : 2x l0“ 6 ) was added and the 
bands allowed to  develop. The reaction was stopped by rin s in g  in  
d is t i l le d  water. The sheets were then thoroughly a ir -d r ie d  before 
autoradiographs were made by exposure o f the sheets on Kodak X-Omat R 
f ilm  fo r  6 days.
2.2 .7 COVALEMT BINDING OF ^C-DPH TO LB AND CHS CELL PROTEINS
The arene oxide is  the pu ta tive  teratogen o f DPH, formed IN VIVO 
by a cytochrome P450 mediated reaction (see Chapter 1 .5 .2 .4 ). This 
reactive intermediate binds to  c e llu la r  proteins ir re v e rs ib ly .  This 
experiment tests  the hypothesis th a t the arene oxide is  formed 
IN VITRO by embryo c e lls  and by modulation o f the pathway may 
e lucidate  the ro le  the o f arene oxide in  the metabolism o f DPH.
DPH was added a t 60 pg/ml cu ltu re  medium (w ith 0.4 pCi 
DPH/dish). The amount o f cova lently  bound rad ioactive m aterial to  
e ith e r LB or CNS cu ltu res was determined in  1) untreated c e lls  2) 
c e lls  derived from p-naphthoflavone induced mothers 3) c e lls  co-
incubated over a f iv e  day period w ith a non-cytotoxic concentration o f 
the epoxide hydratase in h ib ito r ,  trich loropropene oxide 4) c e lls  co­
incubated over a f iv e  day period w ith  20 pg/ml cu ltu re  medium DPH and 
benzimidazole, a cytochrome P450 in h ib ito r ,  also a t non-cytotoxic 
concentration. 5) untreated c e lls  w ith d if fe re n t concentrations o f 
DPH.
The amount o f non-specific/background binding was tested by co- 
incubating untreated LB and CNS c e lls  a fte r  the f iv e  days o f cu ltu re
fo r  30 minutes w ith 0.4 pCi ^C-DPH per d ish.
Method
A fte r the f iv e  day incubation period w ith  ra d io -la b e lle d  compound, 
(0.4 pC i/d ish) the cu ltu re  medium was removed from LB and CNS c e lls .  
Cells were then washed three times in  E arle 's  balanced s a lt  so lu tion  
w ithout phenol red in  calcium and magnesium free so lu tion . The c e lls  
were then incubated a t 37°C fo r  30 mins in  E arle 's  so lu tion  conta in ing 
0.1% (w/v) ethylene diamine te tra a ce tic  acid (EDTA), to  loosen the 
c e lls  from the bottom o f the p e tr i dishes. Cells were then scraped 
o f f  the bottom o f the p e tr i dishes w ith a spatula and centrifuged a t
2,000 r.p.m . fo r  5 minutes (MSE bench ce n tr ifu g e ). The supernatant 
was removed and 3 ml o f 20% (w/v) tr ic h lo ro a c e tic  acid (TCA) was added 
and the c e lls  mixed w e ll. The p rec ip ita te d  DNA was co llec ted  by 
cen trifu g a tio n  a t 2,000 r.p.m . fo r  15 minutes. The p e lle t  was washed
twice more w ith 20% TCA and then washed 6 times in  8 ml o f a 4:1
methanol»water so lu tio n , the p e lle t being resuspended and reco llec ted
by cen trifu g a tio n  inbetween each wash. The p e lle t was then dissolved 
in  1 ml o f 1 N NaOH, and a 0.1 ml a liq u o t removed fo r  p ro te in  
determination (Lowry e t. a l . 1951). The remainder (0.9 ml) was 
counted in  10 ml Readisolve E.P. (Beckman) in  a s c in t i l la t io n  counter 
(In tertechn ique) to determine pro te in  bound ra d io a c tiv ity .
This procedure is  a m odifica tion  o f the methods used by Blake and 
Martz (1980), Martz e t. a l . (1977) and Orton and Lowery (1981).
2.2.8 EXTRACTION AND IDENTIFICATION OF DIPHENYLHYDANTOIN METABOLITES
Embryo c e lls  derived from untreated mothers were coincubated w ith 
60 pg/ml cu ltu re  medium DPH supplemented w ith (0.4  pC i/d ish)
fo r  the 5 day cu ltu re  period. Cells and cu ltu re  medium were then 
analysed to see i f  the c e lls  themselves IN VITRO could metabolise 
DPH.
Extraction Method
The cu ltu re  medium from each c e ll type was removed and pooled 
a fte r  the 5 day period so tha t to ta l volume was approximately 12 m l. 
The c e lls  were then washed twice in  excess E arle 's  balanced s a lt  
so lu tion  w ithout phenol red in  calcium and magnesium free so lu tio n . 
Cells were then removed from the bottom o f the p e tr i dishes (as 
described in  section 2.2.7) and LB c e lls  or CNS c e lls  pooled 
separately. The c e ll samples were then sonicated by a model W.375 
sonicator fo r  5 seconds a t 50% duty cyc le , scale set 3. The co llec ted  
pooled media from each c e ll type and the two d if fe re n t c e ll types were 
then passed through ind iv idua l sep-pack Cl 8-ca rtridges (Waters
Associates) pre-wetted w ith methanol. The metabolites were then 
eluted w ith 2 x 5 ml methanol, and the methanol was evaporated o f f  
under oxygen free n itrogen.
Id e n tif ic a t io n  o f metabolites by high pressure liq u id
chromatography
Sample residues were reconstitu ted  in  a small volume o f methanol 
and in jec ted  on to  a spherisorb 5 n i t r i l e  reversed phase column, 25 cm 
x 4.6 mm (Technicol L td , S tockport, Cheshire); mobile phase - methanol 
: water (5 :95); Flow-2 ml/m in; chart speed -  5 mm/min; range-0.64; 
scan-10 mV; wavelength-210 nm; instrument-Pye-Unicam w ith  an LC-UV 
detector. (Chow e t. a l . 1980, Chow and Fischer 1981). Fractions 
corresponding to  the e lu tion  times o f standard DPH (and i t s  
m etabolites) were co llec ted  (a t 1 min in te rv a ls ) and ra d io a c tiv ity  
estimated by l iq u id  s c in t i l la t io n  counting (section 2 .2 .7 ).
A na lytica l th in  layer chromatography (TLC)
A reference standard o f ^C-DPH, the p. hydroxy, and m. hydroxy, 
m etabolites, r ing  opened acid m etabolite and c e ll and cu ltu re  medium 
samples were applied to  a s i l ic a  gel GF (250p) p la te  (Analtech) and 
developed in  chloroform : methanol *. g la c ia l acetic acid (85 : 10 : 5) 
(Chang e t al 1970). Plates were examined under 254 and 366 nm U.V. 
l ig h t  and then spotted w ith ^ C -  rad ioactive  ink to  aid loca tion  o f 
the autoradiograph. Plates were maintained in  complete absence o f 
l ig h t  under a photographic p la te  (18 x 24 cm Agfa-Gevaert photographic 
p la tes, NDT Systems) fo r  4-7 days, then the photographic p lates were
removed and processed (4 min in  fixe r?  30 seconds in ace tic  acid? 4 
minutes in  developer so lu tio n s ). The spot o f rad ioactive  ink was 
lined  up w ith the spot on the T.L.C. p la te and the re la tiv e  Rf values 
fo r  DPH and i t s  metabolites ca lcu la ted .
A q u a n tif ica tio n  o f the percentage metabolism was estimated using 
a Berthold LB 2722-2, TLC p la te  Dunnschicht-Scanner I I  (scan speed 60 
mm/hr, s l i t  1x10 mm). The to ta l ra d io a c tiv ity  per channel on the TLC 
pla te  was recorded and the percentage ra d io a c tiv ity  (o f to ta l)  
calcu lated per band.
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3. TERATOGENIC POTENTIAL OF DIPHENYLHYDANTOIN
These diverse experiments w ith DPH have been drawn together in  an 
attempt to  understand i t s  teratogenic a c t iv i ty .  F ir s t  o f a ll i t  was 
necessary to estab lish  whether the compound a c tu a lly  crossed the 
placenta, and then to  characterise the IN VITRO e ffe c t o f the compound 
on d if fe re n t ia t in g  ra t embryo c e lls .  Then the IN VITRO response o f a 
group o f s tru c tu ra lly  re la ted compounds was examined so th a t the 
s e n s it iv ity  o f the c e lls  could be sc ru tin ise d .*  F in a lly , the IN VIVO 
tera to logy o f DPH was examined.
* The ra tiona le  behind the choice o f analogues was to t r y  to  block 
the po s ition (s ) o f metabolism on the phenyl r in g , thus showing 
whether metabolism was essentia l fo r  teratogenic a c t iv i ty .
Post Scriptum
Just to re-emphasise th a t w h ils t I re a lise  th a t 'te ra to gen ic ' 
re fe rs  to  the IN VIVO s itu a tio n  fo r  the purpose o f th is  thesis 
reference is  made to  'IN VITRO teratogenesis ' as a means to  id e n t ify  
an IN VITRO end-point w ith possible IN VIVO co rre la tiv e  s ign ifica n ce .
3.1 . TRANSPLACENTAL PASSAGE OF 14C-DPH IN THE RAT
Figure 3.1. i l lu s tra te s  the time course p ro f ile  o f ra d io a c tiv ity  
across the placenta o f a s ing le  i . p .  dose o f 14c-DPH, the protocol 
having been described in  Chapter 2 .2 .4 .
Peak maternal plasma values o f 47±10 pg/ml DPH were reached by 2 
hours post-dose and maintained a t th a t leve l u n t il 4 hours post-dose, 
a fte r  which the p ro f i le  o f e lim ina tion  followed apparent f i r s t  order 
k in e tic s . l^c-Labe lled  material was s t i l l  detectable (17±11 pg/ml) a t 
18 hours post dose. The p ro f i le  o f the C14-la b e lle d  m aterial in  the 
embryo followed the maternal plasma p ro f i le .
A peak concentration o f approximately 250±50 ng/embryo batch was 
obtained 2 hours post dose and e lim ina tion  appeared to fo llo w  f i r s t  
order k in e tic s . ^c -L a b e lle d  m ateria l (58±7 ng/embryo batch) was 
s t i l l  detectable 18 hours post-dose. The apparent h a lf liv e s  in  both 
maternal plasma and whole embryos was calcu la ted and found to be 8 h  
and 6 hours respective ly fo r  both compartments.
Analysis o f the rad io labe lled  m aterial in  both maternal plasma 
and whole embryos 2 hours post dose confirmed tha t i t  was authentic 
T^C-DPH, the Rf values being the same fo r  dosing so lu tion  and 
reference material (0 .42). No other spots s ig n ify in g  a m etabolite 
were present. However a t 8 hours post dose, both maternal plasma and 
whole embryos contained a small amount o f the p. hydroxy. DPH 
m etabolite ( Rf=0.125); the m a jo rity  o f the ra d io labe lled  m ateria l was 
unchanged l^c-DPH.
The percentage o f p. hydroxy. DPH in  maternal plasma a t 18 hours 
was 4.33-5.26% and in  whole embryos 4.01-4.87% (see chapter 2 .2 .8  fo r  
ana ly tica l method).
3 .2 . EFFECT OF DPH ON DIFFERENTIATING RAT EMBRYO CELLS IN VITRO
Mid-brain (CNS) and mesenchymal limb bud (LB) c e lls  were removed 
from 13 day embryos and cu ltu res prepared as described in  Chapter 2. 
Various concentrations o f DPH were added d ire c t ly  to the cu ltu re  
medium in  ethanol (10 pi o f ethanol per ml cu ltu re  medium, a non-toxic 
concentra tion). DPH was le f t  in  contact w ith the c e lls  over the 5 day 
cu ltu re  period during which time the CNS c e lls  d iffe re n tia te d  in to  
foc i o f neurones and LB c e lls  in to  foc i o f chondrocytes. At the end 
o f the cu ltu re  period, c e lls  were processed as described in  Chapter 
2 . 2 . 1 . and the number o f d iffe re n tia te d  foc i per c e ll is land  recorded 
and p lo tted  against concentration o f DPH in  the cu ltu re  medium (Figure
3 .2 .) .  The concentration a t which d if fe re n t ia t io n  was in h ib ite d  by 
50% (the IC50 value) in  each c e ll type was estimated from the graph.
The IC50 value fo r  CNS was 67±18 pg/ml (n=9) and fo r  LB was 91±4 pg/ml 
(n=9).
The data shows th a t CNS c e lls  were more sens itive  to  the e ffe c ts  
o f DPH IN VITRO than LB c e lls  as based on the re la tiv e  IC50 values, 
(p<0.1) but th a t fo r  both c e ll types the DPH IC50 value was < 100 
pg/ml thus q u a lify in g  the compound as having an IN VITRO teratogen ic 
e ffe c t (F l in t  and Orton 1984).
3.3 . EFFECT OF DPH GIVEN IN VIVO ON DIFFERENTIATING RAT EMBRYO CELLS
IN VITRO (EX VIVO TEST)
DPH was administered as a s ing le i . p .  or oral dose a t the maximum 
maternally to le ra ted  dose le v e ls , 200 and 300 mg/kg respec tive ly , to  3 , 
pregnant dams per group a t 3 pm on day 12 o f gestation. Embryos were
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explanted 18 hours la te r  (a t 9 am on day 13 o f gestation) from each 
group o f dams and pooled. This method is  in  accordance w ith the EX 
VIVO method o f F l in t  and Orton (1984). Cultures were prepared and 
foc i number a t the end o f the 5 day cu ltu re  period were compared to 
cu ltu res derived from untreated dams. Results showed th a t there were 
no s ig n if ic a n t d ifferences between foc i number in  e ith e r LB or CNS 
from o ra lly  or i .p .  DPH dosed or untreated dams. In conclusion, DPH 
was considered a negative teratogen by the EX VIVO method o f teratogen 
p red ic tion .
3.4 . QUALITATIVE STRUCTURE-ACTIVITY RELATIONSHIP FOR DPH AND SOME
ANALOGUES IN VITRO
DPH and 28 other s tru c tu ra lly  s im ila r compounds (Tables 3.1 and 
3.2) containing an in ta c t hydantoin r in g , (the exception being DPH 
acid containing a carboxylic acid and amino functional group a t 
positions 1 and 2 re spe c tive ly ), were chosen fo r  th is  study. The 
s tru c tu ra l d ifferences were a l l  a t the 5 pos ition  o f the hydantoin 
r in g , e ith e r a s ing le replacement o f one or both phenyl rin g s , or 
substitu tions  d ire c t ly  on to  one or both phenyl ring s . The analogues 
were chosen fo r  th e ir  subsitu tions on the phenyl r in g (s ) so th a t 
metabolism to  the p. and m. metabolites could be blocked.
Concentration-response curves were obtained fo r  a ll compounds over 
the 5 day incubation period w ith both LB and CNS c e lls ,  and where 
possible IC50 values ca lcu la ted . Log p values, were also ca lcu la ted 
and shown in  Table 3.2 , where p = p a r t it io n  c o e ff ic ie n t ra t io  in  an 
octanol-water reference system (p=co/cw where co is  the compound
Table 3.1
NOMENCLATURE USED IN DPH STRUCTURE 
ACTIVITY RELATIONSHIP STUDY
COMPOUND I COMPOUND
NAME I NUMBER
5-cyclohexyl-5 phenylhydantoin I 1
5-cyclopentyl-5 phenylhydantoin I 2
5-p-methyl diphenyl hydantoin I 3
5-p-hydroxy, 5 p-methyldiphenylhydantoin I 4
5-amino, 5 phenylhydantoin I 5
5, 5 p-p-dichiorodiphenylhydantoin I 6
p-hydroxy. DPH I 7
m-hydroxy. DPH I 8
5, 5 p-p-dihydroxy DPH I 9
5-p-hydroxypheny DPH I 10
5-m ethyl, 5-p-chlorophenylhydantoin I 11
5-p-m-dichlorophenylhydantoin I 12
5-p-chlorophenylhydantoin I 13
5-o-hydroxyphenylhydantoin I 14
5-cyclopropyl, 5-phenylhydantoin I 15
5 -cyc lobu ty l, 5-phenylhydantoin I 16
5-hydroxy, 5-phenylhydantoin I 17
5-methyl, 5-phenylhydantoin I 18
5 -e thy l, 5-phenylhydantoin I 19
Hydantoin I 20
Diphenylhydantoic acid | 21
5-phenylhydantoin I 22
5-methylhydantoin I 23
5-p-aminophenylhydantoin I 24
5-hydroxy, 5-methylhydantoin I 25
5-ethanoic acid hydantoin i 26
5, 5-dimethyl hydantoin I 27
5, 5-dicyclopropylhydantoin I 28
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concentration in  octanol and cw the corresponding concentration in  the 
water phase). Table 3.2 shows the values obtained fo r  each compound, 
IC50 CNS and LB denoted 1b1 and 'c ' on the r ig h t hand side o f each 
s truc tu re . Compounds are also grouped according to the degree o f 
to x ic ity  as compared to  DPH as a reference standard. Compounds w ith 
1b ' and 'c ' corrected log IC50 LB <2.56 or IC50 CNS <2.42 were 
considered more to x ic , these compounds are 1-6, (see Table 3.1 fo r  
numerically corresponding nomenclature). (Corrected log IC50 means 
IC50/mol weight x 1000 i .e .  pmol log) Compounds th a t were less to x ic  
than DPH ie : those compounds w ith 1b 1 and 'c ' values greater than 
those o f DPH were compounds 10-16. Compounds th a t were considered 
hardly to x ic  were 17, 18 and 19 w ith 1b * and 'c ' values s ig n if ic a n t ly  
greater than DPH. Compounds tha t were classed as non-toxic were 20-28 
and generally IC50 values were e ith e r greater than the compounds 
maximum s o lu b il i ty  or above the concentration response range 
investigated.
Given the b io lo g ica l s ign ificance  o f log p ie : th a t i t  is  an 
in d ica to r o f l ip id  s o lu b il i ty  and hence a c c e s s ib ility  o f compound to  
the c e l l ,  graphs were p lo tted  fo r  both LB (Figure 3.3) and CNS (Figure 
3.4) c e lls  o f log IC50, the ind ica tion  o f to x ic ity  against log p. 
Regression lin e  analysis fo r  each graph was madej-
LB Log V lC50 = 3.94 (±0.2) - 0.52 log p, where 3.94 = 
in te rcep t on x ax is , -0.52 = slope.(n=12 observations, 
co rre la tio n  c o e ff ic ie n t r^=89%, s.e=0.26, F=41 (where 
F=goodness o f f i t )  p ro b a b ility  > 99.9%).
CNS Log 1/IC50 = 3.81 (±0.12) - 0.53 log p, where 3.81 = 
in te rcep t on x ax is , -0.53 = slope.(n=13 observations, 
co rre la tio n  c o e ff ic ie n t r2=94%, s.e = 0.18, F=100 (where 
F=goodness o f f i t )  p ro b a b ility  > 99.9%).
The above data shows th a t fo r  both CNS and LB c e lls ,  there is  a 
d e fin ite  co rre la tio n  between to x ic ity  and 1ip o p h il ic i ty ,  the more 
l ip o p h il ic  the compound ( ie :  greater log p value) the more to x ic  th a t 
compound is  ie :  the smaller the log IC50 value).
3.5 IN VIVO TERATOLOGY OF DPH IN THE RAT
The IN VIVO te ra to logy study o f DPH was set up as described in  
Chapter 2 .2 .2 . Group I animals received solvent vehicle on ly,
Group I I  150 mg/kg DPH and Group I I I  300 mg/kg DPH.
The necropsy d e ta ils  fo r each group are summarised in  Table 3.3. 
A dose re la ted change in  maternal weight gain during gestation and 
over the dosing period (both s ig n if ic a n t a t p <0.001 le v e l)  was 
observed. Mean l i t t e r ,  fe ta l body and placental weights were 
s ig n if ic a n t ly  decreased (p <0.001) in  the top dose group and both 
doses showed s ig n if ic a n t decrease (p <0.001) in  empty uterus weight 
and mean am in io tic  f lu id  per fe tus .
C lin ica l observations (Table 3.4) o f the Group I I I  dams shows 
th a t 70% o f the animals suffered p ilo e rec tio n  and 50% suffered 
alopecia in  the la t te r  stages o f gesta tion . Necropsy observations o f 
Group I I I  dams showed 30% o f the animals w ith no abnorm alities
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TABLE 3 .3 .
NECROPSY DETAILS FROM THE DPH TERATOLOGY STUDY
I Parameter Measured i 
1 1 
I 1
Group I 
(n=10)
Group I I  
(n=10)
I Group I I I  1 
1 (n=9)a 1
1 " “  1 
1 Maternal Weight Gain (Days ! 
I 0-20 o f gestation) (g) I
I 1
150.74
(±11.40)
109.95*
(±16.88)
1 33.81* I 
1 (±46.34) I
I I 
I Maternal Weight Gain (Days I 
1 10-15 o f gestation) (g) Ii I
33.85
(±4.18)
-5.85*
(±21.44)
1 -25.93* 1 
(±15.76) 1
1 1 
1 Number o f Live Fetuses/Dam I
1 1 l 1
12.8
(±2.3)
11.8
(±2.8)
12.1 1 
1 (±2.7) I
i 1
1 Number o f Resorptions/Dam I
I II 1
0.5
(±0.6)
0.9
(±0.5)
1.2 I 
(±1.0) I
1 1 
1 Number o f Implantation | 
I sites/Dam 1
I 1
13.3
(±2.2)
12.7
(±2.7)
13.3 I 
(±2.7) I
1 Number o f Corpora Lutea/Dam j
I 1
14.8
(±1.5)
14.1
(±2.3)
14.7 I 
(±0.7) !
l I 
1 Number o f P re-im plantation I 
1 Losses/Dam 1
i I
1.7
(±1.9)
1.5
(±2.0)
1.6 I 
(±2.6) I
! I 
1 Sex Ratio, Male : Female/Dam I
1 1 | I
0.485
(±0.135)
0.455
(±0.120)
0.463 1 
(±0.063) I
1 1 
1 L i t te r  Mean Fetal Body Weight! 
1 (g) 1
3.383
(±0.183)
3.286
(±0.598)
2.419* I 
(±0.440) 1
1 1 
1 L i t te r  Mean Placental Weight 1 
1 (g) 1
0.509
(±0.064)
0.490
(±0.040)
0.395* 1 
(±0.057) I
I Placental Index & j
1 I
15.02
(±1.54)
15.24
(±2.17)
16.97 1 
(±4.60) 1
1 1 
1 Empty Uterus Weight (g) 1 5.10
(±0.67)
4.58*
(±0.79)
4.13* 1 
(±0.52) I
1 1 
1 Mean Amniotic F lu id /Fetus 1 
j Weight (g) I 
1 1
1.128
(±0.307)
0.867*
(±0.586)
0.852* 1 
(±0.108) I
* = S ta t is t ic a lly  d if fe re n t from con tro ls  a t p<0.001 leve l 
a = One dam died
b = ( to ta l placenta weight o f l i t t e r  /  to ta l fe ta l weight o f l i t t e r )  
as a percentage.
detected, 30% w ith renal pe lv ic  ca v ita tio n  and 60% w ith patchy lungs 
(Table 3 .5 ). This evidence supports the data in  Table 3.1. th a t 
Group I I I  animals showed signs o f maternal to x ic i ty .  Group I I  and I 
dams showed no abnormalities e ith e r as c l in ic a l observations or a t 
necropsy. Examination o f the gross appearance, s o ft tissues and 
palates o f each fetus did not show any malformations. However 40% o f 
the l i t t e r s  from Group I I I  dams exh ib ited  domed-shaped heads probably 
a ttr ib u ta b le  to  reduced fe ta l size and fe ta l growth re ta rd a tion .
This study has shown th a t there was a dose re la ted e ffe c t on 
maternal and embryo to x ic ity  but th a t o ra lly  administered DPH is  not 
teratogenic in  A ider!ey Park a lb ino ra ts  under the present 
experimental cond itions.
3.5 . DISCUSSION
The resu lts  presented in  th is  chapter have shown th a t w h ils t DPH 
is  not teratogenic IN VIVO in  the A ider!ey Park s tra in  ra t by the oral 
route i t  does cross the placenta and reach the embryo. In con tras t, 
DPH in h ib its  d if fe re n tia t io n  o f A.P. s tra in  ra t embryo c e lls  IN VITRO.
Furthermore the ra t embryo c e lls  IN VITRO have the a b i l i t y  to  
d is tingu ish  between IN VIVO teratogenic and non-teratogenic hydantoin 
ring  de riva tives w ith in  a homologous series.
DPH is  a well established mouse, ra b b it and human teratogen but 
negative in  the cat and dog (Schardein, 1986). Harbison and Becker 
(1972) however have reported reduced fe ta l body weight, increased 
incidences o f c le f t  pa late, hydrocephalus, hydronephritis and 
shortening o f the long bones o f the appendicular skeleton in  fe ta l
TABLE 3.4.
CLINICAL OBSERVATIONS OF THE TOP DOSE GROUP IN THE 
IN VIVO TERATOLOGY STUDY OF DPH IN THE RAT
I FEMALE 
I NUMBER
OBSERVATION DAYS OF PREGNANCY ON WHICH I 
OBSERVATION MADE 1
1003185 NADa 0-19 1
PILOERECTION 20 1
1003191 NAD 0-12,18,19 1
PILOERECTION 13-17,20 1
1003196 NAD 0-13 |
ALOPECIA 14-20 1
PILOERECTION 20 1
1003199 NAD 0-18 I
ALOPECIA 19,20 1
1003201 NAD 0-18 1
PILOERECTION 19,20 1
1003203 NAD 0-12,17-20 1
BLOOD ON SNOUT AND/OR FOREPAWS 13-16 1
1003207 BITE (SEE DESCRIPTION) 0,1 1
NAD 2-11 1
PATCHY HAIR GROWTH 12 1
ALOPECIA 13 1
PILOERECTION 13-20 1
STAINS AROUND MOUTH 20 I
1003209 NAD 0-17 1
ALOPECIA 18-20 1
PILOERECTION 18-20 1
(003214 NAD 0-17 1
ALOPECIA 18-20 1
PILOERECTION 19,20 1
3 NAD = no abnormalities detected
TABLE 3.5 .
NECROPSY OBSERVATIONS OF THE TOP DOSE GROUP IN THE 
IN VIVO TERATOLOGY STUDY OF DPH IN THE RAT
Group I I I  DPH 3000 MG/KG
1 1 
1 FEMALE | 
I NUMBER |
1 1
1
DAY FEMALE KILLED 1
1
1
OBSERVATIONS 1
1 1 
1 003185 I 
1 |
20 I 
1
Spots /  patches on lungs 1
I I
1 003191 I
1 I
I
20 I 
1
Patchy lungs 1
i I
I 003196 | 
1 |
i
20 I Patchy lungs 1
1 1 
I 003199 |
I i
1
20 | 
I
NADa 1
1 1 
1 003201 I
1 I
1
20 I 
1
NAD 1
1 1 
I 003203 | 
1 |
1
20 1 
1
NAD 1
1 1 
I 003207 |
1 1 
1 |
1
20 1
1
I
Patchy lungs 1 
Renal pe lv ic  c a v ita tio n  I
1 1
1 003209 I
1 1
1 1
1 1
1 1
1 1 
1 I
20 I 
1 
1 
1
1
I
Reduced stomach size 1 
Mottled l iv e r  1 
Small in te s tin e  empty 1 
Large in te s tin e  empty I 
Patchy lungs 1 
Renal pe lv ic  ca v ita tio n  1
1 1 
1 003214 I 
1 1
1
20 I 
1
Renal pe lv ic  ca v ita tio n  1
a NAD = No abnormalities detected
ra ts  o f the Sprague-Dawley (Simonsen) s tra in  when the mother is  
treated w ith 150 mg/kg DPH i . p .  on days 10-15 gestation.
My study was conducted by the oral route (repeated i .p .  
in je c tio n s  to  pregnant animals was not done to  minimise stress and 
discom fort) so a d ire c t comparison o f resu lts  from both studies 
where, d if fe re n t s tra ins  and routes o f adm in istra tion were used, is  
not possib le. The conclusion may be drawn th a t DPH is  a possible 
s tra in  spe c ific  ra t teratogen but is  d e f in ite ly  fe to to x ic .
I t  would appear th a t the in te r-spec ies va ria tio n  in  DPH 
teratogenesis is  not wholly re la ted to the metabolism o f the compound 
as the p r in c ip le  urinary m etabolite o f an oral dose o f DPH to  both 
ra ts  and humans is  the p.hydroxy DPH m etabolite and i t s  glucuronide 
conjugate (Wells and Harbison 1980). Both these species and the mouse 
have detectable leve ls  o f the d ihyd rod io l, catechol and o-methyl- 
catechol metabolites in  the urine fo llow ing  adm in istra tion o f the drug 
(Glazko 1973). The dog, a re s is ta n t species, is  the only one to  
e x h ib it a d if fe re n t metabolic p ro f i le ,  i t s  major m etabolite being 
m.hydroxy DPH. A fu r th e r s im ila r ity  between species, whether 
re s is ta n t or susceptible to  DPH teratogenesis is  tha t high leve ls  o f 
the unchanged drug and low leve ls  i t s  r ing  opened acid m etabolite have 
been detected in  human, ra t and dog urine .
Studies w ith 14c- dph dosed to  pregnant mice (day 17.5 gesta tion) 
showed tha t 6 hours a fte r  the dose the m a jo rity  o f ra d io a c tiv ity  in  
the embryo was unchanged DPH, and only 0.2-5% o f the ra d io a c tiv ity  was 
associated w ith the p.hydroxy. DPH. My studies by 
TLC/autoradiographic analysis o f the rad io labe lled  m ateria l in
maternal plasma and whole ra t embryos (day 13.5 gestation) confirm 
th is j  2 hours post-dose ra d io a c tiv ity  was 100% 14C-DPH, 8 hours post 
dose 95-96% ra d io a c tiv ity  was T4c-DPH, and 4-5% ra d io a c tiv ity  was 14c- 
p.hydroxy.DPH.
Given th a t there appear to be no appreciable d iffe rences between 
species in  metabolic p ro file s  nor amount o f metabolite produced, tha t 
placentation d if fe rs  l i t t l e  between species (Juchau 1981), th a t the 
c lin ic a l condition o f epilepsy i t s e l f  is  not the cause o f te ra ta  
(F inne ll and Chernoff 1984), i t  would appear th a t the in terspecies 
v a r ia b i l i ty  to  DPH teratogenesis remains la rg e ly  unexplained.
DPH is  considered teratogenic in  a va rie ty  o f IN VITRO systems 
inc lud ing ; whole mouse embryo cu ltu re  (Sadler e t .a l .  1982, Brown 
e t .a l.  1979), ra t  embryo c e ll cu ltu re  (F l in t  e t .a l .  1984, F l in t  and 
Orton 1985, Brown e t .a l .  1986 a ,b .) and human fe ta l pa lata l mesenchyme 
c e lls  (P ra tt and W ill is  1985). IN VITRO systems are ideal fo r  
e luc ida ting  the mechanisms o f teratogenesis as the complication o f the 
ro le  o f maternal metabolism and the physio log ica l b a rr ie r  o f the 
placental u n it are om itted. That DPH is  considered a p o s itive  
IN VITRO teratogen in  a system u t i l iz in g  A lderley Park s tra in  ra ts  
(but not IN VIVO) implies tha t in s u ff ic ie n t leve ls  o f DPH reach the 
embryo i t s e l f  from the mother IN VIVO. The concentration a t which 
d if fe re n tia t io n  o f ra t embryo c e lls  IN VITRO is  in h ib ite d  by 50% is  
91±4 pg/ml fo r  LB c e lls  and 67±18 pg/ml fo r  CNS c e lls ,  while the peak 
concentrations achieved a fte r  a s ing le  i .p .  dose to  the mother in  
whole embryos is  0.30 ± 0.05 pg/embryo. IN VITRO the compound remains 
in  contact w ith the c e lls  a t a high, steady-state concentration fo r  5
days w h ils t IN VIVO embryos are exposed to a low concentration 
(apprent t^=8 hours). The IN VIVO p ic tu re  becomes more complex as DPH 
is  known to induce i t s  own metabolism (Glazko 1973) and therefore the 
passage o f DPH i t s e l f  is  diminished as the concentration decreases due 
to metabolism on the maternal side re su ltin g  in  less ava ilab le  DPH fo r  
tra n s fe r to  the embryo. The question o f the ra t 's  resistance to DPH 
te ra to g e n ic ity  IN VIVO is  probably not as simple as the concentrations 
reaching the embryo not being s u ff ic ie n t to  e l i c i t  a response, but may 
be a combination o f in s u ff ic ie n t concentrations and the s e n s it iv it ie s  
o f the embryo c e lls  themselves. Table 1.8 in  Chapter 1 h ig h lig h ts  the 
minimum doses a t which a teratogenic e ffe c t is  observed fo r  teratogens 
between d if fe re n t species and i l lu s tra te s  th a t ce rta in  species are 
more sensitive  to  a p a rt ic u la r teratogen th a t others e.g. thalidom ide, 
the most sens itive  species being man and ra b b it.
The human therapeutic plasma concentration range fo r  DPH is  10-20 
pg/ml (t%=8-12 hours) (Hvidberg and Dam 1976). The peak plasma 
concentration in  the ra t fo llow ing  a s ing le  i . p .  dose is  approximately 
50 pg/ml, the mean plasma concentration 20-40 pg/ml over a 12 hour 
period (apprent t k = 8  hours), so th a t the concentration in  ra t plasma 
is  double th a t fo r  human a t any given time po in t. However the human 
is  probably more susceptible than the ra t to  DPH teratogenesis, 
implying th a t fo r  human embryo c e lls  i t  is  not the concentration o f 
DPH but the inherent s e n s it iv ity  o f the c e lls  themselves which governs 
the teratogenic outcome.
S tru c tu re -a c tiv ity  studies w ith f iv e  hydantoin de riva tives  in  the 
mouse IN VIVO (Brown e t .a l .  1982) have shown tha t there is  a common
mechanism fo r  te ra to g e n ic ity  o f the closed ring  hydantoins, o f 
le th a l i ty  fo r  the substitu ted hydantoins and th a t potencies were 
determined p r im a rily  by l ip id  s o lu b i l i ty .  In my study w ith  28 
hydantoin de riva tives w ith d if fe re n t ia t in g  ra t embryo c e lls  IN VITRO 
the same conclusions can be drawn ie* the in ta c t hydantoin rin g  w ith  
a t leas t one phenyl rin g  attached a t the 5 pos ition  is  required fo r  a 
tox ic  e ffe c t and tha t th is  is  accompanied by high 1ip o p h il ic i ty  (a 
high log p value). The two graphs (Figures 3.3 and 3.4) i l lu s t r a te  
the co rre la tio n  between the two parameters ( to x ic ity  vs log p ).
Other points regarding the s tru c tu re -a c t iv ity  re la tio n sh ip  o f 
th is  series o f hydantoins compared to  DPH can be made and in c lu d e :-
1) Compounds th a t were non-toxic (numbers 20-28) had an a lip h a tic  
group a t pos ition  5 on the hydantoin ring  and negative log p 
values. Exceptions to  th is  were DPH acid (21) which had 2 phenyl 
rings a t pos ition  5 but a broken hydantoin ring  and 5-p- 
aminophenylhydantoin (24) which had a (substitu ted ) phenyl r in g  
a t pos ition  5, however both compounds had negative log p values. 
Compound 28 had 2 cyclopropyl rings which may rupture in  the 
cu ltu re  medium and thus a lte r  the log p value to a negative value 
corresponding to  the other a lip h a t ic a lly  substitu ted compounds. 
5-phenylhydantoin (22) was to ta l ly  non to x ic  IN VITRO and has 
been reported as a negative IN VIVO human teratogen (F inne ll and 
D ilb e r t i 1983), however i t  had a low but po s itive  log p value. 
This observation im plies th a t there may be a receptor-mediated 
e ffe c t which requires the presence o f 2 phenyl rings since the
only d iffe rence between th is  compound and DPH is  an extra phenyl 
ring  a t pos ition  5 in  the la t te r  compound, which makes DPH 3 
times more l ip o p h il ic  than 5-phenylhydantoin.
2) Compounds th a t were weakly to x ic  to  the c e lls  (17-19) had s ing le  
phenyl rings a t the 5 position  and an a lip h a tic  group ( in  place 
o f the second phenyl ring  o f DPH) and moderately low log p 
values.
3) Compounds th a t were less to x ic  than DPH (10-16) a ll had a s ing le  
phenyl ring  a t the 5 p o s itio n . Compounds 15 and 16 had 
cyclopropyl and cyclobutyl rings respective ly  a t the other 5 
p o s itio n , which being s te r ic a lly  stra ined probably ruptured over 
the 5 day cu ltu re  period rendering them as a lip h a tic  groups. 
Compounds 11,12 and 13 had a Cl group a t the para pos ition  on the 
phenyl r in g , 12 and 13 had only hydrogen a t the other 5 pos ition  
and compound 11 a methyl s u b s titu tio n , compound 12 was d ich lo ro - 
substitu ted on the phenyl r in g , para and meta. Compounds 12 and 
13 can be d ire c t ly  compared to compound 22 and compound 11 
compared to  18 as they are ch lo rina ted subs titu tions  on the 
phenyl r in g . The re s u lt o f a ch lo rine  su b s titu tio n  appears to  
both increase log p values and to x ic i ty .
Compounds 10 and 14 are mono-hydroxy substitu tions  o f the phenyl 
rin g  a t the para and ortho positions respective ly  and can be 
compared to compound 22 (5-phenylhydantoin). The re s u lt o f a
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hydroxy sub s titu tio n  appears to lower the log p values (from a 
po s itive  one fo r  22 to  a negative one fo r  both 10 and 14) but 
to x ic ity  is  increased. This observation im plies th a t the 
in t r in s ic  a c t iv i ty  o f the hydroxy analogues is  greater than th a t 
o f the mono-phenyl-hydantoin.
A ll compounds th a t were classed as less to x ic  than DPH and had
lower log p values in d ica tin g  th a t they were less l ip o p h il ic  than
DPH.
4) Compounds th a t were eq u i-to x ic  w ith DPH were hydroxy de riva tives  
(7 -9 ). Compounds 7 and 8 were mono-hydroxy substitu ted a t para 
and meta positions respective ly , compound 9 was dihydroxy 
substitu ted , one on each phenyl ring  a t the para p o s itio n . A ll 
compounds were su b s ta n tia lly  less l ip o p h il ic  than DPH, but were 
equ itox ic , implying th a t despite less a c c e s s ib ility  to  the c e lls  
the compounds were in t r in s ic a l ly  more to x ic  than DPH i t s e l f .
5) Compounds th a t were more to x ic  to  the c e lls  than DPH were 
compounds 1-6. Compounds 1 and 2 contained a phenyl r in g  and 
saturated 6 or 5 membered rings respective ly  and were 
sub s tan tia lly  more l ip o p h il ic  than DPH. Compound 3 was methyl
substitu ted a t the p position  on one o f the phenyl r ing s ; th is
sub s titu tio n  su b s ta n tia lly  increased the log p value and hence 
rendered the compound more to x ic  than DPH. Compound 4 was the p 
hydroxy de riva tive  o f compound 3, the hydroxy su b s titu tio n  
decreased the log p value but did not a lte r  the to x ic  p o ten tia l
again implying tha t the in t r in s ic  a c t iv i ty  o f the phenolic 
compound was greater than th a t o f the non-hydroxy substitu ted 
compound. Compound 5 contained a s ing le  phenyl group and an amino 
func tion , both a t the 5 pos ition  and a low log p value, however 
the compound was more to x ic  than DPH. I t  is  probably th a t th is  
compound is  p a r t ia l ly  ionised a t pH7 and therefore the log p 
value is  not an accurate value fo r the IN VITRO/IN SITU 
s itu a tio n . Compound 6 contained both phenyl rings and was the p- 
d ich loro analogue o f DPH, th is  compound was the most l ip o p h il ic  
and most to x ic  compound o f the series.
In summary i t  would appear th a t the potency o f a drug is  
con tro lled  by the amount o f free drug a t the receptor, except fo r  
the phenolic de riva tive s , i t  would appear tha t a c c e s s ib ility  o f 
the compound to l ip id  bound receptors in  embryo c e lls  (which is  
governed by l ip id  s o lu b il i ty ,  log p) is  the prime fa c to r 
determining teratogenic outcome.
The teratogenic po ten tia l had 89% co rre la tio n  c o e ff ic ie n t w ith  LB 
c e lls  and 94% w ith CNS. This study has shown the a b i l i t y  and 
s e n s it iv ity  o f ra t embryo c e lls  IN VITRO fo r  the p red ic tion  o f 
teratogenic hazard, even s tru c tu ra lly  s im ila r compounds w ith in  a 
homologous series, however i t  remains to be seen whether the 
pred ic tion  fo r  a ll the compounds holds up IN VIVO.
The overall conclusion is  th a t DPH te ra to g e n ic ity  in  the ra t  IN 
VIVO/EX VIVO versus micromass IN VITRO is  probably a function  o f 
embryo ce ll pro tection  in  the whole animal, however the micromass 
IN VITRO system is  very useful fo r  s tru c tu re /a c t iv ity  analys is.
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4. IMMUNOCYTOCHEMICAL IDENTIFICATION OF EMBRYO CYTOCHROME P450'S
I f  embryo c e lls  are to  have the capacity to  ac tiva te  teratogens 
then i t  is  essential to  demonstrate the presence o f the m etabolising 
enzymes. The a v a ila b i l i ty  o f spe c ific  antibodies provided a sens itive  
method o f detecting the cytochrome P450 metabolising enzymes. The 
technique o f immunocytochemical s ta in ing  using various cytochrome P450 
antibodies (see Chapter 2. fo r  the technique and the antibody 
ch a ra c te ris tic s ) was used to  id e n t ify  the c o n s titu tiv e  leve ls  o f 
cytochrome P450's in  5 day old cu ltu res o f LB and CNS c e lls .  The 
amounts o f cytochrome P450's in  the c e lls  fo llow ing  induction was also 
investiga ted. This chapter provides the f i r s t  evidence fo r  the 
presence and in d u c ib i l i ty  o f cytochrome P450's in  d if fe re n t ia t in g  ra t  
embryo c e lls  IN VITRO.
4.1 CONSTITUTIVE AND INDUCIBLE LEVELS OF EMBRYONIC CYTOCHROME P450
4.1 .1 . IN VITRO INDUCTION
The highest non-cytotoxic concentrations (N.C.C) o f PB, 3MC and 
pNF IN VITRO were found by the method described in  Chapter 2 .2 .1 . 
(Table 4 .1 .) .  LB and CNS c e lls  were coincubated over the 5 day 
cu ltu re  period in  the absence and presence o f each inducer and the 
presence o f cytochrome P450 isoenzymes detected by the degree o f 
peroxidase sta in ing  (s ig n if ie d  by brown coloured s ta in ) w ith  
haematoxylin counterstain (blue) against the d if fe re n t antibodies was 
scored v is u a lly . The scoring system was as fo llo w s j 0 = absent, (+) = 
less than minimal, + = minimal, ++ = moderate, +++ = strong.
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Table 4 .1 .
DOSING LEVELS FOR INDUCERS BOTH IN VITRO AND IN VIVO
I INDUCER
IN VITRO HIGHEST 
NON CYTOTOXIC 
CONCENTRATION 
(pg/ml)
IN VIVO DOSING | 
PROTOCOL |
I PB 250 0.1% (w/ v ) in  I 
d rink ing  water I 
during days 4-13 ! 
o f gestation |
I 3MC 0.5 25 mg/kg i .p .  on| 
day on days 10- j 
12 o f gestation I
1 pNF 2.5 35 mg/kg i .p .  I 
day on days 10- 1 
12 o f gestation |
Table 4 .2 .a shows the resu lts  obtained from untreated c e lls  and c e lls  
coincubated IN VITRO w ith e ith e r PB, 3MC or pNF. Results ind icated 
th a t there was a minimal c o n s titu tiv e  leve l o f the cytochrome P448 
isoenzymes in  both LB and CNS c e lls .  This leve l was induced to 
moderate leve l in  CNS c e lls  by both 3MC and pNF. In LB c e lls  the 
leve l was moderately inducib le  by 3MC and strongly inducib le  by pNF, 
as gauged against a l l  3 P448 antibod ies. Fig 4.1 i l lu s t ra te s  the 
comparison between a. untreated c e lls ,  pre-immune serum b. 
c o n s titu tiv e  leve l c. 3MC induced and d. pNF induced fo r  LB c e lls  
against the P450c antibody. Fig 4.2 shows the same comparison o f 
treatments against the same antibody but forembryonic CNS c e lls .  Fig
4.3 shows the same comparison o f IN VITRO induction w ith the inducers 
in  LB c e lls  stained against the CTL/Hammersmith 3:4:2 monoclonal 
antibody and Fig 4.4 the same comparison w ith 3:4:2 antibody but fo r  
CNS c e lls .
CNS and LB c e lls  both showed a moderate c o n s titu tiv e  leve l o f 
the PB-type P450 isoenzyme but th is  was not induc ib le . Fig 4.5 
i l lu s tra te s  the c o n s titu tiv e  leve l o f P450 (p ic tu re  b) and the leve l 
fo llow ing  coincubation w ith PB IN VITRO (4 .5 .c ) in  LB c e lls  stained 
against the Surrey-derived PB P450b antibod ies. Fig 4.6 shows the 
same but w ith CNS c e lls .
Both c o n s titu tiv e  and inducib le  cytochrome P450's were loca lise d  
around the foc i o f d iffe re n tia te d  chondrocytes (LB) and neurones (CNS) 
in  the c e lls  tha t were d if fe re n t ia t in g ; very l i t t l e  P450 was detected 
in  the c e lls  th a t had d iffe re n tia te d . This im plies th a t teratogen 
b io ac tiva tion  must therefore be undertaken only by susceptible 
d if fe re n t ia t in g  c e lls .
Table 4.2 .a
CONSTITUTIVE AND IN VITRO INDUCIBLE LEVELS
OF EMBRYONIC CYTOCHROME P45G's
Cytochrome
a.!
I ^ j  Antibody to
Untreated PB 3MC /5 n f
Type LB CNS LB CNS LB CNS LB CNS
P448
CT L/Hammervnith 
3:4:2  h + + + + +  + 4  +
P44S
R. Wolf. 3M C, 
(  Levin d )1
+ ( + ) / / +  + ( + ) +  + + +
p448
R. Wolf. 3MC2 
(  Levin c)C + + 1/ 1/ + + + 4 +
P450
Surrey PB -  P4 5 Q 
( Levin b t ^
+ + + + + + + + +  + +  4 * +  + 4 4
P4 5 0
R. Wolf. PB,
{ W exmen P B j ) ' ( + ) O ( + ) ( + ) / / A/
p450
R. Wolf, PB2 
IPB2 )f  s
+  + +  + + + 4 - + A/HA/
p450
R. Wolf, PB3
(  Levin b!e 1 ( + ) O ( + ) ( + ) A/ A /
O * absent,(+ ). barely present. +  .minimal, + +  .  moderate, +  +  +  .  *«ronf 0 « n o t  c tirt
a. The antibodies to  cytochrome P450 isoenzymes were derived from three 
separate laboratories. Dr G Gibson, University of Surrey, Dr C R 
Wolf, University of Edinburgh and Prof. D Davies, R.P.M.S., 
Hammersmith, London, as Indicated In Table 2 .1 .
b. A monoclonal antibody derived from ^NF Induced mouse.
c. Polyclonal antibody derived from 3MC Induced Sprague Dawley ra t live r  
mlcrosomes.
d. Polyclonal antibody derived from PB Induced Wistar ra t liv e r  
mlcrosomes.
e. Polyclonal antibody derived from PB Induced sprague Dawley ra t liv e r  
mlcrosomes.
f .  I t  should be noted that no consistent nomenclature P450, and the 
mixed nomenclature Is that of CTL/Hammersmith, Wolf e t .a l .  1984, Ryan 
e t .a l .  1982, and Gibson e t .a l .  1982. Where possible, a consistent 
nomenclature is given In parenthesis according to  Levin e t .a l .  1978.
CONSTITUTIVE AND IN VITRO INDUCIBLE LEVELS OF EMBRYO CYTOCHROME
P448 IN LB CELLS (VS: ^ 4 5 0  c ANTIBODY)
a. u n t re a te d  c e l l s ,  pre-immune b. u n t re a te d  c e l l s
sera  ( c o n s t i t u t i v e  l e v e l ,
minimal 4)
c. c e l l s  co - incubated  d. c e l l s  co - incubated
with 3MC (moderate +4) with (3NF (strong 444)
CONSTITUTIVE AND IN VITRO INDUCIBLE LEVELS OF EMBRYO CYTOCHROME
P448 IN CNS CELLS (VS ^ 4 5 0  c ANTIBODY)
a. untreated c e l l s  , pre-immune b. u n t re a te d  c e l l s
sera  ( c o n s t i t u t i v e  l e v e l ,
minimal 4)
c.  c e l l s  co - incubated  
w ith  3MC (min imal  4)
d. c e l l s  c o - incubated
with 3NF (moderate,  44)
CONSTITUTIVE AND IN VITRO INDUCIBLE LEVELS OF EMBRYO CYTOCHROME P448
IN LB CELLS (VS CTL/HAMMERSMITH 3:4:2 ANTIBODY)
a. untreated cells
sera
, pre-immune b. u n t re a te d  c e l l s
( c o n s t i t u t i v e  l e v e l ,  
minimal +)
c. c e l l s  c o - incubated  d. c e l l s  c o - inc ubated
with 3MC (minimal 4) with (3NF (moderate,  + + )
CONSTITUTIVE AND IN VITRO INDUCIBLE LEVLES OF EMBRYO CYTOCHROME P448
IN CNS CELLS (VS CTL/HAMMERSMITH 3:4:2 ANTIBODY)
s * 7 -  * .
t  ■» /* v
a. untreated cells
sera
, pre-imraune b. u n t r e a te d  c e l l s
( c o n s t i t u t i v e  l e v e l ,  
minimal 4)
c.  c e l l s  co - incubated  
w ith  3MC (min imal  4)
d. c e l l s  co - incubated
with PNF (moderate,  44)
LEVELS OF PB-TYPE CYTOCHROME P45Q IN UNTREATED AND INDUCED
LB CELLS (VS SURREY ~ I )1:K 1 VI I ) I* - h A N T I  BODY
a. u n t re a te d  c e l l s *  pre-immune
sera
b.  u n t re a te d  c e l l s
( c o n s t i t u t i v e  l e v e l ,  
P450, moderate +4)
d. in  utero exposure to
PB (moderate 44)
c.  c e l l s  co - incubated  
w i th  PB in  v i t r o  
(moderate ,  44)
LEVELS OF PB-TYPE CYTOCHROME P45Q IN  UNTREATED AND INDUCED 
CNS CELLS (VS SURREY -  DL1\ I V 1:1) l \ c n  b ANTIBODY
uni fluted cells pre-immune b.  u n t re a te d  c e l l s
sera  ( c o n s t i t u t i v e  l e v e l ,
P450,  moderate 4+)
c,  c e l l s  co - incubated  
w i th  PB in  v i t r o  
(moderate 44)
d. in  utero exposure to
PB (moderate,  44)
4 .1 .2 .TRANSPLACENTAL INDUCTION
The maternal dosing regimen fo r  transplacental induction o f 
cytochrome P450's is  described in  Chapter 2 .2 .3 . (values are given in  
Table 4.1) and was known to  induce maternal cytochrome P450jS as 
gauged by increased peroxidase s ta in ing  o f the maternal l iv e r .
13 day embryos from e ith e r untreated or pre-induced mothers were 
explanted and LB and CNS ce ll cu ltu res prepared; the embryos therefore 
e ffe c t iv e ly  received an IN UTERO exposure to  the various inducers. 
A fte r a subsequent 5 day cu ltu re  period c e lls  were processed by the 
immunocytochemical s ta in ing  technique (Chapter 2 .2 .5 .) against the 
various cytochrome P450 antibodies and scored fo r  in te n s ity  o f 
peroxidase s ta in . The code fo r  scoring the degree o f s ta in  in te n s ity  
is  described in  section 4.1 .1 . and is  given in  Table 4.2.b along w ith 
the scoring re su lts .
The re su lts  showed a minimal c o n s titu tiv e  level o f the cytochrome 
P448 isoenzyme in  both c e ll types and th a t th is  level was moderately 
inducib le  in  LB c e lls  (but not CNS) by 3MC. However, the leve ls  were 
strongly induced in  both CNS and LB c e lls  by pNF. Fig 4.7 i l lu s ta te s  
the comparison between a. untreated c e lls ,  pre-immune sera, b. 
c o n s titu tiv e  level o f cytochrome P448, c. 3MC induced and d. pNF 
induced LB c e lls  against CTL/Hammersmith 3:4:2 antibody. Fig 4.8 
shows the same comparison but fo r  CNS c e lls .  Fig 4.9 shows the same 
comparison o f pre-treatment w ith LB c e lls  stained against P450c 
antibody and Fig 4.10 the same but fo r  CNS c e lls .
There was a moderate c o n s titu tiv e  leve l o f the phenobarbitone- 
type cytochrome P450 present in  cu ltu res o f both untreated LB and CNS 
c e lls ,  however th is  leve l was not increased by a p r io r  IN UTERO
Table 4.2.b
CONSTITUTIVE AND IN UTERO INDUCIBLE LEVELS OF 
EMBRYONIC CYTOCHROME P450‘ s
Cytochrome
Type
*.F
Antibody to
Untreated PB 3MC 0 N F
LB CNS LB CNS LB CNS LB CNS
'P44B
CT L/Hammersmith 
3:4:2  b
+ + + * + + + +++++
PA48
R. Wolf. 3M C 1 
( Levin d )c
+ (+) / + ( + ) + + +
P448
R. Wolf, 3M C2 
(  Levin c)C
+ + / + + + - f * + + +
P450
Surrey PB -  P450  
( Levin b I ^ ++ ++ ++ ++ + +
4-4 -
P450
R. W o ll PB,
( Wex man PB^)C (+) O (+) O / /J / /
P450
R. Wolf. PB2 
(PBj)6 ++ ++ ++ ++ / I / / I 1 /
P450
R. Wolf, PB3 ( Levin b)c (+) o (+) (+) / / / /
O * absent. (+ )* barely present, +  • minima^  +■+ * moderate. +  +  +  « stronp ested
a. Antibodies were the same as in  Table 4 .2 .a. and footnotes a - f  have 
the id e n tica l meaning again as given in  Table 4 .2 .a.
CONSTITUTIVE AND IN UTERO INDUCIBLE LEVELS OF EMBRYO CYTOCHROME P448
IN LB CELLS (VS CTL/HAMMERSMITH 3:4:2 ANTIBODY
a- untreated cells f pre-immune b.  u n t r e a te d  c e l l s
sera  ( c o n s t i t u t i v e  l e v e l ,
P448, minimal 4)
c. 3MC induced
(minimal,  +)
d. 3NF induced ( s t r o n g ,  
4 4 4 )
CONSTITUTIVE AND IN UTERO INDUCIBLE LEVELS OF EMBRYO CYTOCHROME P448
IN CNS CELLS (VS CTL/HAMMERSMITH 3;4:2 ANTIBODY
untreated c e l l s  , pre-immune b. u n t re a te d  c e l l s
sera  ( c o n s t i t u t i v e  l e v e l ,
P448,  minimal 4 )
c. 3MC induced
(minimal,  4)
d. |3NF induced ( s t r o n g ,  
4 4 4 )
CONSTITUTIVE AND IN UTERO INDUCIBLE LEVELS OF EMBRYO CYTOCHROME P448
IN LB CELLS (VS ^ 4 5 0  C ANTIBODY)
'3‘ untreated cells , pre-immune b. u n t re a te d  c e l l s
sera  ( c o n s t i t u t i v e  l e v e l ,
P 448 , minimal 4)
c.  3MC induced  
(moderate ,  44)
d. 3NF induced
(moderate, 44)
CONSTITUTIVE AND IN UTERO INDUCIBLE LEVELS OF EMBRYO CYTOCHROME P448
IN CNS CELLS (VS p4 5 0 ' c ANTIBODY)
a - u n t re a te d  c e l l s . ,  pre-immune b.  u n t re a te d  c e l l s
sera  ( c o n s t i t u t i v e  l e v e l ,
m in im al ,  + )
c. 3MC induced
(minimal,  +)
d. (BNF induced  
(moderate ,  +4)
exposure to  PB. Fig 4 .5 .b . and d. shows the comparison between 
c o n s titu tiv e  and PB IN UTERO exposed LB c e lls  stained against the 
Surrey-derived P450b antibody, and Fig 4 .6 .b . and d. the same but w ith 
CNS c e lls .
Both c o n s titu tiv e  and inducib le  cytochrome P450 was loca lised  
around the foc i o f d iffe re n tia te d  chondrocytes (LB) and neurones (CNS) 
in  the d if fe re n t ia t in g  c e lls .
4.1.3 EFFECT OF DPH AND BENZIMIDAZOLE ON EMBRYO CYTOCHROME P450's
Chronic adm in istra tion o f DPH and benzimidazole have both been 
shown to cause induction o f cytochrome P450 in  ra t l iv e r .  IN VITRO 
co-incubation o f LB/CNS c e lls  over a 5 day period w ith e ith e r DPH or 
benzimidazole did not increase the in te n s ity  o f s ta in ing  over the 
c o n s titu tiv e  leve ls  when stained against e ith e r Surrey-derived 450b or 
CTL/Hammersmith 314s2 antibodies. Fig 4.11 i l lu s tra te s  s ta in ing  fo r  
a) untreated c e lls ,  pre-immune sera, b) c o n s titu tiv e , c) DPH co­
incubation d) Benzimidazole co-incubation o f LB c e lls  vs. 
CTL/Hammersmith 3:4:2 antibody. Fig 4.12 i l lu s tra te s  the same 
treatments but w ith CNS c e lls .
4.2 . IN VIVO AND IN VITRO COMPARISON OF EMBRYONIC CYTOCHROME P450»S
AT DAY 18 OF DEVELOPMENT
Rat embryos from untreated mothers were explanted on day 18 o f 
gestation, as th is  corresponds to the stage o f development a t the end 
o f the cu ltu re  period ( fo r  the IN VITRO system embryos were explanted 
on day 13 o f gestation and cultured fo r  5 days, g iv ing a to ta l o f 18 
days o f development). Embryo m id-brain and fore-lim bs were removed
LEVELS OF CYTOCHROME P448 IN UNTREATED AND VA&IQPSLY CO-TREATED 
LB CELLS (VS. CTL/HAMMERSMITH 3 ; 4 : 2  ANTIBODY)
u n tre a te d  c e l l s ,  pre-immune b. u n t r e a te d  c e l l s
sera  ( c o n s t i t u t i v e  l e v e l ,
P448, min imal,  4)
c. Co- incubated  w i th  
DPH (m in im a l ,  4)
d.  Co- incubated  w i th
benz im idazo le  (m in im a l  4)
LEVELS OF CYTOCHROME P448 IN UNTREATED AND VARIOUSLY CO-TREATED 
CNS CELLS (VS. CTL/HAMMERSMITH 3»4:2  ANTIBODY)
a. u n t rea te d  c e l l s  t pre-immune b. u n t re a te d  c e l l s
sera  ( c o n s t i t u t i v e  l e v e l ,
P448,  m in im al ,  4)
c.  Co- incubated w i th  
DPH (m in im a l ,  4)
d. Co- incubated w i th
be nz im idazo le  (m in im al  4)
and placed immediately in  l iq u id  n itrogen, c ryosta t sections were then 
cut and the sections stained against e ith e r Surrey-derived-P450c or 
CTL/Hammersmith 3*4:2 antibodies. Fig 4.13 shows the presence o f both 
major forms o f cytochrome P450 in  day 18 embryo, a t c o n s titu tiv e  
leve ls  s im ila r to those from IN VITRO CNS/LB c e lls ,  (compare to  Figs
4.3 b/4 .4 b and Fig 4.5 b/4 .6 b) The lo c a lis a tio n  o f cytochrome 
P450's was in  the perichondria l tissue in  both day 18 embryos and 
cu ltu red LB c e lls  (ind ica ted  by arrows). There also appeared to  be 
some cytochrome P450 present in  the myogenic tissue from day 18 
embryos (Fig 4.13 a and c ) . M id-brain sections revealed the presence 
o f cytochrome P450's in  the connective tissue o f the brain and in  
n e u ro fib r ils  which corre la ted to  the lo c a lis a tio n  in  CNS c e lls  
cu ltu red IN VITRO (Fig 4.13 b and d ). The phenobarbitone-type 
isoenzyme o f cytochrome P450 was present in  both tissues a t a higher 
level than the P448 isoenzyme (as gauged by in te n s ity  o f s ta in ing ) 
which corre la tes w ith the IN VITRO observation (Table 4 .2 , moderate ++ 
fo r  PB-type P450 and minimal + fo r  P448). The untreated sections 
coincubated w ith pre-immune sera were completely devoid o f brown 
s ta in ing  (data not shown).
4.3 DEVELOPMENTAL PROFILE OF EMBRYO CYTOCHROME P450'S IN VITRO
Embryo c e lls  th a t had been cu ltu red fo r  0, 1, 2, 3, 4 and 5 days 
were stained against Surrey-derived-P450c and CTL/Hammersmith 
antibodies and the day on which s ta in ing  was f i r s t  detected (and the 
corresponding in te n s ity )  was recorded (Table 4.3 a).
Results showed th a t the phenobarbitone-type cytochrome P450 f i r s t  
appeared on day 1 o f cu ltu re  and plateaued on day 5 o f cu ltu re  fo r
LOCALISATION OF CYTOCHROME P45Q's IN  LB AND 
CNS SECTIONS FROM DAY 18 EMBRYOS
a. F o re -lim b  s e c tio n  (VS b. F o re -lim b  s e c tio n
Surrey  '450  0| (VS CTL/Hammersmith
3 :4 :2 )
d. M id -b ra in  s e c tio nc . M id -b ra in  s e c tio n
(VS S urrey PB-P450) (VS CTL/Hammersmith 3 :4 :2 )
Developmental Onset of Cytochromes P^ n  Vitro
TABLE 4-5 a
A n tib o d y  T y p e
Days in c u ltu re  fo r L B /C N S
0 1 2 3 4 5
S u rre y -d e riv e d  P 4 5 (}tr — (+) (+ ) + +  + +  +
C T L  /  H a m m e rs m ith  
3 : 4 : 2
— — — (+) (+) +
E ffe c t  o f /3 N F  in U te ro  In d u c tio n  on D e v e lo p m e n ta l P a tte rn  o f  
P 4 4 8  A p p e a ra n c e  in V i t r o
_  ___ _ , D ays in C u ltu re  fo r  L B  and C N S  C ells
TABLE 4 .5  b ________________________________ '_________________________
Treatm ent 
vs : 3 : 4  : 2 A b .
0 1 2 3 4 5
Untreated — — — (+ ) (  +  ) +
(3 N F In Utero  
35m g/kg, i.p ,
D , 10  — 12  gestation
— ' — — + . .++ + + +
C ode : — = absent, (+ ) = p resen t, +  =  m in im a l, + +  = m o d e ra te , + + +  =  m assive
both LB and CNS c e lls .  The cytochrome P448 isoenzyme was f i r s t  
detected on day 3 o f cu ltu re  and reached a minimal (+) leve l on day 5 
o f cu ltu re  ( fo r  both LB and CNS c e lls ) .
IN UTERO exposure to  pNF did not cause a precocious development 
o f cytochrome P448 (Table 4.3 b) but did increase the in te n s ity  o f 
s ta in ing  (minimal to  moderate) over days 3-5 o f cu ltu re  fo r  both ce ll 
types.
4.4 IMMUNOLOGICAL IDENTIFICATION OF EMBRYO CYTOCHROME P450‘S BY
WESTERN BLOTTING
The method o f Western b lo t is  described in  Chapter 2.2.6 5 day 
old cu ltu res o f LB and CNS c e lls  derived from e ith e r untreated or (3NF 
induced mothers were pooled, homogenised and an a liq u o t 
electrophoresed, transfe rred to n itro c e llu lo s e  paper and then stained 
against e ith e r a) Surrey derived-P450c antibody b) P450d antibody or 
c) Wolf 3MC2 antibody. Samples were then post-labe lled  w ith  125 i_ 
labe lled  prote in A and autoradiographs produced. The re su lts  are 
shown in  Fig 4.14. The f i r s t  tra ck , LB c e lls  from untreated mothers, 
the second track LB c e lls  from pNF induced mothers, the th ird  CNS 
c e lls  from untreated mothers, the fou rth  CNS c e lls  from pNF induced 
mothers and the f i f t h  track ( fa r  r ig h t)  corresponds to  appropria te ly  
induced ra t l iv e r  microsomes against which each antibody was 
d irected . Results ind ica te  th a t there was a high leve l o f non­
spec ific  binding (probably due to high prote in loading) but i t  was 
possible to  demonstrate the presence o f bands o f embryonic prote ins 
(cytochrome P450) corresponding to the major induced ra t l iv e r  
microsomal P450's (ind icated by arrow). The untreated and pNF induced
WESTERN BLOT IDENTIFICATION OF EMBRYO CYTOCHROME P450's IN
UNTREATED AND gNF TRANSPLACENTALLY INDUCED LB AND CNS CELLS
a -(v s  S urrey  PB-P450) b - (v s  W olf 3MC^) c - (v s  W olf 3 MC2 )
^ c L & U C a  w c'b 
M clJ j
Lci^ccca a cU
C ode:- LC = u n tre a te d  LB c e l ls  LB -  3NF induced LB c e l ls
CC = u n tre a te d  CNS c e l ls  CB = (3NF induced CNS c e l ls
LB and CNS c e lls  showed a uniform leve l o f PB-P450 (vs Surrey PB-P450 
antibody) th a t was unaffected by e ith e r c e ll type or induction (Fig 
4.14 a). However both pNF induced LB and CNS c e lls  showed a greater 
degree o f s ta in ing  in te n s ity  than c e lls  derived from untreated mothers 
when stained against e ith e r P450c or P450d antibodies (Fig 4.14 b and 
c ).
4.5 DISCUSSION
Results from th is  Chapter have shown th a t ra t embryo c e lls  have 
a) c o n s titu tiv e  leve ls  o f cytochrome P448, and b) i t  was inducib le  by 
3MC and pNF (by both immunocytochemical s ta in ing  and increased leve ls  
o f P448 prote in  detected by Western b lo tt in g )  c) trans-p lacenta l pNF 
induction was more potent than IN VITRO co-incubation w ith pNF. d) DPH 
and benzimidazole do not act as inducers e) the IN VIVO d is tr ib u t io n  
pattern and leve ls  o f cytochrome P450's are pa ra lle led  IN VITRO f )  
there was developmental regula tion o f the appearance o f cytochrome 
P450's IN VITRO g) pNF does not cause a precocious development o f 
cytochrome P448 but increases the le ve ls .
Immunocytochemical evidence fo r  the c o n s titu tiv e  and non­
inducib le  leve ls  o f PB-type cytochrome P450 show an anomaly (Table 
4 .2 ), in  tha t Surrey PB-P450 which is  formalised as Levin 1b 1 form 
p a ra lle ls  the observed sta in ing  in te n s ity  as Wolf PB2 , not Wolf PB3 , 
which is  also formalised as Levin 1b * form. An unsuccessful attempt 
was made to d is tingu ish  the cross re a c t iv ity  o f a l l  3 antibodies by 
Ouchterlony double d iffu s io n  technique, so th a t i t  remains in  unknown 
which antibody is  the true Levin 1b ■ or which is  a m ixture or 
a lte rn a tiv e ly  they are products o f s tra in  d ifferences to  PB induc tion .
Despite th is  anomaly a ll 4 PB-P450 antibodies showed the same 
re s u lt;  LB and CNS c e lls  have a c o n s titu tiv e  leve l o f PB-type P450 
th a t was not inducib le  by PB co-incubation e ith e r IN UTERO or IN 
VITRO. However embryo cytochrome P448, which a t a c o n s titu tiv e  level 
was not as abundant as cytochrome P450, was found to be inducib le  by 
both 3MC and (3NF. This isoenzyme was inducib le  by both transplacental 
exposure to inducers or by coincubation IN VITRO w ith inducers a t non- 
cy to tox ic  concentrations. A ll three P448 antibodies showed th a t 
w h ils t 3MC induction IN VITRO was as potent as an IN UTERO exposure, 
fo r  pNF th is  was not so. IN UTERO exposure caused a greater s ta in ing  
in te n s ity  (vs. CTL/Hammersmith 3:4:2 antibody). This d iffe rence  in  
in d u c ib i l i ty  by BNF a fte r  IN UTERO exposure ind ica tes e ith e r a) th a t 
maternally mediated metabolism o f pNF possibly enhanced i t s  induction 
po ten tia l in  embryo c e lls  or b) a higher dose o f pNF was de livered to 
the embryos a fte r  IN UTERO exposure. For 3MC, maternal metabolism 
apparently did not appear to be an important fa c to r fo r  i t s  induction 
p o te n tia l. The observation th a t embryo cytochrome P450 was non­
inducib le  w h ils t cytochrome P448 was, is  re fle c ted  in  the l i te ra tu r e ;  
fe ta l ra t hepatocytes were found to increase substrate turnover only 
when exposed to cytochrome P448 inducers (Worell 1984, C reste il e t . a l . 
1984, Mizokami e t .a l .  1982). In ad d itio n , mouse limb bud organ 
cu ltu res could activa te  cyclophosphamide a fte r  IN UTERO exposure to 
Aroclor 1254 but were re fra c tiv e  w ith  PB pretreatment (Neubert and 
Bluth 1981). Furthermore, whole ra t embryos could ac tiva te  2-acetyl 
aminofluorene a fte r  3MC pretreatment but not a fte r  PB treatment 
(Juchau e t . a l . 1985).
The antibodies th a t were d irected against PB induced ra t l iv e r  
microsomal cytochrome P450 showed d ifferences in  the c o n s titu tiv e  
level o f the haemoprotein in  both c e ll types and th is  d iffe rence  may 
have been due to  each antibody recognising d if fe re n t epitopes on the 
same p ro te in . The antibodies th a t were d irected against pNF-inducible 
P448 (CTL/Hammersmith 3:4*2) and 3MC-inducible P448 (P450c and P450d) 
a ll showed a s im ila r low c o n s titu tiv e  leve l o f the cytochrome P448 
isoenzyme in  LB and CNS c e lls .  However induction by e ith e r IN UTERO 
or IN VITRO exposures showed th a t LB c e lls  cons is ten tly  contained more 
o f these cytochrome P448 isoenzyme than CNS c e lls  i .e .  by a l l  3 
antibodies. There also appeared to be l i t t l e  d iffe rence in  e ith e r 
c o n s titu tiv e  or induced leve ls  scores and th is  ind icates th a t the 
antibodies may be recognising the same or a very s im ila r epitope on 
the cytochrome P448 pro te ins.
The observation th a t both IN VITRO and IN VIVO lo c a lis a tio n  o f 
embryo cytochrome P450's appeared to be mainly in  the 
d if fe re n t ia t in g  c e lls  around e ith e r the d iffe re n tia te d  fo c i o f 
chondrocytes (LB) or neurones (CNS) IN VITRO and perichondria l tissue  
(LB) or connective tissue (CNS) IN VIVO would tend to  ind ica te  th a t 
cytochrome P450b has an endogenous ro le  in  d if fe re n t ia t io n  because o f 
i t s  lo c a lis a tio n  and lack o f in d u c ib i l i ty  by PB. However the 
developmental regula tion o f each isoenzyme showed th a t cytochrome 
P450B appeAred f i r s t  (day 1 o f cu ltu re ) reaching a maximum on day 4 o f 
cu ltu re  and cytochrome P450c appeared la te r  (day 3 o f cu ltu re ) 
reaching i t s  maximum on day 5. However, cytochrome P450b a tta ined  a 
higher leve l as gauged by s ta in ing  in te n s ity . I f  the ro le  o f
cytochrome P450l s was so le ly  in  d if fe re n t ia t io n  o f embryo c e lls  i t  
would be expected th a t the enzyme would be moderately ac tive  a t a 
re la t iv e ly  ea rly  stage in  cu ltu re . I t  is  possible tha t the non­
inducib le  PB-type cytochrome P450's have th e ir  major ro le  in  
d if fe re n tia t io n  o f c e lls ,  c r i te r ia .  However tha t the cytochrome P448 
isoenzyme (cytochrome P450c) appeared la te r  in  cu ltu re  and was shown 
to be induc ib le , though no precocious development was observed by pNF 
induction , may ind ica te  th a t the ro le  o f th is  isoenzyme is  d if fe re n t 
from tha t o f the PB-type cytochrome P450. I t  is  postulated th a t th is  
isoenzyme form (cytochrome P450c) is  the active  form o f embryo 
cytochrome P450's capable o f xenobiotic metabolism and dat w i l l  be 
presented in  subsequent Chapters to  substantiate th is  conclusion.
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5. MODULATION OF CYTOCHROME P450 ACTIVITY IN EMBRYO CELLS
These sets o f experiments were designed to show th a t the embryo 
cytochrome P450's id e n tif ie d  immunocytochemically in  Chapter 4. were 
functional in  metabolising xenobio tics. I t  was also hoped th a t by 
modulation o f the leve ls  o f embryo cytochrome P450's by e ith e r 
in h ib it io n  or induction , tha t u ltim a te ly  the e ffe c t o f DPH and CPA on 
ra t embryo c e ll d if fe re n tia t io n  IN VITRO could also be modulated thus 
g iv ing evidence fo r the ro le  o f embryo cytochrome P450's in  chemically 
induced teratogenesis.
5.1 COMPARATIVE EFFECTS OF DPH AND ITS METABOLITES ON IN VITRO
DIFFERENTIATION OF EMBRYO CELLS
DPH, i t s  major hydroxy m etabolite p.hydroxy.DPH, i t s  minor 
hydroxy m etabolite m.hydroxy.DPH and the ring  opened acid m etabolite 
diphenylhydantoic acid were added d ire c t ly  to  the cu ltu re  medium a t 
the beginning o f the cu ltu re  period and l e f t  fo r  f iv e  days w ith e ith e r 
LB or CNS c e lls .  Concentration-response curves were prepared and the 
re la tiv e  IC50s calculated (concentration a t which compound in h ib its  
d if fe re n tia t io n  by 50%). These re su lts  are summarised in  Table 5.1 , 
and show th a t DPH and i t s  two hydroxy metabolites were equ itox ic  to  LB 
and CNS c e lls  IN VITRO. However the ring  opened acid m etabo lite , 
formed by a non-P450 mediated reaction IN VIVO, was to ta l ly  non- 
in h ib ito ry  to  c e lls  up to  i t s  maximum s o lu b i l i ty .  Furthermore the 
re su lts  showed tha t both DPH and the p.hydroxy m etabolite were 
s ig n if ic a n t ly  (pcO.OOl and p<0.01 respective ly) more to x ic  to  the CNS 
c e lls  than LB c e lls .
Table 5.1
COMPARATIVE EFFECTS OF DPH AND ITS MAJOR METABOLITES 
ON CNS AND LB CULTURESa IN VITRO
I COMPOUND IC50 CNS 
(pg/ml)
1
IC50 LB | 
(pg/ml) 1 
1
NUMBER OF I 
EXPERIMENTS I
I DPH 67 ± 18
1
91 ± 4b I 9 1
I p.hydroxy DPH 54 ± l i a 90 ± 9ab| 6 1
1 m.hydroxy DPH 79 ± 8a 84 ± 9a | 6 1
1 DPH acid > 250c >250c I 
1
6 1
a There were no s ig n if ic a n t d ifferences between the IC50 o f DPH and 
i t s  major hydroxy metabolites in  CNS or LB.
b S ig n ifica n t d ifferences (p < 0.001 and < 0.01 respective ly) were 
found between the IC50' s o f DPH and p.hydroxy DPH in LB cu ltu res  
compared to  CNS.
c Maximum s o lu b il i ty  in  cu ltu re  medium.
5.2 EFFECT ON DPH RESPONSE IN VITRO BY COINCUBATION WITH INHIBITORS
OF DRUG METABOLISM
The highest non-cytotoxic concentrations (NCC) found fo r  the 
cytochrome P450 in h ib ito rs  are l is te d  in  Table 5.2. In h ib ito rs  were 
coincubated a t th e ir  N.C.C. w ith d if fe re n t concentrations o f DPH over 
the f iv e  day cu ltu re  period and IC50■s calcu lated in  CNS and LB 
cu ltu res as before. Figure 5.1 shows, fo r  a representative 
experiment, the d if fe re n t concentration response curves obtained from 
co-incubating DPH in  the presence and absence o f c im etid ine w ith  LB 
c e lls .  In the presence o f cim etid ine there was a s h i f t  to the l e f t  
in d ica ting  a more to x ic  response to  DPH. Table 5.2 summarises the 
values obtained fo r  LB and CNS IC50' s ±  standard e rro r o f mean. The 
percentage changes in  to x ic ity  o f DPH w ith the in h ib ito rs  are 
represented graph ica lly  in  Figure 5.2. The resu lts  showed th a t 
benzimidazole, e l l ip t ic in e ,  a sp ir in  and metyrapone were the most 
potent in h ib ito rs  to both LB and CNS c e lls ,  s ig n if ic a n t ly  increasing 
the to x ic ity  o f DPH by 67-82% in  LB c e lls  and 41-52% in  CNS c e lls ,  
a-naphthoflavone was a strong in h ib ito r  to  CNS c e lls  increasing 
to x ic ity  by 42% and only acted as a weak in h ib ito r  in  LB c e lls  
increasing to x ic ity  by 22%. Cimetidine and SKF 525A w h ils t increasing 
to x ic ity  by 15 and 3% respective ly  in  CNS c e lls  were found not to  be 
s ta t is t ic a l ly  s ig n if ic a n t, however both compounds s ig n if ic a n t ly  
increased DPH to x ic ity  in  LB c e lls  by 48 and 13% respective ly .
No s ig n if ic a n t d ifferences were found in  the DPH IC50 values w ith  
LB or CNS when coincubated w ith e ith e r ra n it id in e  (Figure 5 .3 ), 
sucrose or inosine (Table 5 .2 ). No modulation o f the IC50 values fo r  
the p.hydroxy. DPH m etabolite was observed fo llow ing  coincubation w ith
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REPRESENTATIVE EXPERIMEOT SHOWING THE 
EFFECT OF CIMETIDINE ON THE CONCENTRATION-RESPONSE 
OF DPH ON LB CELLS IN VITRO
cimetidine (4 0 0 /x g /m  
cimetidine
1 3 0 -
120  -
1 0 0 -
10 20 30 40 50 60 70 80 90 100
C|C50 : 39/xg/ml C|C50 : 87^9 / m 
peg diphenylhydantoin / ml culture medium
FIGURE 5.2
EFFECT ON TH E TO XIC ITY OF D IPH EN YLH YD A N TO IN  
GY COINCUBATION W ITH  CYTO CHRO M E P/,50 IN H IB ITO R SlOOn
BEN
ASP ELL
d’O-
ELL
CIM,SP
40 - BEN
0; NF20 -
SKF
DPH
SKF
LBNS
a -  In h ib ito rs  are abbreviated  as in  Table 5 .2  
* = p<0.001
DPH alone is  considered 100%. The percentage  
increase in  to x ic i ty  was th e re fo re  c a lc u la te d  b y :-
f iC50 UPH + in h ib i to r ^  x ]_qq _ ^qq 
\  IC50 DPH alone /
e ith e r a-naphthoflavone or c im etid ine (Figure 5 .4 ). The CNS c e lls  
were more sensitive  than LB to  p.hydroxy DPH even in  the presence o f 
the in h ib ito rs  (p<0.01) data not shown.
5.3 MODULATION OF THE IN VITRO RESPONSE OF DPH AND CYCLOPHOSPHAMIDE 
BY INDUCERS
5.3.1 COINCUBATION WITH INDUCERS
The highest non-cytotoxic concentrations fo r  the inducers 
phenobarbitone (PB), 3-methylcholanthrene (3MC) and (3-naphthoflavone 
were obtained in  the same way as fo r  in h ib ito rs  (see chapter 2 .2 .1 .)
These values are lis te d  in  Table 5.3. Various concentrations o f 
DPH were coincubated w ith N.C.C. leve ls  o f each inducer fo r  5 days 
w ith e ith e r LB or CNS c e lls .  Results show th a t none o f the inducers 
modulated the e ffe c t o f DPH on CNS c e lls  and only co-incubation w ith 
3MC (not PB nor p.NF) could modulate the e ffe c t o f DPH on LB c e lls .  
3MC s l ig h t ly  increased the to x ic  e ffe c t o f DPH IN VITRO (21% ± 8 ).
Cyclophosphamide (CPA) was to ta l ly  n o n -in h ib ito ry  to  e ith e r LB 
or CNS c e lls  up to i t s  maximum s o lu b i l i ty  (pg/ml) in  the presence o f 
any o f the inducers, (data not shown).
5 .3 .2 . MODULATION OF THE IN VITRO RESPONSE OF DPH AND CPA FOLLOWING 
TRANSPLACENTAL INDUCTION 
Results from the transplacental passage o f ra d io -la b e lle d  ^C-PB 
and 14C-3MC show tha t ra d io a c tiv ity  was present in  the embryos. 
(Experimental procedure described in  Chapter 2 .2 .3 ). Table 5.4 
summarises the data and shows the percentage o f the maternal dose in  
the embryos, and c le a rly  demonstrates th a t both o f these inducers o f
Nu
m
be
r 
of 
di
ffe
re
nt
ia
te
d 
fo
ci
Figure 5.3
EFFECT OF RANITIDINE ON THE IN  VITRO RESPONSE 
OF DPH WITH LB CELLS a
160-1
•  + Ranitidine (750/xg/m!) 
O — Ranitidine
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diphenylhydantoin / ml culture medium
a R epresen ta tive  experim ent i . e .  1 o f 3
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Finure 5 . A
EFFECT OF CIMETIDINE ON THE IN VITRO RESPONSE OF 
P.HYDROXY. DPH WITH LB CELLS *1 8 0 -
1 7 0 -
1 6 0 -
1 5 0 -
1 4 0 -
1 3 0 -
120 -
O + cimetidine (400/xg/m l) 
e  — cimetidine
T
0 10 20 30 40 50 60 70 80 90 100
L*- IC50 : 79 f i g  /  ml 
—► IC50 : 77 peg / m
i i g  p.hydroxy DPH /  ml culture medium
2 Representative experiment i.e. 1 of 3
Table 5.3
MODULATION OF THE IN VITRO RESPONSE 
OF DPH BY COINCUBATION WITH 
INDUCERS IN VITRO
I INDUCER
NON-CYTOTOXIC 
CONCENTRATION 
(pg/m l)
DPH.IC50a 
(pg/m l) 
LB
DPH.IC50a I 
(pg/ml) 1 
CNS I
I DPH ALONE 91 ±4 67+18 I
I PHENOBARBITONE 250 81 ±7 62+5 I
I 3-METHYLCHOLANTHRENE 0.5 70+12*> 59+2 I
I p-NAPHTHOFLAVONE 2.5 82+10 65+5 I
a = mean and standard e rro r where n = 3 experiments.
b = S ig n ific a n tly  d if fe re n t from DPH alone (p<0.02)j 21% increase in  
to x ic ity .
drug metabolising enzymes can cross the placenta and reach the embryo. 
However the )4c ra d io a c tiv ity  represents both parent compound and 
m e tabo lite (s ), given more time the proportion and id e n t if ic a t io n  would 
have been desirab le . Neither l^c-PB nor 14C-3MC e q u ilib r ia te  w ith the 
embryo ( ra t io  o f maternal plasma to  embryo < 1) but leve ls  ind ica te  
exposure.
The dosing protocols fo r  PB, 3MC and pNF are fu l ly  described in  
chapter 2 .2 .4 . and doses were found not to  impair e ith e r reproductive 
a b i l i t y  or cause any discernable embryo abnorm alities. Results o f the 
modulation o f the IN VITRO response o f DPH in  the presence o f LB or 
CNS c e lls  derived from pre-induced mothers are summarised in  Table 
5.5. DPH IC50 was not modulated by CNS c e lls  derived from any 
tra nsp lacen ta lly  induced embryos, however LB c e lls  from e ith e r p-NF or 
3MC pretreated dams showed an increased tox ic  response to  DPH (30%tl0 
and 20%±5 re sp e c tive ly ). Phenobarbitone was w ithout e ffe c t.
Coincubation o f CPA w ith e ith e r LB or CNS c e lls  derived from the 
various ly  pretreated dams showed th a t only LB c e lls  derived from p-NF 
pretreated mothers had the a b i l i t y  to  ac tiva te  CPA and hence show a
to x ic  response. LB c e lls  from 3MC or PB pretreated dams showed no
response as did CNS c e lls  from a ll 3 pretreatments, (data not shown).
Figure 5.5 shows the dose response o f LB c e lls  from p-NF pretreated
dams w ith CPA. The recorded IC50 was 44 pg/ml. This experiment was 
repeated twice more and confirmed th a t only LB c e lls  derived from p-MF 
pretreated dams could ac tiva te  CPA, however there was a large 
v a r ia b i l i ty  in  IC50 values (12, 44 and 99 pg/m l), Table 5.6.
Table 5.4
TRANSPLACENTAL PASSAGE OF RADIOLABELLED INDUCERS
A. 14c-PHEN0BARBIT0NEa
I PREGNANT 
I ANIMAL
MATERNAL PLASMA 
CONCENTRATIONS 
(ngl4c-PB/ml)
EMBRYOS I 
(ng 14C-PB/mg)|
DISTRIBUTION 1 
RATIO 1 
EMBRYO/MOTHER 1
I 1 9.32 0.96 | 0.1030 1
1 2 11.14 1.08 I 0.0969 1
1 3 9.23 0.81 | 0.0877 1
1 4 8.09 0.44 | 0.0543 1
a Dams recieved 0.1% 14c_pb (e 0.75 pC i/day)in the drink ing water 
fo r  10 days (gestationa l days 4-13) and were k i l le d  a t 8.00 am on 
day 13 o f gestation.
B. 14C-3-METHYLCH0LANTHRENEb
I PREGNANT 
I ANIMAL
MATERNAL PLASMA 
CONCENTRATIONS 
(ngl4c-3MC/ml)
I EMBRYOS I 
I(ng 14c-3MC/mg)|
DISTRIBUTION 1 
RATIO I 
EMBRYO/MOTHER I
I 1 3.72 1 15.45 | 0.00041 1
1 2 1.67 1 6.15 | 0.00037 1
1 3 1.64 I 28.90 | 0.00176 1
b Dams received 25 mg/kg/ day (»3.3 pCi/animal/day) i .p .  dose fo r  3 
days (gestational days 10-12) and were k i l le d  a t 8.00 am on day 13 
gestation, i .e .  24 hours a fte r  the la s t dose.
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Table 5,5
MODULATION OF THE IN VITRO RESPONSE OF DPH 
BY TRANSPLACENTALLY ADMINISTERED INDUCERS
I INDUCER DOSING REGIMEN
DPH.IC50
(pg/ml)
LB
DPH.IC50 | 
(pg/ml) I 
CNS |
I NONE 91 ±4 67+18 I
I PHENOBARBITONE 0.1% DRINKING 
WATER D4-13
90+14 65+6 |
I 3-METHYLCHOLANTHRENE 25 mg/kg i .p . 73+5 57+3 I
D 10-12 (20*)
1 p-NAPHTHOFLAVONE 35 mg/kg i .p . 64+12 56+5 |
D 10-12 (30*)
Results are mean and standard e rro r where n = 3 e xp ts '.
Figures in  parenthesis are % increase in  to x ic ity  
* s ig n if ic a n t ly  d if fe re n t from DPH alone (p < 0.001); sudents t . t e s t .
Table 5.6
EFFECT OF INDUCERS ON CPA
ACTIVATION IN VITRO
I Inducer 
1 IN VITRO
CPA IC50 
CNS 
pg/ml
1
CPA IC50 I 
LB | 
pg/ml I 
1
Inducer 
IN VIVO
CPA IC50 
CNS 
pg/ml
CPA IC50 1 
LB | 
pg/ml I
I CPA alone > 1000
1
>1000 | 
1
CPA alone > 1000 >1000 I
1 PB > 1000
1
>1000 | 
1
PB > 1000 >1000 I
1 3MC > 1000
1
>1000 I 
1
3MC > 1000 >1000 I
1 PNF >1000 > 1000 | 
1
PNF > 1000 99,44,12 I
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Figure 5.5
REPRESENTATIVE EXPERIMENT OF CYCLOPHOSPHAMIDE 
ACTIVATION BY g-NAPHTHOFLAVONE PRETREATED LB CELLS
150
112.5 -
CONTROL
75
37.5 -
(3MC + PB no effect)
12.50 25 37.5 50 62.5 10087.575
Cyclophosphamide yKgy^ml
5.4 DISCUSSION
In summary resu lts  from th is  chapter have shown th a t modulation 
o f cytochrome P450 a c t iv ity  in  embryo c e lls  by use o f in h ib ito rs  IN 
VITRO and inducers IN VITRO and IN UTERO can subsequently modulate the 
IN VITRO response o f DPH in  both LB and CNS c e lls  and CPA in  LB 
c e lls .
F ir s t ly ,  I have shown th a t, o f the 3 metabolites tested IN VITRO 
only DPH acid was to ta l ly  n o n -in h ib ito ry  to d if fe re n t ia t in g  ra t embryo 
c e lls .  Both hydroxy-metabolites and DPH i t s e l f  were approximately 
equ itox ic , and i t  would therefore appear th a t the only completely 
de tox ify ing  pathway o f the ones studied, is  cleavage o f the hydantoin 
ring  and formation o f the acid product.
I t  is  in te re s tin g  to  note th a t a fte r  both m and p hydroxyla tion 
o f the phenyl ring  o f DPH, a ch ira l centre is  generated thus y ie ld in g  
sterochemically d is t in c t  hydroxylated m etabolites. While th is  has 
been recognised as a general face t o f metabolism o f th is  class o f 
compounds (Kaminsky e t a l . 1984) i t  must be emphasised th a t th is  
aspect was not addressed in  my studies and is  c e rta in ly  an area th a t 
should be addressed in  fu tu re  work re la ted  to  the IN VITRO teratogenic 
po ten tia l o f hydroxylated DPH m etabolites.
Recent reports (Clapper e t .a l .  1985, Clapper and K le in 1986) 
postulate tha t i t  is  e ith e r a maternal serum drug-protein complex th a t 
is  the u ltim a te  teratogen or the catechol m etabolite (B il l in g s  and 
M ilton 1985) or a free radical intermediate derived from a 
prostaglandin synthetase mediated b io a c tiva tio n  (Wells e t .a l .  1986) or 
the arene oxide intermediate derived from a cytochrome P450 mediated 
reaction (see Chapter 1 .5 .2 .4  fo r  references and experimental
evidence). Since these reactive  intermediates are unstable i t  was not 
possible to  look a t th e ir  e ffe c t d ire c t ly  IN VITRO.By modulating the 
metabolism to the reactive species i t  was possible to id e n t ify  the 
most potent compound. The study w ith DPH co-incubated w ith a wide 
va rie ty  o f f a i r ly  spe c ific  and broad cytochrome P450 in h ib ito rs  showed 
th a t (w ithout exception) DPH to x ic i ty  was increased in  the presence o f 
metabolic in h ib ito rs . This increase in  to x ic ity  was not due to  
physico-chemical factors such as pH change, osm ola lity or excess 
solvent vehicle (as ne ither inosine nor sucrose, 2 ethanol soluble 
non-teratogens, a lte red the in h ib ito ry  e ffe c t o f DPH). R an itid ine  
which is  pharmacologically and s tru c tu ra lly  s im ila r to c im etid ine but 
w ithout the P450 in h ib ito ry  properties (Bell e t.a l 1983, Watts e t .a l .  
1982), was w ithout e ffe c t on DPH IC50 IN VITRO (Figure 5.3) whereas 
cim etid ine caused an increase in  to x ic i ty  (15% CNS, 48% LB). This 
observation strongly suggests th a t the increased e ffe c ts  o f DPH when 
coincubated w ith cytochrome P450 in h ib ito rs  is  due e n tire ly  to  the 
in h ib it io n  o f metabolism by the cytochrome P450 system.
This study im plies th a t d if fe re n t ia t in g  ra t embryo c e lls ,  
especia lly  the LB c e lls  have the a b i l i t y  to metabolise DPH.
The fa c t th a t p.hydroxy.DPH s t i l l  represents a substantia l 
teratogenic hazard IN VITRO im plies th a t hydroxylation is  not a 
completely de tox ify ing  reaction un like  hydantoin rin g  cleavage to  
DPH.acid.
D irec t coincubation IN VITRO o f DPH w ith the various cytochrome 
P450 inducers showed tha t only LB c e lls  co-incubated w ith 3MC 
increased DPH to x ic i ty ,  p-NF and PB were in e ffe c tiv e . CNS c e lls  were 
re fac to ry  w ith a ll inducers. I t  would appear tha t the only compound
to act IN VITRO was 3MC and the only responsive tissue LB. The N.C.C. 
leve l o f 3MC was 0.5 pg/ml compared to  PB (N.C.C. 250 pg/m l). and p-NF 
(N.C.C. 2.5 pg/m l). That 3MC was able to modulate DPH to x ic i ty  a t such 
a low N.C.C. leve l im plies th a t i t  is  a very powerful inducer.
IN VIVO studies o f the transplacental passage o f ra d io lab e lled  PB 
and 3MC have shown th a t both these inducers cross the placenta a t 
leve ls  comparable w ith other compounds e.g. l^C-DPH d is tr ib u t io n  ra t io  
embryo/mother on day 11 gestation a fte r  a s in lge  i .p .  dose in  the ra t 
was 0.1 (Stevens and Harbison 1975). I ^ c- pb reached a higher 
d is tr ib u tio n  ra t io  embryo/mother (0.103 - 0.0543) than 14c_3mc 
(0.00176 -0.00041). This observation may be a re s u lt o f 14c_pb being 
administered ad lib itu m  in  the d rink ing  water and therefore samples 
were from constant exposure as opposed to ^c_3MC samples which were 
taken 24 hours a fte r  the la s t  i . p .  dose. Therefore the actual 
d is tr ib u tio n  ra tio s  may have been more a lik e  had sampling and dosing 
regimens been id e n tic a l. Embryo c e lls  from PB-induced dams could 
ne ither modulate DPH to x ic i ty  IN VITRO nor ac tiva te  CPA. That PB was 
present in  the embryos a fte r  maternal adm in istra tion but was s t i l l  
unable to modulate teratogenic e ffe c ts  im plies th a t PB is  not an 
inducer o f embryo cytochrome P450, although i t  was active  in  the 
maternal l iv e r .  A lte rn a tiv e ly  PB may induce embryonic cytochrome 
P450, but the sp e c ific  isoenzyme(s) induced do not a lte r  the 
teratogenic po ten tia l o f DPH.
Transplacental exposure to  both cytochrome P448 inducers (J3NF and 
3MC) caused increased to x ic ity  o f DPH in  LB c e lls  IN VITRO, however, 
only p-NF pretreated LB c e lls  could ac tiva te  CPA IN VITRO. Although a 
s t r ic t  comparison o f IN VIVO versus IN VITRO induction is  not possible
(concentrations o f inducers IN VITRO is  lim ite d  by th e ir  d ire c t 
to x ic i ty ) ,  the e ffec ts  o f exposing embryos transp lacen ta lly  to  P448 
inducers caused a greater response than by d ire c t ly  coincubating 
embryo c e lls  w ith e ith e r 3MC or p-NF (no e f fe c t) .  I t  would appear 
tha t a m aternally mediated reaction (or metabolism o f the inducer) 
enhances the inductive e ffe c ts  on embryo cytochrome P448, espec ia lly  
w ith  p-NF as transp lacen ta lly  exposed LB c e lls  had the a b i l i t y  
(s u f f ic ie n t  cytochrome P448) to  ac tiva te  CPA.
This study shows th a t embryo cytochrome P448 is  ind uc ib le , 
especia lly  by p-NF, but th a t th is  phenomenon is  tissue s p e c ific  as CNS 
c e lls  were re frac to ry  to a ll transp la cen ta lly  administered and IN 
VITRO inducers. The observation th a t cytochrome P450 was not 
inducib le whereas cytochrome P448 was in  embryo c e lls  is  in  accordance 
w ith the l i te ra tu re  (Pelkonen 1980, Juchau e t .a l .  1985, Mizokami 
e t .a l .  1982 and Worrell 1984).
The e ffe c ts  o f DPH IN VITRO can be increased by modulation o f the 
le v e ls /a c t iv ity  o f the cytochrome P450 system by both in h ib ito rs  and 
inducers, which makes i t  d i f f i c u l t  to  determine whether DPH i t s e l f  or 
some m etabolite(s) or both, is  the u ltim a te  teratogen. In h ib it io n  o f 
the cytochrome P450's increased the e ffe c ts  o f DPH IN VITRO to  a 
greater extent than inducers. The maximum reduction in  IC50 
(increased to x ic ity )  w ith  an in h ib ito r  was benzimidazole and LB c e lls  
82%±6 and w ith an inducer, p-NF transp la cen ta lly  induced LB 30%±10. 
That in h ib ito rs  increased to x ic ity  o f DPH in  both LB and CNS c e lls  
implies tha t i t  is  DPH i t s e l f  and not a m etabolite which is  the 
u ltim ate teratogen, however how e ffe c tiv e  or precise ( fo r  a p a r t ic u la r  
isoenzyme, an in h ib ito r  may block one pathway and consequently
increase another) the in h ib it io n  o f cytochrome P450's was, remains a 
matter fo r  speculation.
Only LB c e lls  from cytochrome P448 induced dams had the a b i l i t y  
to modulate DPH to x ic i ty  IN VITRO so implying fo r  LB c e lls  a 
m etabolite o f DPH is  the u ltim ate  teratogen. However CNS were 
re frac to ry  to the inductive e ffec ts  o f both 3MC and p-NF. I t  would 
seem th a t these inducers may be increasing the leve ls  o f p.hydroxy.DPH 
(which was found to be equ itox ic w ith DPH IN VITRO) or producing 
another m etabolite not generally formed by induced embryo c e lls  eg; 
dihydrodiol or 0-m ethyl-catechol. However these resu lts  i l lu s t r a te  
the complexity o f whether DPH i t s e l f  or some metabolic product which 
is  the u ltim ate teratogen; data from th is  chapter presents evidence 
fo r  both cases. That p.hydroxy.DPH is  equ itox ic  w ith DPH suggests 
tha t i t  could be both DPH and the p.hydroxy, m etabolite ; th is  w i l l  be 
considered in  conjunction w ith the evidence from chapters 6 and 7.
The main conclusion from th is  chapter is  tha t there are changes in  
compound to x ic ity  fo llow ing  modulation o f cytochrome P450 a c t iv i ty  in  
embryo c e lls ,  by appropriate IN VITRO and IN VIVO manipulations.
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6.  ROLE OF THE ARENE OXIDE INTERMEDIATE OF DPH IN IN VITRO
TERATOGENESIS
The major metabolites o f DPH are the p. and m. hydroxy de riva tives  
o f the phenyl group a t pos ition  5 o f the hydantoin r in g . These 
m etabolites could have been derived by isom erisation o f an epoxide 
interm ediate. Epoxides are reactive  species and may be the causative 
agent in  DPH to x ic ity  and covalent binding to embryo prote ins has been 
used as a measure o f reactive  DPH arene oxide m etabolite form ation.
The assignment o f an epoxide as the reactive  species o f DPH has been 
examined by increasing i t s  formation (v ia  P450 inducers), decreasing 
i t s  d e to x ific a tio n  (v ia  epoxide hydrolase in h ib it io n )  and increasing 
i t s  d e to x ific a tio n  (v ia  th io l supplementation).
6.1 IRREVERSIBLE BINDING OF 14C-DPH TO EMBRYO CELL PROTEINS
Since the y ie ld  o f prote in  from cu ltu red embryo c e lls  was so small 
(6 u te r i a 72 embryos » 350 pg prote in  in  LB or 100 pg pro te in  in  CNS) 
12 u te r i embryos were pooled fo r  each experiment. Each o f the 
d if fe re n t coincubations or pretreated c e lls  had i t s  own c o n tro l, c e lls  
derived from untreated mothers coincubated over the same period o f 
time w ith the appropriate concentration o f DPH and the same fixe d
concentration o f l^c-DPH. I t  was found th a t a 30 minute incubation o f
5 day old cu ltu red c e lls  w ith 14c- dph did not  give r is e  to any 
covalent binding (data not shown).
A concentration-response o f covalent binding fo r  DPH a t 20, 40 and 
60 pg/ml (and a fixed  concentration o f 0.4 pCi 1 4 c - D P H /d is h )  w ith  LB
and CNS c e lls  showed th a t increasing concentrations o f DPH did not
s ig n if ic a n tly  a lte r  the degree o f cova lently  bound m etabolites over
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Table 6.1
IRREVERSIBLE BINDING OF 14C-DPH TO EMBRYO CELL PROTEIN
1 Concentration o f 
1 DPH (pg/ml) Cell type
DPH equivalents3 1 
mol x 10“ 15/mg 1 
pro te i n I
1 20 LBb 2.18 I
CNSc 2.34 I
1 40 LB 2.02 |
CNS 2.50 I
1 60 LB 2.02 |
CNS 2.15 |
a calcu lated by reference 14c_dph, 1 D.P.M = 6 x 10“ ^5 moles DPH.
b Pooled c e lls  from 12 u te r i,  48 islands y ie lded 673 pg p ro te in  and 
245 D.P.M.
c Pooled c e lls  from 12 u te r i5 48 islands y ie lded 403 pg pro te in  and 
157 D.P.M.
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Table 6.2
THE EFFECTS OF COINCUBATION AND TRANSPLACENTAL INDUCTION OF 
ON IRREVERSIBLE BINDING OF 14c DPH TO EMBRYO CELLS
1 1
I CO-TREATMENT I 
1 1 
1 1
CELL TYPE |
DPH equivalents^ 
Mols x 10 "!5/mg 
prote in
T '  ------------(------------- 1
I CONTROL^  I DPH I 
1 Mols x 10-15/mg| b inding0 1 
1 prote in  \ [ %  CONTROL)I 
1 1 1
1 1 LB | 7.92 1 20.15
1 1 
1 1
1 1 LB | 9.33 1 10.56 I 32.6+ 8.2 |
1 1 LB | 5.73 I 15.82 1 1
I BENZIMIDAZOLE I LB | 3.41 1 16.47 1 1
I (200 pg/ml) 1 1 1
I w ith  DPH a t I 1 1
1 20 pg/ml. I CNS | 33.38 I 97.03 1 1
CNS | 0.48 1 1.00 I 67.7+27.2 |
1 1 CNS | 1.37 1 1.46 1 1
1 1 
1 1
CNS I 1.32 1 3.24 1 1 
1 1
1 I 
1 1 LB | 46.76 I 20.12
1 1 
1 1
1 1 LB | 31.62 I 26.85 1 176.75 I
1 1 LB | 23.51 1 16.37 I + 55.4 I
1 TCPO (1pg/ml) | LB | 34.03 I 15.76 1 1
1 w ith DPH a t I 1 1
I 60 pg/ml. I 1 1
1 1 CNS | 90.98 I 37.73 1 1
1 1 CNS | 3.76 1 1.00 I 298.25 I
1 1 CNS I 5.38 1 3.22 I +114.45 I
1 1 
1 1
CNS I 6.00 1 1.46 1 1 
1 1
1 1 
1 1 LB | 43.32 1 20.11
I 1 
1 1
1 1 LB | 29.35 1 27.02 1 175.5 I
1 1 LB | 23.24 1 16.44 1 + 6 1 . 3  I
I p-NF IN UTERO I LB | 37.71 1 15.83 1 1
I exposure w ith I 1 1
1 DPH a t I 
1 60 pg/ml | 
1 1 
1 1 
1 1 
1 1
CNS I 
CNS | 
CNS I 
CNS I
48.81
4.23
3.62
5.36
1 37.72 
1 1.00 
1 3.23 
1 1.47
1 1 
I 255.75 I 
I + 158.3 I 
1 1
a calculated by reference 14C-DPH, 1DPM ■ 6 x 10"!5 mol s.
b The appropriate binding data o f DPH in the absence o f 
coincubation or transplacental induction .
c Calculated fo r  each separate experiment (n=4), mean and 
standard e rro r.
th is  lim ite d  substrate range (Table 6.1) and resulted in  2.02 - 2.50. 
pmol o f DPH bound/mg p ro te in .
The e ffe c t o f two d if fe re n t coincubations and pNF pretreatment on 
the amount o f m etabolite ir re v e rs ib ly  bound to embryo LB and CNS c e lls  
was examined*- Benzimidazole a t i t s  highest non cy to tox ic  
concentration (200 pg/ml) w ith DPH a t 20 pg/ml, trich loropropene oxide 
(TCPO) a t i t s  highest non-cytotoxic concentration (1 pg/ml) and DPH a t
60 pg/ml, and p-NF pre-induced c e lls  w ith  DPH a t 60 pg/ml. The
resu lts  are summarised in  Table 6 .2 . The re su lts  show th a t
coincubation w ith benzimidazole causes a decrease in  the amount o f
cova lently bound 14c-DPH metabolites to  33% o f the contro l value in  LB 
and to  67% in  CNS c e lls .  Coincubation w ith TCPO increases the amount
s
o f covalent binding by 1.76 fo ld  in  LB and 2.98 fo ld  in  CNS c e lls  over
c e lls  cu ltured w ith DPH in  the absence o f the in h ib ito r .  
Transplacentally p-NF induced embryonic c e lls  increased covalent 
binding o f DPH by approximately the same amount as TCPO, i .e .  1.76
fo ld  in  LB and 2.55 fo ld  in  CNS c e lls  re la t iv e  to the co n tro l,
covalent binding in  embryonic c e lls  derived from untreated mothers.
6.2 MODULATION OF THE EPOXIDE PATHWAY IN VITRO
Coincubation o f LB or CNS c e lls  w ith e ith e r TCPO or th io l 
supplementing agents (N -acetyl-cyste ine or g lu ta th ione) a t th e ir  
highest non-cytotoxic concentrations w ith d if fe re n t concentrations o f 
DPH did not re s u lt in  a lte ra tio n  o f DPH to x ic ity  expression as 
assessed by the IC50 value (Table 6 .3 ).
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Table 6.3
EFFECT ON DPH TOXICITY BY MODULATING THE 
DETOXIFICATION OF THE ARENE OXIDE INTERMEDIATE
CNS LB I
I COMPOUND CO- I 
I INCUBATED | 
1 WITH DPH |
COMPOUND ADDED 
AT NON-CYTOTOXIC 
LEVEL (pg/ml)
IC50 OF DPH 
(pg/m l)a/ b
IC50 DPH + I 
(pg/m l)a/b  |
I DPH ALONE | - 67 + 18 9 1 + 4  I
1 TRICHLORO- | 
I PROPENE OXIDE|
1 63 ± 7 90 + 4 I
1 N-ACETYL | 
I CYSTEINE |
1000 62 + 5 86 + 5 |
I GLUTATHIONE I 100 63 + 4 90 + 3 |
a Mean and standard e rro r from 3 experiments
b No s ig n if ic a n t d ifferences found between a l l  te s t and con tro l 
values, in  both CNS and LB c e lls .
6.3 DISCUSSION
Results from th is  Chapter have shown th a t the degree o f 
irre ve rs ib le /co va le n t binding o f l^c-DPH to ra t embryo c e lls  IN VITRO 
can be modulated by both inducers and in h ib ito rs  o f cytochrome P450 
and an expoxide hydrolase in h ib ito r  (TCPO). However, TCPO and th io l 
supplementing agents did not modify the to x ic i ty  o f DPH IN VITRO.
I t  is  to be expected th a t an inducer o f the cytochrome P450 
system such as p-NF would increase the ox ida tive  metabolism (r in g  
hydroxylation) o f DPH and since in  the case o f DPH, hydroxylation is  
thought to proceed via  the reactive  arene oxide intermediate (see 
Chapter 1 .5 .2 .4  and Figure 1.4) the amount o f reactive interm ediate 
ava ilab le  fo r  covalent binding to  essentia l proteins would also be 
expected to increase. In my study th is  was observed; p-NF 
tra nsp lacen ta lly  induced LB c e lls  had 1.75 fo ld  greater covalent 
binding than the con tro ls and CNS c e lls  2.55 fo ld  greater.
S im ila rly  an in h ib ito r  o f the cytochrome P450 system such as 
benzimidazole would be expected to have the reverse e ffe c t and th is  
was observed. Benzimidazole coincubated a t a non-cytotoxic 
concentration w ith LB reduced the covalent binding o f ^c-DPH by 32% 
re la tiv e  to  the contro l and CNS by 67%. I t  should be noted th a t 
whereas pNF caused an increase in  covalent binding and benzimidazole a 
decrease, both compounds caused an increase in  DPH to x ic i ty  as gauged 
by a decrease in  IC50 (Results from Chapter 5).
The v a r ia b i l i ty  in covalent binding o f con tro ls  and c e lls  
coincubated w ith TCPO or benzimidazole or transp lacen ta lly  induced 
c e lls  was large but th is  was to  be expected since the binding to  ra t 
l iv e r  microsomes (a more cons is tan tly  reproducible system) o f 14c-
practa lo l metabolites also produced great va ria tion  and standard e rro r 
(120% control values) (Orton and Lowery 1981).
One o f the d e to x ific a tio n  pathways fo r  reactive arene oxide 
intermediates is  hydration to the dihydrodiol m etabolite, mediated by 
the enzyme epoxide hydrolase (Oesch 1982). TCPO, which is  an 
in h ib ito r  o f th is  enzyme, would be expected to  cause an increase in  
the amount o f reactive arene oxide ava ilab le  fo r  covalent binding and 
in  th is  study th is  was observed; LB c e lls  had 176.75 ± 55.45% the 
amount o f ^C-DPH bound re la tiv e  to con tro ls  and CNS 298.25 t  114.45%. 
This study o f the ir re v e rs ib le  binding o f ^C-DPH to ra t embryo c e lls  
has shown tha t the enzymes regu la ting  metabolism to , and 
d e to x ific a tio n  o f, the arene oxide are not only present but functiona l 
a t an early  stage o f organogenesis IN VITRO.
My find ings are in  accordance w ith the l i te ra tu re ,  th a t both 
human (Pelkonen 1980) and ra t (Pelkonen and Karki 1975) embryos were 
capable o f epoxidation a t ea rly  stages o f gestation. However despite 
th is  biochemical evidence pre lim inary immunocytochemical work on the 
id e n t if ic a t io n  o f the epoxide hydrolase antibody (using an antibody to 
ra t l iv e r  epoxide hydrolase raised in  the goat) proved negative, but 
th is  was probably due to  in c o rre c t / in s u ff ic ie n t concentrations o f 
e ith e r the 1st or 2nd antibody in  the technique (Chapter 2 .2 .5 ), and 
therefore these re su lts  must be considered te n ta tiv e .
Coincubation o f DPH w ith e ith e r TCPO or th io l supplementing 
agents (which de tox ify  the arene oxide by conjugation w ith th io l 
groups to  an esse n tia lly  non-reactive interm ediate) (Oesch 1982), were 
found to  be in e ffe c tiv e  a t modulating the response o f e ith e r LB or CNS 
c e lls  to  DPH IN VITRO, as gauged by a lte r in g  the IC50 values and
therefore not able to modify DPH to x ic i ty .  However TCPO was found to  
increase the degree o f covalent binding o f l^c-DPH in both LB and CNS 
c e lls .  This find in g  im plies th a t despite the e ffe c t o f TCPO on the 
degree o f covalent b inding, the arene oxide does not play an important 
ro le  in  the to x ic ity  o f DPH IN VITRO. This concept w i l l  be fu rth e r 
discussed in  Chapter 8.
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7. IDENTIFICATION OF 14c_DPH METABOLITES FORMED IN VITRO BY EMBRYO
CELLS
l^C-DPH was incubated w ith ra t embryo c e lls  (pooled from 12 
untreated mothers) a t i t s  maximum non-cytotoxic concentration, 50 pg? 
0.2 pCi/ml 14c-DPH cu ltu re  media. A fte r the f iv e  day incubation 
period po ten tia l metabolites were extracted from LB and CNS c e lls  and 
LB and CNS cu ltu re  media by the methods described in  chapter 2 .2 .8 . 
The extracts were then analysed by an H.P.L.C. method w ith  U.V. 
detection and the ra d io a c tiv ity  in  the fra c tio n s  counted by a l iq u id  
s c in t i l la t io n  technique, see chapter 2.2 .7 fo r  method d e ta ils . The 
contro l experiment was 50pg; 0.2 pCi/ml T4c_DPH incubated fo r  5 days 
in  cu ltu re  medium in  the absence o f ra t embryo c e lls .
The re ten tion  times and minimal leve ls  o f detection fo r  each o f 
the metabolites (p.hydroxy. DPH, m.hydroxy. DPH, DPH acid) and DPH 
i t s e l f  were recorded and are presented in  Figure 7.1. The most po lar 
m etabolite , DPH acid , eluted f i r s t ,  re ten tion  time 2 mins, minimum 
leve l o f detection (m .l.d ) a t 0.0.8 s e n s it iv ity  was 1 ng/m l. The 
subsequent order o f e lu tio n  was p.hydroxy.DPH, (6 mins, m .l.d . 10 
ng/ml) m.hydroxy.DPH (7.5 mins, m .l.d . 10 ng/ml) and DPH (14 mins, 
m .l.d . 2 pg/m l). Figure 7.2. i l lu s tra te s  the HPLC trace and re la t iv e  
ra d io a c tiv ity  o f DPH incubated w ith cu ltu re  medium in  the absence o f 
c e lls  and shows tha t no rad ioactive metabolites were produced.
7.1 IDENTIFICATION OF DPH METABOLITES IN RAT EMBRYO CELLS
Analysis o f the extracts from LB and CNS c e lls  are shown in  
Figure 7.3. LB c e lls  showed th t  the m a jo rity  o f the ra d io -a c t iv ity  
was present as 14q-DPH (71.5%) but th a t by area under curve
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comparison, 3.5% o f ra d io a c tiv ity  was DPH-acid and 5.3% p.hydroxy.DPH. 
An un id en tified  peak a t 20 mins represented 19.6% o f the 
ra d io a c tiv ity . CNS c e lls  showed th a t the m a jo rity  o f ra d io a c tiv ity  
was l^C-DPH (92.5%), o f the to ta l.  The only other two m etabolites 
present were id e n tif ie d  as DPH acid (3.2%) and p.hydroxy.DPH (4.3%).
7.2 IDENTIFICATION OF DPH METABOLITES FORMED IN THE CULTURE MEDIA
BY RAT EMBRYO CELLS
Analysis o f the extracts  from the cu ltu re  media from LB and CNS 
c e ll incubates are shown in  Figure 7.4. Both sets o f media ex trac ts  
showed, by HPLC and ra d io a c tiv ity  in  the corresponding e luants, the 
presence o f DPH acid and p.hydroxy.DPH m etabolites. LB c e lls  showed 
tha t 79.5% o f the to ta l ra d io a c tiv ity  was ^ c_dPH, 17% p. hydroxy. DPH 
and 3.4% DPH acid . CNS c e lls  showed th a t 93.7% o f to ta l ra d io a c tiv ity  
was l^c-DPH, 5.4% p.hydroxy. DPH and 0.8% DPH acid.
7.3 DISCUSSION
Results from th is  chapter ind ica te  th a t ra t embryo c e lls  IN VITRO 
have the a b i l i t y  to  metabolise DPH by both ring  opening to the acid 
m etabolite and hydroxylation to  the p.hydroxy.DPH m etabolite and th a t 
LB c e lls  have a greater metabolic capacity than CNS. This conclusion 
is  based on re la tiv e  re ten tion  times on the HPLC and comparison to  
authentic standards, and i t  is  recognised th a t, time pe rm itting  a more 
po s itive  id e n t if ic a t io n  o f the metabolites by physical methods (e .g . 
mass spectrometry) would have been desirab le . DPH alone w ith media 
did not show any metabolites present (Figure 7.2) This confirmed th a t 
the observed peaks from HPLC a n a ly s is /ra d io a c tiv ity  in eluants were 
genuine metabolites formed by the c e lls  themselves.
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The method o f HPLC analysis employed a reverse phase Cl8 carbon- 
n i t r i l e  column which meant h igh ly polar compounds eluted f i r s t  w ith  
high reso lu tion  and s e n s it iv ity  o f de tection . Extracts from the 
samples o f 14c-DPH shows th a t peaks were more retarded (average peak 
o f DPH from samples was a t 18 minutes compared to 14 minutes w ith 
standard pure DPH) and the peak shapes were broader and more 
fla tte n e d . However the re ten tion  time o f DPH th a t had been extracted 
from a 5 day incubation period w ith cu ltu re  medium in  the absence o f 
c e lls  showed th a t i t s  re ten tion  time lengthened to  16.5 minutes. I t  
is  not understood why cu ltu re  medium should cause th is  e ffe c t,  s ince, 
serum proteins were previously removed by Sep-pak f i l t r a t io n  (see 
method in  chapter 2 .2 .8 ).
LB c e lls  had 3 . 5 % ,  and CNS 3.2% ra d io a c tiv ity  present as the DPH 
acid which im plies equal a b i l i t ie s  o f both types o f c e lls  to rupture 
the hydantoin ring  to form the acid product. However LB c e lls  had 
5.3% compared to  4.3% ra d io a c tiv ity  in  CNS c e lls  as the p.hydroxy.DPH 
m etabolite which tends to  ind ica te  th a t LB c e lls  were s l ig h t ly  more 
e ffe c tiv e  a t hydroxylation than CNS.
LB c e lls  also had an u n ide n tifie d  m etabolite th a t was less po lar 
than DPH and represented 19.6% o f the to ta l ra d io a c tiv ity . This 
m etabolite could not have been the dihydrodio l or catechol since these 
polar m etabolites should have eluted around the same time as the 
p.hydroxy.DPH m etabolite (Chow e t al 1980, Chow and Fischer 1981). I t  
could possibly be a protein-bound DPH fra c tio n  th a t was not completely 
removed by the Sep-pak extraction  procedure, a novel m etabolite or 
a r t i fa c t .  In te re s tin g ly  th is  peak was only found in  LB c e lls  and not 
the medium.
Analysis o f the media from LB c e ll incubates showed th a t 17% o f 
the to ta l ra d io a c tiv ity  was the p.hydroxy.DPH m etabolite compared to 
5.4% w ith the CNS and LB c e lls  had 3.4% compared to  0.8% in CNS o f DPH 
acid. This ind ica tes th a t LB c e lls  are more active  a t producing each 
metabolite than the CNS c e lls  since the metabolites would pass across 
the membranes to  a more d ilu te  medium.
Based on b ila ry  excretion data, pregnant ra ts  (days 19-21 
gestation) convert a t le a s t 50% o f an oral dose o f DPH to  p.hydroxy 
DPH w ith in  5 hours (Vore e t al 1978). In the 2nd trim este r o f 
pregnancy humans also convert 48% i  21 o f an oral dose o f DPH to  
p.hydroxy DPH w ith in  6 hours o f an oral dose (Kochenour e t al 1980).
In conclusion these re su lts  have shown th a t w h ils t in t r a -c e llu la r  
leve ls  o f metabolites were approximately equal in  LB and CNS c e lls  the 
e x tra -c e llu la r  concentrations ind icated th a t LB c e lls  were more 
e ffe c tiv e  a t hydroxylation and hydantoin ring  opening than CNS c e lls .  
Also LB c e lls  had over the 5 day incubation period approximately V 3 
the metabolic capacity fo r  p.hydroxy.DPH formation compared to  
maternal l iv e r  over a 5 hour period; ( fo r  a comparable time period LB 
c e lls  had 0.014% metabolic ca p a b ility  o f the maternal l iv e r ) .
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8.1 EVIDENCE FOR PRESENCE AND FUNCTIONALITY OF RAT EMBRYO CYTOCHROME
P450's
Results from th is  thesis have shown the f i r s t  q u a lita tiv e  evidence, 
by means o f immunocytochemistry (Chapter 4 ), o f the presence o f 
cytochrome P450's in  d if fe re n t ia t in g  ra t embryo c e lls  IN VITRO. The 
im plica tions o f detecting these enzymes a t such an early  stage o f 
organogenesis in  the ra t are fa r  reaching. H is to r ic a lly ,  rodent embryos 
are known to be la te  developers o f smooth endoplasmic re ticu lum  and 
hence re la t iv e ly  d e fic ie n t in  microsomal cytochrome P450's compared to  
human or primate embryos (Remmer and Merker 1963). Accordingly, 
detection o f c o n s titu t iv e , and in  some cases induc ib le , leve ls  o f 
cytochrome P450's in  ra t embryo LB and CNS c e lls  would almost c e r ta in ly  
suggest th e ir  presence, and probably a t higher leve ls  in  human embryo 
c e lls  a t the same stage o f organogenesis.
Isoenzymes o f cytochrome P450 (PB-inducible form 1b1 and 3MC- 
inducib le  type forms 'c ' and 1d ’ ) were c o n s titu tiv e ly  present in  
untreated embryo c e lls ,  however, only the cytochrome P450'c' and 1d1 
isoenzymes were found to be induc ib le . This observation was in  
accordance w ith re la ted published l i te ra tu re  (Mizokami e t al 1982, 
Sunouchi e t al 1983, Faustman-Watts e t al 1984, Juchau e t al 1985), and 
maybe associated w ith the fa c t th a t cytochrome P450'c' and 1d1 
isoenzymes are the only isoenzymes inducib le  in  cu ltu red c e lls  
(Guengerich 1986). The placenta, (p a rt o f which is  con tribu ted by the 
embryo), is  also reported to only have inducib le  cytochrome P450'c' and 
*d* forms despite having a c o n s titu tiv e  leve l o f cytochrome P4501b 1 
(Juchau 1980), and so in d ire c t ly  consolidate ny find ings .
The method o f Western B lo ttin g  was used to  confirm th a t the 
increased leve ls  o f s ta in ing  in  c e lls  observed by immunocytochemistry 
w ith exposure to cytochrome P450 'c ' and ' d1 form inducers was 
cytochrome P450 'c 1 p ro te in . Results showed th a t in  fa c t pNF pre­
exposure o f both LB and CNS c e lls  resu lted in  more prote in present in  
the bands corresponding to  p u r if ie d  ra t l iv e r  microsomal P450 'c 1. The 
leve ls  o f PB inducib le  P450 1b 1, w h ils t present a t a moderately high 
c o n s titu tiv e  leve l were re fra c to ry  to induction . Given these find ings  
in  conjunction w ith the s ta in ing  re s u lts , the conclusion can be made 
th a t ra t embryo cytochrome P450 'C  is  inducib le  but PB-inducible P450 
1b ' is  not.
The ontogeny o f the two major forms o f cytochrome P450 in  cu ltu re  
over the 5 day incubation period showed th a t the (non-inducib le) PB-type 
P450 'b ' appeared f i r s t  and reached a higher steady-state leve l than the 
(induc ib le ) P450 'c 1 form. I t  would be tempting to speculate th a t PB- 
type P450 1b ' has an endogenous ro le  and hence, despite having the 
correct epitope to be id e n tif ie d  by immunocytochemical s ta in in g , would 
not respond to  PB induction .
The P450 'c 1 isoenzyme appeared la te r  in  the cu ltu re  period 
(midway, on day 3 ), and th is  developmental time pattern was unaltered by 
p r io r  IN UTERO exposure to  pNF. Only increased leve ls  were observed a t 
the end o f the cu ltu re  period. This re s u lt ind ica tes th a t induction o f 
embryo c e ll cytochrome P450 'c ' is  a process invo lv ing  'pre-programming' 
and th a t embryo c e lls  'memorise' the pNF exposure, perhaps because the 
gene coding fo r  P450 'c ' has not ye t been expressed and so induced 
leve ls  are seen 4 days a fte r  the la s t  exposure, i . e .  day 12 IN UTERO = 
la s t  exposure, day 3 IN VITRO = increased leve l and f i r s t  appearance.
That DPH to x ic ity  IN VITRO was modulated by coincubation w ith cytochrome 
P450 in h ib ito rs , inducers and transp lacen ta lly  administered 
inducers would ind ica te  th a t the embryo cytochrome P450's observed 
immunocytochemically and detected by Western B lo ttin g  were also 
functional ( i .e .  capable o f xenobiotic metabolism). A ll o f the 
cytochrome P450 in h ib ito rs  tested th a t were coincubated w ith LB c e lls  
caused an increase in  DPH to x ic i ty  (re su lts  from Chapter 5 ), but only 5 
out o f the 7 caused an increase in  to x ic i ty  w ith CNS c e lls .  Modulation 
o f DPH to x ic ity  w ith cytochrome P450 inducers was only observed w ith  LB 
c e lls  (3MC but not pNF IN VITRO and transp lacen ta lly  administered 3MC 
and pNF). Phenobarbitone was w ithout e ffe c t.  S im ila rly  only LB c e lls  
derived from pNF pretreated dams could ac tiva te  CPA, a ll other inducers 
were w ithout e ffe c t and CNS c e lls  were re fra c to ry  to a ll forms o f co­
treatment w ith inducers. Modulation o f compound to x ic ity  provided 
in d ire c t assessment o f metabolism in  the embryo c e lls .  D irec t evidence 
was provided by detection o f DPH m etabolites. A greater percentage o f 
metabolites o f DPH were formed by LB c e lls  than CNS c e lls  (Chapter 7) 
not only ind ica tes tha t embryo c e lls  IN VITRO have a s u ff ic ie n t 
c o n s titu tiv e  leve l o f xenobiotic metabolising enzymes to  hydroxyl ate 
DPH, but th a t some tissues have a greater metabolic po ten tia l and 
c a p a b ility  than others, and tha t the cu ltu red c e lls  p a ra lle l the IN VIVO 
metabolism o f DPH.
In conclusion my re su lts  have shown 1) a c o n s titu tiv e  leve l o f 
embryo cytochrome P450's 2) only embryo cytochrome P450 'c ' and 'd 1 are 
inducib le  and 3) LB c e lls  are more biochem ically active  and more 
susceptible to cytochrome P450 'c ' inducers than CNS c e lls .
8.2 ROLE OF METABOLISM IN THE BIOACTIVATION OF DPH
DPH has well documented teratogenic e ffe c ts  in  man (Hanson and 
Smith 1975, Hanson 1976), ra b b it (Schardein 1983) and mouse (Harbison 
and Becker 1970, Wells and Harbison 1980, F innell and Chernoff 1984), 
however, the data fo r  ra t is  equivocal (Harbison and Becker 1972 and 
resu lts  from Chapter 3 .1 ). The issue o f species s e n s it iv ity  (v iz  ra t 
versus others) w ith  regard to  se lec tive  m etabolite formation was 
discussed in  chapter 3.5 and showed th a t there were no obvious 
metabolic d ifferences in  the metabolism o f DPH th a t could account fo r  
the observed d ifferences in  species s e n s it iv ity  (Glazko 1973). My IN 
VIVO DPH te ra to logy study conducted in  the Aider!ey Park ra t s tra in , 
DPH proved to be negative despite showing signs o f an embryotoxic 
e ffe c t, but d ire c t coincubation o f DPH w ith d if fe re n t ia t in g  ra t  embryo 
c e lls  IN VITRO showed tha t the compound in h ib ite d  d if fe re n t ia t io n  o f 
embryo c e lls .  I t  was concluded th a t an in s u ff ic ie n t concentration o f 
DPH (or i t s  m etabo lite (s)) reached the embryo fo r  a teratogenic e ffe c t 
to  be observed IN VIVO.
A qu an tita tive  s tru c tu re -a c t iv ity  study w ith 28 hydantoin rin g  
analogues i l lu s tra te d  not only th a t embryo c e lls  IN VITRO were capable 
o f d is tingu ish ing  between s tru c tu ra lly  re la ted compounds but th a t the 
degree o f to x ic ity  to  embryo c e lls  was c lose ly  corre la ted to  
l ip o p h i l ic i t y  which tends to argue against metabolism playing a ro le  
in  to x ic ity .
Given the inform ation th a t DPH was a p o s itive  IN VITRO ra t 
teratogen and th a t the embryo c e lls  IN VITRO could d is tingu ish  between 
s tru c tu ra lly  s im ila r compounds then the study o f coincubating the 
major metabolites o f DPH d ire c t w ith the c e lls  should be p o te n tia lly
able to d is tingu ish  the u ltim ate teratogenic e n t ity .  However, both 
the hydroxy (m and p) metabolites were equ itox ic  w ith DPH and only the 
r ing  opened acid product was to ta l ly  n o n -in h ib ito ry  (up to i t s  maximum 
s o lu b il i ty  in  cu ltu re  medium). I t  was, the re fo re , concluded (on the 
basis o f the metabolites studied) th a t the only completely de tox ify ing  
pathway IN VIVO is  hydantoin ring  cleavage to the acid product and 
th a t hydroxylation o f DPH re su lts  in  the formation o f an equ itox ic  
compound. However, i t  must be emphasised th a t in  l ig h t  o f the 
previously discussed sterochemical aspects o f DPH hydroxyla tion, 
d if fe re n t isomer production and inherent to x ic it ie s  may have a ro le  to 
play in  the IN VITRO system described in  th is  thes is .
I t  is  important a t th is  po in t to  re-emphasize the dichotomy in  
the l i te ra tu re  as to  whether DPH i t s e l f  or the m etabo lica lly  derived 
arene oxide interm ediate, or the hydroxy (m and p) metabolites being 
the u ltim ate teratogen. Evidence th a t shows DPH i t s e l f  is  the 
u ltim ate  teratogen inc ludes:-
a) DPH is  d ire c t ly  to x ic  to ra t embryo c e lls  (F l in t  and Orton 
1985) and whole mouse embryos IN VITRO (Bruckner e t al 1983), however, 
evidence from Chapter 7 would ind ica te  th a t embryos are capable o f 
lim ite d  xenobiotic metabolism IN VITRO and therefore in  re a l i ty  
exposure may have been to  DPH and metabolites derived by the embryo 
c e lls  themselves.
b) A/J mice fed a p u r if ie d  d ie t had decreased hepatic cytochrome 
P450 le ve ls , increased maternal blood DPH concentrations and showed a 
3 fo ld  increase in  the teratogenic e ffe c ts  (McClain and Rohrs 1985). 
However, i t  cannot be excluded th a t the p u r if ie d  d ie t may also have 
caused disturbances in  endogenous metabolism leading to  hormone 
imbalance and hence an increased s u s c e p tib ility  to  teratogens.
c) SKF 525A pretreatment increased both maternal plasma 
concentrations o f DPH and te ra to g e n ic ity  w h ils t PB pretreatment 
decreased maternal plasma DPH concentrations and te ra to g e n ic ity  
(Harbison and Becker 1970). However, embryo leve ls  o f e ith e r DPH or 
p.hydroxy .DPH were unaffected. D ihydrodiol leve ls  were not 
reported.
d) Studies w ith the major metabolites a t equimolar doses on the 
teratogenic response o f the mouse showed th a t the maximum response o f 
any o f the metabolites tested was only 10% o f th a t o f DPH i t s e l f  
(Harbison and Becker 1974). The dihydrodiol m etabolite , however, 
remains to  be examined.
Evidence th a t the arene oxide intermediate is  formed during DPH 
metabolism is  ir re fu ta b le  (Claesen e t al 1984, M ilton e t al 1985, 
Pantarotto e t al 1982, Wells e t al 1980, 1983, Spielberg e t al 1981) 
but the evidence showing th is  m etabolite as the u ltim ate teratogen is  
sparse and obviously c ircum stan tia l. Martz e t al 1977 showed a 
co rre la tio n  between the degree o f cova lently  bound 14c_dph to  
gestational tissue and te ra to g e n ic ity  in  the mouse by use o f 
modulation o f epoxide hydrolase pathway. However, in  th e ir  studies 
ne ither in h ib it io n  o f epoxide hydrolase (by TCPO) nor sequestering o f 
the arene oxide (by g lu ta th ione) was complete as HPLC analysis 
revealed traces o f free dihydrodiol m etabolite present in  gestational 
tissue and maternal plasma.
Given th a t the l i te r tu r e  stands divided as to the ro le  o f 
metabolism in  the b io ac tiva tio n  o f DPH, I shall now summarise the 
evidence obtained from Chapters 5, 6 and 7.
Coincubation o f a va rie ty  o f in h ib ito rs  o f cytochrome P450 w ith  
DPH IN VITRO caused an increase in  the to x ic  e ffe c t as gauged by 
lowering o f the IC501s o f DPH in  both LB and CNS compared to  IC50' s o f 
DPH alone. The e ffe c ts  were greater in  LB c e lls  compared to CNS.
There did not seem to be any co rre la tio n  between the potency o f each 
in h ib ito r  and i t s  e ffe c t on DPH to x ic i ty  modulation (Table 5 .2 ). The 
most potent in h ib ito rs  were benzimidazole, (a broad non-specific  
cytochrome P450 in h ib ito r ) ,  e l l ip t ic in e  (a sp e c ific  IN VITRO P450 'c 1 
in h ib ito r )  and asp irin  (which is  not a c lass ica l P450 in h ib ito r  but 
acts v ia i t s  major metabolite gen tisc ic  acid in  in h ib it in g  the P450- 
driven prostaglandin synthesis pathway) i t  is  also a m ild cyc lo - 
oxygenase in h ib ito r .  Given th a t one o f the curren t theories o f DPH 
teratogenesis is  th a t a free radical intermediate generated by a 
prostaglandin synthetase mediated b io a c tiv a tio n , is  the u ltim a te  
teratogen (Wells e t al 1986), a s p ir in , which would in h ib i t  th is  
m etabolite form ation, was found to  be p e cu lia rly  e ffe c tiv e  a t 
modulating DPH to x ic i ty ,  despite i t s  weak cytochrome P450 in h ib it io n  
p roperties. This re s u lt may ind ica te  th a t indeed such a PG synthetase 
derived m etabolite may be involved in  DPH teratogenesis. However, 
despite extensive e ffo r ts  the l i te ra tu re  does not appear to  document 
the prostaglandin synthetase/cylo-oxygenase in h ib it io n  properties o f 
the other in h ib ito rs  tested.
The weakest modulator o f DPH to x ic i ty  was SKF.525A. The mode o f 
in h ib it io n  o f th is  compound is  thought to  be via a m etabolite (N etter 
1979) and hence i f  the embryo c e lls  were unable to  metabolise SKF.525A 
then the in h ib it io n  would be in e ffe c t iv e . Cimetidine was a moderately 
strong modulator o f DPH to x ic ity  IN VITRO whereas i t s
pharmacologically s im ila r analogue ra n it id in e  (which does not have 
P450 in h ib it io n  properties) was not. This ind icates th a t indeed i t  is  
the enzyme in h ib it io n  properties o f the in h ib ito rs  which was 
responsible fo r  the observed increases in  DPH to x ic ity  fo llow ing  co­
incubation. This set o f experiments would tend to ind ica te  th a t DPH 
i t s e l f  is  the u ltim ate  teratogen. Coincubation o f DPH w ith a va rie ty  
o f cytochrome P450 inducers IN VITRO showed tha t only 3MC and LB c e lls  
could produce an e ffe c t, re su ltin g  in  increased to x ic i ty .  Following 
transplacental adm in istra tion o f the inducers, again only LB c e lls ,  
derived from pNF or 3MC pretreated dams showed any response (a 30 and 
20% increase in  to x ic ity  re sp e c tive ly ). These modulations in  DPH 
to x ic ity  fo llow ing  induction would ind ica te  th a t indeed a m etabolite 
is  the u ltim ate teratogen and c o n flic ts  w ith the re su lts  from 
in h ib ito r  stud ies. However, i t  should be noted th a t only cytochrome 
P450 'c ' inducers in  LB c e lls  could cause an e ffe c t and th a t th is  
e ffe c t was a 20 - 30% increase in  to x ic i ty  (depending on the inducer) 
compared to 13 - 82% increase in  to x ic i ty  w ith various in h ib ito rs  in  
LB c e lls  and 3 -  52% increase w ith various in h ib ito rs  in  CNS c e lls .
CNS c e lls  were re frac to ry  to  modulation o f DPH to x ic ity  by inducers 
and ye t immunocytochemically were shown to  be induced (Chapter 4) but 
were capable o f DPH to x ic ity  modulation when coincubated w ith 
inducers. That in h ib ito rs  increased the to x ic i ty  o f DPH in  both LB 
and CNS c e lls  would ind ica te  th a t DPH i t s e l f  is  the u ltim a te  teratogen 
y e t how e ffe c tiv e  or precise (one pathway may be blocked and 
consequently another increased) the in h ib it io n  o f cytochrome P450's 
was remains a matter fo r  speculation. I t  would seem th a t inducers may 
be increasing the leve ls  o f p.hydroxy.DPH formed IN VITRO (which was
found to be equ itox ic w ith DPH) and may be producing another 
m etabolite(s) not generally formed by uninduced c e lls ,  e.g. free 
radica l interm ediate, d ihydrodiol or o-methyl catechol, which may have 
been more to x ic  than DPH i t s e l f .  However, th is  theory was not 
confirmed by H.P.L.C. ana lys is. I t  was found tha t uninduced c e lls ,  
especia lly  LB, were capable o f lim ite d  p.hydroxy DPH and DPH acid 
production. This re s u lt coupled w ith the fa c t th a t LB c e lls  were more 
re s is ta n t to  the e ffec ts  o f DPH IN VITRO than CNS would ind ica te  th a t 
hydroxylation to the p.hydroxy m etabolite is  a d e to x ific a tio n  pathway, 
but not a completely de tox ify ing  process since p.OH DPH is  equ itox ic  
w ith DPH.
The ro le  o f the arene oxide intermediate in  DPH teratogenesis 
appears to  be in s ig n if ic a n t since modulation o f the epoxide hydrolase 
pathway did not re s u lt in  a lte red  DPH to x ic ity  IN VITRO. However, 
covalent binding (an ind ica tion  o f the leve l o f arene oxide m etabolite 
produced) was found to  a lte r  w ith various co-treatments and th is  did 
not co rre la te  w ith the modulation o f to x ic i ty .  Benzimidazole which 
increased DPH to x ic ity  IN VITRO by 82 i  6% in  LB c e lls  caused a 32% 
decrease in  covalent b inding. S im ila r ly , benzimidazole caused a 42±
6% increase in  DPH to x ic ity  w ith CNS c e lls  but a 67% decrease in  
covalent b inding. Transplacental exposure to  (3NF caused a 30% 
increase in  DPH to x ic ity  in  LB c e lls  and a 175% increase in  covalent 
b inding, no modulation o f DPH to x ic i ty  in  CNS c e lls  but a 255% 
increase in  covalent b inding. TCPO (an in h ib ito r  o f epoxide 
hydrolase, the enzyme responsible fo r  enzymatic d e to x ific a tio n  o f the 
arene oxide intermediate to the d ihydrod io l) was to ta l ly  in e ffe c tiv e  
a t modulating DPH to x ic ity  IN VITRO in  e ith e r LB or CNS c e lls  but
caused a 176% and 298% increase in  covalent binding in each c e ll type 
respective ly . In summary, the degree o f covalent binding was found 
not to co rre la te  w ith the degree o f DPH to x ic ity  IN VITRO, and so i t  
is  concluded th a t, despite evidence fo r  the formation o f the arene 
oxide intermediate IN VITRO, i t  does not play an important ro le  in  DPH 
teratogenesis.
In conclusion, the ro le  o f metabolism in  the b io a c tiva tio n  o f DPH 
remains p a r t ia l ly  unresolved. I t  has been established th a t the 
p.hydroxy m etabolite is  equ itox ic  w ith  DPH and th a t hydroxylation is  
not a completely de tox ify ing  reaction , only hydantoin r in g  cleavage to  
the acid product is  to ta l ly  de tox ify ing . In h ib it io n  studies would 
tend to  ind ica te  th a t DPH i t s e l f  is  the u ltim ate  teratogen while 
inducer studies would tend to  ind ica te  th a t a m etabolite , but probably 
not the arene oxide interm ediate, is  the u ltim ate teratogen. To 
explain DPH teratogenesis is  not simply a question o f parent compound 
vs m etabolite as the u ltim ate  teratogen but may be the re s u lt o f more 
than one m etabolite and a combination o f DPH i t s e l f .
8.3 FUTURE WORK
The re su lts  o f th is  thesis have established the presence o f 
cytochrome P450 and po ten tia l xenobiotic metabolising c a p a b ilit ie s  o f 
embryo c e lls ,  especia lly  LB c e lls ,  the lo g ica l extension o f the 
p ro jec t should be f i r s t l y  to  id e n t ify  how much embryonic metabolism 
contributes to  chemically induced teratogenesis, by expanding the 
number o f examples eg. diazepam, CPA and a ld r in . As a phenomenon i t  
is  important to  remember th a t human embryos have greater leve ls  o f 
cytochrome P450 than rodents, and th a t exposure to environmental
chemicals and cytochrome P450,c l and 1d1 inducers is  more l ik e ly  in  
the human ( i . e .  smoking or d ie ta ry  contaminants).
Besides examining embryo metabolism o f other compounds the 
spe c ific  areas in  which the importance o f the ro le  o f embryonic 
metabolism could be fu rth e r investigated are*-
1) The re la t iv e  leve ls  o f m etabolites produced by 
transp lacen ta lly  induced embryo c e lls  and c e lls  coincubated w ith  
cytochrome P450 in h ib ito rs .
2) The function o f the non-inducible cytochrome P450 'b 1 form.
3) The reason why transplacental induction does not cause a 
precocious development o f cytochrome P450 'C  and 'd 1 isoenzymes.
4) The ontogeny o f cytochrome P450 mRNA's.
5) Investiga tion  o f the hydroxylated stereoisomers o f DPH by a 
more extensive and precise s truc tu re  a c t iv ity  study.
Further experimentation is  also required to  e lucidate  the ro le  o f 
metabolism in  the b io ac tiva tio n  o f DPH th is  could be achieved bys-
1) Comparison o f the metabolites produced by ra t embryo c e lls  IN 
VITRO to those produced by a DPH-sensitive species, i . e .  mouse LB 
c e lls .
2) Comparison o f the IC50 values o f DPH and i t s  m etabolites IN 
VITRO in  a DPH-sensitive species ( i . e .  mouse LB c e lls  to  ra t LB 
c e lls ) .
3) Coincubating serum from DPH pretreated dams (both DPH 
sensitive  and non-sensitive species) w ith embryo c e lls .
4) Incubating embryo c e lls  w ith  DPH in  the presence o f maternal 
l iv e r  microsomes (induced w ith a va rie ty  o f inducers).
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Abstract— Rapid and accurate prediction of teratogenic hazard had been achieved using cultures of 
differentiating limb mesenchyme (LB) and midbrain (CNS) cells from 13-day-old rat embryos. In this 
study we have used these cultures to examine the role of metabolism in the in vitro teratogenic activity 
of diphenylhydantoin (DPH) and cyclophosphamide (CPA). Two approaches were used. The first involved 
modulation of cytochrome P-450 activity by co-incubation in vitro with a variety of inhibitors at 
concentrations that were non-cytotoxic to the cells. This enhanced the toxicity o f DPH  by 13-82% in LB 
and by 3-52% in CNS cells. Benzimidazole and ellipticine caused the greatest enhancement and SKF 525A 
the least. D PH  appears to be the proximate teratogen and there appear to be embryo-tissue cytochrome 
P-450s that assist in its detoxification. Following prior transplacental induction, CPA was toxic in vitro 
to LB cells from /?-naphthoflavone-pretreated mothers. CPA was non-toxic in cells of control, 
phenobarbitone- or 3-methylcholanthrene-treated embryos. Thus there appear to be inducible levels of 
cytochrome P-448 in embryo cells. In  the second approach, positive immunocytochemical staining of the 
cells with both monoclonal and polyclonal P-450 antibodies identified phenobarbitone, /5-naphtho- 
flavone- and 3-methylcholanthrene-inducible cytochrome P-450s at a constitutive level. Cytochromes 
P-448 (j5-naphthoflavone type) and P-450 (phenobarbitone type, PB3 fraction) were inducible, confirming 
that cytochrome P-450s are in fact present in the embryo cells.
Introduction
Well-designed animal tests should detect the majority 
of potential human drug teratogens but they are 
resource intensive, requiring large numbers of 
animals and skilled staff to analyse the foetuses. The 
demand on these resources would be diminished if 
there were a simple rapid and highly predictive in 
vitro  system for hazard assessment early in the screen­
ing programme for new drugs. One such screen is the 
micromass teratogen test which uses primary cultures 
of differentiating rat embryo limb bud (LB) and 
midbrain (CNS) cells (Flint, 1980; Flint & Orton, 
1984; Flint, Orton & Ferguson, 1984) and which has 
an accuracy greater than 90%.
A major problem with any in  v itro  test for terato­
gens is that foetal-placental-matemal interactions 
are not available (see also Flint, 1986). Since some 
teratogens may require bioactivation, the inclusion of 
a reliable metabolizing system or source of metabo­
lites may be important. There are several ways of 
doing this:
(i) Use of serum from whole animals pretreated
with the test compound (Chatot, Klein, Piatek &
Abbreviations: CNS =  central nervous system cultures (i.e. 
midbrain cells); DPH =  diphenylhydantoin; DM SO =  
dimethylsulphoxide; EBSS =  Earle’s balanced salt solu­
tion; HPLC =  high-pressure liquid chromatography; 
LB =  limb bud cells; M FO  =  mixed-function oxidase; 
TCPO =  trichloropropene oxide; TLC =  thin-layer 
chromatography.
Pierro, 1980; Klein, Plenefisch, Carey et al. 1982).
(ii) Induction of xenobiotic-metabolizing enzymes 
(cytochrome P-450) in the cultured cells by treat­
ing the embryo with classical P-450 inducers in 
uiero (via the dam) prior to removal for culture. 
Limb-bud organ cultures from mice pretreated 
with Aroclor 1254 bioactivate the pro-teratogen 
cyclophosphamide while uninduced controls show 
no effect (Neubert & Bluth, 1981).
(iii) Co-culture with isolated hepatocytes, which 
are capable of both phase I and II metabolism 
(Manson & Simons, 1979).
(iv) Co-incubation with hepatic microsomes plus 
co-factors (S-9 mix) from Aroclor 1254-induced 
male rodents or rabbits (Flint, 1986; Flint & Orton, 
1984; Kitchin, Schmid & Sanyal, 1981).
In addition we suggest the following methods that 
might be experimentally useful but that have not yet 
been reported in the literature:
(i) Addition of purified components of the mixed- 
function oxidase (MFO) system.
(ii) Use of S-9 fractions from pregnant females 
pretreated with MFO inducers.
(iii) Incubation of the compound with an S-9 mix 
and then addition of the filtrate to the in v itro  test 
system.
Many teratogens that are well metabolized in vivo, 
such as diphenylhydantoin (DPH; Wells & Harbison, 
1980), aspirin (Greenaway, Bark & Juchau, 1984) and 
diazepam (Idanpaan-Heikkila, Jouppila, Poulakka &
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Vorne, 1971) are, however, directly toxic in the 
micromass culture test in the absence of added micro­
somal metabolizing enzymes (Flint & Orton, 1984). 
Cyclophosphamide is the notable exception; This 
compound requires bioactivation by S-9 mix in order 
to become teratogenic (Flint & Orton, 1984; Hales, 
1981; Hill, Laster & Struck, 1972).
In this study we have used the differentiating rat 
embryo cells in v itro  to examine the contribution of 
metabolism by the cells themselves to the teratogenic 
activity of DPH. Two approaches were used-modula- 
tion of the cytochrome P-450 activity of the cultured 
cells either by co-incubation of the test compound 
with non-cytotoxic concentrations of a variety of 
inhibitors of cytochrome P-450 or by using cells 
exposed transplacentally to cytochrome P-450 in­
ducers, and secondly identification of cytochrome 
P-450 isozymes in the cultured cell by immuno- 
cytochemical staining with both monoclonal and. 
polyclonal P-450 antibodies.
Experimental
Compounds. Test compounds of the highest purity 
commercially available were used. DPH, ellipticine, 
saccharin, cimetidine, aspirin, inosine, 3-methylchol- 
anthrene, phenobarbital and /J-naphthoflavone were 
obtained from Sigma Chemical Co., Poole, Dorset, 
benzimidazole and a-naphthoflavone from Fluka 
AG, Buchs, Switzerland, and m-hydroxydiphenyl- 
hydantoin, p  -hydroxydiphenylhydantoin and tri- 
chloropropene oxide (TCPO) from Aldrich Chemical 
Co. Ltd, Poole, Dorset. SKF 525A and ranitidine 
hydrochloride were gifts from Smith, Kline and 
French Laboratories Ltd, Welwyn Garden City, 
Herts., and from Glaxo Research Group, Ware, 
Herts, respectively, and diphenylhydantoic acid was 
synthesized by the Organic Chemistry Department at 
ICI pic, Alderley Park. Culture media and sera were 
obtained from Gibco Biocult, Paisley, Scotland.
Animals. Virgin female Alderley Park (Alpk/AP) 
strain I rats (250-300 g) were mated overnight with 
breeder males and vaginal smears were examined for 
sperm next morning to confirm copulation. Animals 
were killed on day 13 of pregnancy (mid-organo­
genesis).
Preparation o f  embryo cell cultures
Animals were killed by cervical dislocation and 
the embryos (34-36 somites) were then removed 
aseptically to a 1:1 (v/v) mixture of horse serum 
and Earle’s balanced salt solution (EBSS) at 37°C. 
Midbrain cells (CNS) were prepared from the 
mesencephalon and limb bud cells (LB) from the 
fore-limb buds. Essentially, tissues were dissociated 
into individual cells by successive washing in calcium- 
and magnesium-free medium (CMF) followed by 
digestion with trypsin (1%, v/v, in CMF). Cells were 
then resuspended in culture medium at 1 x 105/20 p \ 
(CNS) and 4 x 105/20 ^1 (LB). The culture medium 
consisted of Ham’s F12 containing 10% foetal calf 
serum.
The LB and CNS cell suspensions were delivered in 
10-/il quantities to plastic culture dishes (30 mm in 
diameter, Falcon 300IF) and left for 2 hours at 37°C 
to allow the cells to adhere to the bottom. Excess
culture medium (2 ml at 37°C) containing control 
vehicle or test substances was then added to each dish 
and the cultures were incubated for 5 days at 37°C in 
an atmosphere of 5% C 0 2 in air and 100% humidity. 
Each 10 p \  of cell suspension left a small circular 
island of cells approximately 6-7 mm in diameter in 
the culture dish. Four CNS or four LB islands were 
cultured in each dish. These remained intact and did 
not spread during the culture period. After 5 days of 
culture small foci of chondrogenic (cartilage-forming) 
cells or neurons had differentiated in LB and CNS 
cultures, respectively, and at this stage the cells were 
processed and subjected to morphometric analysis. 
LB cultures were fixed in 10% formaldehyde contain­
ing 1 % cetylpyridinium chloride and the accumulated 
proteoglycans were stained with alcian blue. CNS 
cultures were fixed in 10% formaldehyde and the 
cells were stained with haematoxylin. The numbers of 
differentiated foci per cell island from fixed and 
stained cultures were counted automatically using a 
40-10 image analyser (Analytical Measuring Systems 
Ltd, Saffron Walden, Essex). In LB cultures only the 
differentiated darkly stained foci of chondrocytes 
were counted and in CNS cultures only the darkly 
stained foci of neurons were counted.
Graphs of the number of differentiated foci per cell 
island against the concentration of the compound 
(/ig/ml) were plotted. The highest concentrations 
inhibiting differentiation by 50% of the control 
values (IC50) were determined from the graphs.
Exposure o f  cultures to test substance or vehicle
DPH, w-hydroxyDPH and DPH acid were dis­
solved in ethanol and added at 1.0%, v/v, to the 
culture medium, p-hydroxyDPH dissolved in di- 
methylsulphoxide (DMSO) was incorporated at 
0.5%, v/v, in the culture medium, and cyclophos­
phamide in EBSS was incorporated at (1.0%, v/v). 
The test compounds in the appropriate solvent 
vehicle were added directly to the culture medium at 
the beginning of the 5 days of culture. Exposure was 
therefore effectively over a 5-day period in vitro. 
Concentration-response curves of the various 
cytochrome P-450 inhibitors were obtained and 
the inhibitors were added at their highest non-toxic 
concentrations in combination with DPH at the start 
of the culture period.
Immunocytochemical staining o f  cytochrome P -450 in 
L B  and CNS cultures
The peroxidase-antiperoxidase technique de­
scribed by Wolf, Moll, Friedberg et al. (1984) was 
used on 5-day-old cultures of LB and CNS. Fresh 
cultures were stained against a variety of P-450 
antibodies. Polyclonal phenobarbitone-raised P-450, 
P-naphthoflavone-raised P-448 and clofibrate-raised 
P-452 were provided by Dr G. Gibson. The mono­
clonal P-naphthoflavone-raised antibody 4:2 was a 
gift from the ICI Central Toxicology Laboratory and 
Hammersmith Hospital, London. The polyclonal 
3-methylcholanthrene-raised P-448 and phenobarbi­
tone-raised P-450 antibodies were gifts from Dr C. R. 
Wolf, Pharmacology Department, Western General 
Hospital, Edinburgh.
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Transplacental induction o f  metabolizing enzymes in 
the embryo
Dams were dosed in vivo and the embryos were 
subsequently removed on day 13 of gestation. Cul­
tures were prepared as described above. The dosing 
schedules used were as follows: 3-methylcholanthrene 
(in arachis oil), 25 mg/kg given ip on days 10-12 
of gestation; /? -naphthoflavone (in arachis oil), 
35 mg/kg given ip on days 10-12 of gestation; 0.1% 
sodium phenobarbitone, supplied ad lib. in the 
drinking-water on days 5-13 of gestation.
Results
M odulation o f  cytochrome P -450 activ ity
Effect o f  D P H  and its m ajor metabolites. DPH and 
its hydroxy metabolites appear to be approximately 
equitoxic when CNS and LB cultures were considered 
separately (Table 1) but DPH and its major hydroxy 
metabolite (the para  form) were significantly more 
toxic to CNS than to LB cultures. The ring-opened 
acid metabolite was non-toxic up to its maximum 
solubility and is thus a possible detoxification route 
in vivo.
Co-treatment with cytochrome P-450 inhibitors  in 
vitro. Co-incubation of DPH with a variety of cyto­
chrome P-450 inhibitors in v itro  (at their non-toxic 
concentrations) increased DPH toxicity to both LB 
and CNS cultures (Table 2). DPH toxicity was en­
hanced to a greater extent in LB than in CNS cultures 
by all the inhibitors except a-naphthoflavone. Benz- 
imidazole, ellipticine, aspirin and metyrapone were 
the most effective (67-82% increases in toxicity in LB 
and 41-52% in CNS cultures). SKF 525A was the 
least effective with a 13% increase in LB and 3% in 
CNS cultures.
Ranitidine has the same pharmacological proper­
ties as cimetidine (both are H2 antagonists) and is 
structurally similar. It is not, however, an inhibitor of 
cytochrome P-450 (Bell, Gower, Martin et al. 1981) 
and did not alter the IC50 of DPH when co-incubated 
at non-toxic concentrations. Saccharin and inosine 
are both non-teratogens, with no inhibitory effect 
on cytochrome P-450. Co-incubation with either of 
these compounds had no effect on the IC50 of DPH. 
TCPO is an epoxide hydratase inhibitor and when it
Table 1. Comparative effects of diphenylhydantoin (DPH) and its 
major metabolites on CNS and LB cultures in vitro
Compound
IC50 values (pg/m l)
CNS
cultures
LB
cultures
DPH 67 + 18** 91 + 4
p -Hydroxy DPH 54+11* 80 + 9
m-HydroxyDPH 79 + 8 84 +  9
DPH acid >250f >250
CNS = Midbrain cells LB =  Limb bud cells 
fMaximum solubility in culture medium.
Values are means ±  SD for at least three determinations. There were 
no significant differences between the IC50 values for DPH and 
its major hydroxy metabolites. Values marked with asterisks 
differ significantly from the corresponding value for LB cultures: 
*P  <  0.01; * *P  >0.001.
was co-incubated with DPH no appreciable effect on 
DPH toxicity was observed. The toxicity of the p -  
hydroxy metabolite was unaffected by co-incubation 
with either cimetidine or a-naphthoflavone.
Effect o f  in vivo pretreatment. Following in vivo 
transplacental exposure to cytochrome P-450 in­
ducers and subsequent culture of the cells, it was 
found that only LB cells from ft -naphthoflavone- 
pretreated dams could activate the pro-teratogen 
cyclophosphamide (Fig. 1); 3-methylcholanthrene 
and phenobarbitone pretreatments had no effect on 
either type of cell. Addition of the inducers directly 
to the culture at non-cytotoxic concentrations had no 
effect (data not shown).
Identification o f  cytochrome P-450 isoenzymes in L B  
and CNS cultures
Constitutive levels of cytochromes P-450 (pheno- 
barbitone-inducible) and P-448 (3-methylcholanth- 
rene-inducible) were detected in 5-day-old cultures of 
both LB and CNS cells, with generally higher levels 
in LB than in CNS (Table 3). PB2 was the prominent 
form of phenobarbitone-inducible P-450. Pheno­
barbitone induced a P-450 isoenzyme in CNS cul­
tures but not in LB (PB3 type; Wolf et al. 1984). None 
of the other PB forms were induced by transplacental 
exposure to phenobarbitone. Transplacental expos­
ure to /? -naphthoflavone, but interestingly not to 
3-methylcholanthrene, induced a P-448 type of iso­
enzyme in both LB and CNS cultures, but to a 
greater extent in LB cultures. 3-Methylcholanthrene
Table 2. Modulation of diphenylhydantoin (DPH) toxicity in vitro
Compound ( x )  
co-incubated 
with DPH
CNS cultures LB cultures
Non-cytotoxic 
level of 
compound x 
(^g/ml)
IC50 of DPH 
+  compound x 
(/ig/ml)*
Increase in 
toxicity
(% )t
Non-cytotoxic 
compound x 
(^g/ml)
IC50 of DPH 
+  compound x 
(/ig/ml)*
Increase in 
toxicity
(% )t
SKF 525A 3 . 64 + 2 3 + 1 1 79+1 13 + 2
/J-Naphthoflavone 4 42 +  5 37 + 5 4 7 1 + 9 22+ 10
Cimetidine 400 57 +  9 15 +  10 400 47 + 3 48 + 3
Metyrapone 250 39 + 8 4 1 + 8 10 30 + 4 67 +  5
Aspirin 50 35 +  6 47 ± 8 100 28 + 6 69 ± 6
Ellipticine 0.001 32 + 2 52 ± 2 0.001 27 ± 2 70 ± 2
Benzimidazole 200 39 +  6 42 ± 6 200 16 + 6 82 +  6
TCPO 1 63 + 7 5 ±  7 1 90 ± 4 1 + 3
Saccharin 600 64 + 5 3 + 4 600 90 + 3 1 + 3
Inosine 500 66 ± 6 1 ± 6 500 89 + 5 2 + 5
Ranitidine 250 . 65 + 6 3 + 6 250 93 ± 2 2 + 2
TCPO =  Trichloropropene oxide 
♦Values are means ±SD  for at least three experiments. 
fRelative to the ICJ0 of DPH alone (see Table 1).
CNS = Midbrain cells LB = Limb bud cells
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Fig. 1. Activation of cyclophosphamide (CPA) to a toxic metabolite by cultured rat embryo limb bud cells 
following in vivo transplacental induction of the embryos with /J -naphthoflavone (j3NF). The control line 
is from cultures of cells not pretreated with /IN F  in vivo and the dotted lines indicate the calculation of
the IC 50 (44 /i g/ml).
did not appear to induce any forms of cytochrome 
P-450.
Discussion
In  v itro  modulation of DPH toxicity (increased 
effect) by a variety of cytochrome P-450/P-448 
inhibitors implies that the cells themselves have 
the ability to metabolize DPH and that DPH is 
the ultimate teratogen. Assuming that metabolism 
in v itro  follows a similar pattern to that found in vivo 
(Fig. 2), co-incubation with cytochrome P-450
inhibitors influences ring hydroxylation. (It is not 
known whether hydroxylation proceeds by direct 
insertion or via the arene oxide.)
We have also shown that the embryo cells possess 
cytochrome P-450 isoenzymes. Immunocytochemical 
identification of cytochromes P-450 has shown that 
both LB and CNS cells have a constitutive level of 
both cytochromes P-450 and P-448, and that there is 
selective transplacental induction. The P-448 inducer 
P -naphthoflavone induced P-448 in LB cells and this 
was associated with an ability to activate the pro­
teratogen cylophosphamide. P-448 was also induced
Table 3. Immunocytochemical identification of cytochrome P-450 in LB and CNS cultures
Response* in:
Untreated
cultures
Cultures treated with:
3MC PB j?NF
Antibody LB CNS LB CNS LB CNS LB CNS
Gibson/polyclonal. 
Anti-PB-raised 
P- 450 + + + + + + +
CTL/Hammersmith 
monoclonal 4:2. 
Anti-/?NF-raised 
P-448 + + + + NT ' NT +  +  + +  + (  +  )
Wolf/polyclonal. 
Anti-PB-raised 
P-450 PB1 ( +  ) 0 NT NT ( +  )'■ 0 NT NT
Wolf/polyclonal. 
Anti-PB-raised 
P-450 PB2 +  + +  + NT NT +  + +  + NT NT
Wolf/polyclonal 
Anti-PB-raised 
P-450 PB3 ( +  ) 0 NT NT ( +  ) ( +  ) NT NT
Wolf/polyclonal. 
Anti-3MC-raised 
P-448 3MC, + ( + ) NT NT : NT : NT NT NT
Wolf/polyclonal. 
Anti-3MC-raised 
P-448 3MC2 + + + • + NT NT NT NT
3MC =  3-Methylcholanthrene PB = Phenobarbitone /INF = /?-Naphthoflavone 
LB =  Limb bud cells CNS = Midbrain cells NT =  Not tested 
•Grading of response: 0 =  absent; ( +  ) =  less than minimal, but present; +  =  minimal; +  +  =  moderate; +  +  +  =very strong.
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hydantoin ring opening 
(non F^ 50)
V
450\  isomerisation
arene oxide 
(reactive intermediate)
HN NH epoxidehydratase
dihydrodiol -  DPH
diphenylhydantoic acid 
/
phenylglycine @-rr
HN NH
V
iio
R1 =  OH;R" =  H =  p -  hydroxy -  DPH 
R’ =  H; R" =  OH =  m -  hydroxy -  DPH.
FURTHER METABOLISM & EXCRETION 
Fig. 2. Probable routes of metabolism of diphenylhydantoin (DPH) in vivo.
in CNS cells (as gauged by a qualitative increase in 
staining) but these cells were unable to activate 
cyclophosphamide. Whole rat embryos cultured in 
the presence of cyclophosphamide have also been 
shown to be mainly susceptible to P-448 inducers 
(Faustman-Watts, Giachelli, Greenaway et a l  1984; 
Juchau, Giachelli, Fantel et al. 1985; Pelkonen, 1980); 
immunocytochemical identification of these enzymes 
was not undertaken by these authors. This is the first 
report identifying cytochromes P-450 in differentiat­
ing embryo cells. In addition we observed induction 
of the PB3 form of the phenobarbitone-induced iso­
enzyme in CNS cultures.
Whether DPH or an arene oxide intermediate is the 
ultimate teratogen has been widely debated in the 
literature. Evidence in support of DPH as the terato­
genic species includes the findings that the teratogenic 
response induced by the major metabolities at equi- 
molar doses in mice in vivo was only 10% of that 
caused by DPH itself (Harbison & Becker, 1974), that 
DPH teratogenicity was increased threefold in mice 
fed a purified diet and was associated with raised 
blood levels of DPH due to depressed MFO activity 
(McClain & Rohrs, 1985), and that SKF 525A 
pretreatment increased DPH teratogenicity in the 
mouse in vivo and was associated with raised levels 
of DPH in the blood. Conversely phenobarbitone 
pretreatment decreased DPH teratogenicity and 
decreased blood concentrations of DPH (Harbison & 
Becker, 1970 & 1974).
Evidence for the arene oxide intermediate of DPH 
metabolism as the ultimate teratogen includes in vitro  
studies on covalent binding, presumably of the reac­
tive arene oxide to foetal tissue (Blake & Martz, 1980;
Martz, Fallinger & Blake, 1977; Milton, Hansen & 
Billings, 1985), showing a correlation between the 
teratogenic effect and the amount of covalently 
bound material in the gestational tissue of the mouse 
following administration of [14C]DPH. Furthermore, 
co-administration of TCPO (an epoxide hydratase 
inhibitor) and DPH doubled the incidence of terata 
and covalent binding to gestational tissue (Martz et 
a l  1977). This contrasted with our findings (Table 2) 
that co-incubation of TCPO and DPH in v itro  did not 
alter DPH toxicity.
The evidence we present argues strongly that DPH 
itself is the ultimate and most potent teratogen (at 
least in v itro ) and that embryo cells contain inducible 
cytochromes P-450 capable of metabolizing DPH, 
probably to its hydroxy metabolites. DPH and its p -  
and m -hydroxy metabolites appear to be equitoxic 
(Table 1). The cytochrome P-450 inhibitor studies, 
however, show DPH to be more toxic. The hydroxy 
metabolites still represent a substantial teratogenic 
hazard. That hydroxylation is not a completely 
detoxifying pathway may explain the apparent dis­
agreement in the literature about the nature of the 
ultimate teratogen. The only completely detoxifying 
pathway available appears to be ring opening with 
the formation of diphenylhydantoic acid (a non-P- 
450-mediated reaction). Confirmation of the actual 
metabolic pathways followed in v itro  awaits TLC and 
HPLC assessment of the metabolites formed.
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SUMMARY
Using-differentiating rat embryo (13 days post coitum) limb cells in 
vitro i t  has been shown that 1) the toxicity of diphenylhydantoin to 
the d ifferentiating cells is increased in the presence of a variety of 
inhibitors of cytochrome P450, 2) following transplacental induction by 
B-naphthoflavone the cells can activate cyclophosphamide ( a proximate 
teratogen) to toxic reactive m etabolite(s), 3) structure - toxic ity  
relationships with substituted triazoles indicate toxicity is mediated 
by metabolism, and 4) i t  is possible to identify both constitutive and 
inducible levels of cytochrome P450 isozymes in the cultured cells by 
staining with specific monoclonal and polyclonal antibodies. Thus, 
four independent lines of evidence argue strongly that rat embryo cells  
(during organogenesis) are capable of xenobiotic metabolism.
INTRODUCTION
The complexity of the embryo's relationship with maternal drug 
pharmacokinetics and metabolism in teratogenicity is exemplified by 
cyclophosphamide. Co-administration during organogenesis of the 
cytochrome P450 inducer phenobarbital either reduced* in the mouse or 
increased^ in the rat the number of observed fetal abnormalities. 
Although this may in part be due to differences of route, dose and 
duration of administration i t  is d if f ic u lt  to avoid the perplexing 
conclusion that in one species cyclophosphamide can act as a 
proteratogen and in another as an ultimate teratogen.
In v itro  experiments using either the whole rat embryo in culture or 
-cultures of d ifferentiating  rat embryo mid-brain and limb cells provide 
unequivocal evidence(the necessity for an external hepatic metabolising 
system-S9 mix) that cyclophosphamide requires metabolism to a reactive 
metabolite to express its  embryotoxicity.^>4 j^ us tfle confounding 
factor in the in vivo experiments must be the rate and extent to which 
maternal metabolism detoxifies the reactive metabolite.
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The d iffic u lty  of understanding teratogenic mechanisms by in vivo 
experiment alone is further exemplified by diphenylhydantoin. As with 
cyclophosphamide d ifferent experiments argue, with equal force, that 
diphenylhydantoin is either a proteratogen or an ultimate teratogen.
Diphenylhydantoin as proteratogen:
1. The incidence of c le ft  lip  and palate in Swiss ICR mice following 
a single dose (50mg/kg) of diphenylhydantoin on day 11 is doubled 
(as is covalent binding of the compound to the embryo cells) 
following co-treatment with the epoxide hydratase inh ib itor 
trichloropropene oxide®. A toxic arene oxide intermediate appears 
to be the ultimate teratogen.
2. The incidence of diphenylhydantoin induced abnormalities is 
inversely proportional to maternal circulating glutathione
C
levels . This would follow i f  a toxic arene oxide intermediate 
were being conjugated (detoxified) with glutathione.
Diphenylhydantoin as ultimate teratogen:
1. Pretreatment of Swiss Webster mice with phenobarbitone enhances the 
metabolism of diphenylhydantoin to the p.hydroxy derivative, 
presumably via arene oxide formation, yet teratogenicity is  
significantly decreased^.
2. I f  maternal basal drug metabolising ac tiv ity  is lowered (purified  
diet study® or in ter-s tra in  differences of metabolism^) the 
incidence of diphenylhydantoin related abnormalities is increased.
In vitro  studies with the whole mouse embryo*^ or cultures of 
d ifferen tia ting  ra t embryo mid brain and limb cells** appear to indicate 
that diphenylhydantoin is a direct acting teratogen not requiring 
metabolic activation by medium supplements of metabolising enzymes 
(prepared from homogenates of adult rat l iv e r  - S9 frac tion ). But 
direct toxic ity  of diphenylhydantoin in v itro  does not confirm the 
absence of metabolic activation, since the cultured embryo or its
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dissociated ce lls , may metabolise the compound. Some of the 
conflicting in vivo data might be explained in terms of the amount of 
unchanged diphenylhydantoin or reactive metabolite that reaches the 
embryo. The question of whether diphenylhydantoin is a proteratogen or 
ultimate teratogen remains unanswered on the basis of the in vivo data 
alone and w ill'on ly  be fu lly  answered by additional studies with 
cultures of embryos or embryo ce lls .
Evidence has only recently begun to accumulate that, during
11 i p
organogenesis, the mammalian embryo is capable of drug metabolism.
We present here four new lines of evidence using cell cultures which 
confirm that rat embryo limb buds are able to metabolise drugs. We also 
show that diphenylhydantoin is metabolised by the embryo cells in v itro  
but this appears to be a partial detoxification.
METHODS
Compounds: Test compounds of the highest purity commercially available
were used. Diphenylhydantoin, e ll ip t ic in e , cimetidine,
3-methylcholanthrene, phenobarbitone and B-napthofl avone were obtained 
from Sigma Chemical Company, Poole, Dorset, U.K. Benzimidazole was 
obtained from Fluka, A.G. Buchs, Switzerland, 
m.hydroxydiphenylhydantoin, p-hydroxydiphenylhydantoin and 
trichloropropene oxide were obtained from Aldrich Chemical Company 
Ltd., Dorset, U.K. Ranitidine hydrochloride was a g if t  from Glaxo 
Research Group, Ware, Herts, U.K. and diphenylhydantoic acid was 
synthesised by the Organic Chemistry Department a t IC I, Alderley Park. 
Culture media and sera were obtained from Gibco Biocult, Paisley, 
Scotland.
Preparation of rat limb cell cultures: The technique has been
previously described in detail by F lin t and co-workers. 4,13,14 
Essentially, embryos of 34-36 somites are collected from pregnant 
female rats approximately 13 days a fte r conception. Forelimbs are 
dissected free and following enzymatic dissociation, single cell 
suspensions are prepared in culture medium (Ham's F12 plus 10% fe ta l
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calf serum). Cell suspensions are adjusted to give 2 X 10  ^ limb cells  
per ml. Ten or 20 ul drops are delivered to culture dishes (normally 5 
drops per 35 mm diam. culture dish).
Sufficient replicate dishes are prepared for a ll subsequent 
treatments. The cells in each drop are allowed to settle  and adhere to 
the dish over two hours at 37°C. The dish is then flooded with excess 
culture medium which may be supplemented with the test substance or 
vehicle control. The adhering cells form separate micromass islands of 
from 6-8 mm diameter. These are cultured for 5 days at 37°C and 5% CO2 
i n ai r.
During the five days of culture a proportion of the cells in each 
micromass island d ifferen tia te  to form small foci of chondrocytes.
After fixation these foci are preferentially stained by alcian blue 
becoming regions of high contrast easily detectable with an automated 
image analyser. Counts of d ifferentiated foci are compared in test 
substance exposed and control cultures. A concentration dependent 
inhibition p ro file  is prepared and from this the concentration (IC50) 
inhibiting d ifferen tiation  by 50% control values is estimated.
Imnunocytochemical staining of cytochrome P450 in limb cultures: The
peroxidase anti-peroxidase technique described by Wolf et a l.*®  was 
used on cultures of limb cells a fte r 5 days incubation. Fresh cultures 
were stained against a variety of a n ti-ra t cytochrome P450 antibodies. 
Polyclonal phenobarbitone raised P450, B-naphthoflavone raised P448 and 
clofibrate raised P452 were a g if t  from Dr G Gibson, Biochemistry 
Department, University of Surrey. The monoclonal B-napthoflavone 
raised antibody 3:4:2 was a g if t  from Central Toxicology, Alderley 
Park, Macclesfield Cheshire and Hammersmith Hospital, London. The 
polyclonal 3-methylcholanthrene raised P448 and phenobarbitone raised 
P450 antibodies were a g if t  from Dr C R Wolf, Pharmacology Department, 
Western General Hospital, Edinburgh.
Transplacental Induction of Embryo Metabolising Enzymes:
0 P F l i n t  6
Dams were dosed in vivo and the embryos subsequently removed at day 13 
of gestation. Cultures were prepared as described. The dosing 
schedules were: 3 methylcholanthrene (in arachis o i l)  25 mg/kg, i . p . , 
days 10-12 gestation; B-napthoflavone (in  arachis o il) 35 mg/kg, i.p .  
days 10-12 gestation; 0.1% sodium phenobarbitone was supplied ad 
libitum in the drinking water, days 6-13 gestation. These dosing- 
regimes were known to raise hepatic cytochrome P450 levels in the dam.
RESULTS
Activation of cyclophosphamide by rat embryo cells in vitro: 
Cyclophosphamide has no inhibitory effect on limb cell d ifferen tia tion  
(number of d ifferentiated foci) unless a preparation of arochlor 1254 
induced actively metabolising adult rat liv e r enzymes (S9 plus NADPH) 
is  present (Fig 1 ). Thus cyclophosphamide is an excellent positive 
control for bioactivation studies. Following transplacental induction 
by B-naphthoflavone d ifferen tia tion  was inhibited by cyclophosphamide 
in limb cell cultures (Fig 2) suggesting the presence of (functional 
and) inducible cytochromes P450. Neither transplacental exposure to 
3-methylcholanthrene nor phenobarbitone affected cyclophosphamide 
tox ic ity .
Identification  of cytochrome P450 isozymes in limb cultures: 
Constitutive levels of cytochrome P450 (phenobarbitone type inducible) 
and P448 (3-methylcholanthrene type inducible) were detected in 5 day 
cultures (Table 1). In terestingly, transplacental induction was only 
observed with B-napthoflavone (inducing a P448 type of isozyme).
Neither 3-methylcholanthrene nor phenobarbitone induced isozyme levels  
above the constitutive. These observations are in close agreement with 
the a b ility  of these inducers (see above) to provoke cyclophosphamide 
metabolism by the embryo ce lls . The possibility that 
3-methylcholanthrene and phenobarbitone do not reach the embryo in  
su ffic ien t quantities is being investigated.
Modulation of cytochrome P450 ac tiv ity  in v itro  using diphenylhydantoin 
as a model teratogen: Diphenylhydantoin appears to be equitoxic to rat
limb ce lls  (IC50: 9 1 + 4  ug/ml) with its  major p.hydroxy (IC50 : 80 + 9 
ug/ml) and minor m.hydroxy (IC50 : 84 + 9 ug/ml) metabolites.
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The ring opened diphenylhydantoic acid is non toxic up to its  maximum 
solubility  in culture medium (250 ug/ml) and may represent a 
detoxification pathway. The acid is excreted in limited quantities in 
the urine of laboratory animals and man but certain esters of the acid 
formed in vivo can undergo rapid ring closure at body temperature and 
physiological pH to form diphenylhydantoin,*® thus giving a false
impression that the acid is a minor metabolite.
A number of inhibitors of cytochromes P448/P450, including cimetidine 
(Fig 3), increased the toxicity  of diphenylhydantoin in vitro when 
co-incubated at concentrations previously determined to be non 
cytotoxic (Table 2).
The increase in toxicity  appeared to be specifically caused by 
inhibition of (cytochrome P450 mediated) metabolism of 
diphenylhydantoin since cimetidene had no effect on the toxicity of the 
major metabolite p.hydroxydiphenylhydantoin (Fig 4).
Ranitidine, a non cytochrome P450 inhibiting pharmacological analogue 
of the inh ib itor cimetidine did not a lte r  the toxicity  of
diphenyl hydantoin confirming that increase in toxicity  is not a
non specific e ffec t.
Trichloropropene oxide was non inhibiting thus arguing against arene 
oxide formation being responsible for to x ic ity  (Table 2) and 
suggesting, also that i f  the hydroxy metabolites are formed in v itro  i t  
is by direct ring hydroxylation.
Since the p.hydroxy metabolite is toxic in v itro  i t  cannot be argued 
that diphenylhydantoin is the only potential ultimate teratogen but on 
the evidence of the inhib itor studies i t  may actually be the most toxic 
en tity . Direct ring hydroxylation in v itro  however probably forms the 
s t i l l  toxic p.hydroxy metabolite. The toxic ity  of both the parent 
compound and its  major metabolite may go some way towards explaining 
apparently conflicting in vivo studies of teratogenicity and 
diphenylhydantoin metabolism (see Introduction).
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S tru c tu re -a c t iv ity  re la tionships amoung tr ia z o le  anti fungals:
Some t r ia z o le  antifungals (basic structure in Tables 3,4) are 
te ra togen ic .*^  Toxic ity  appears to be d ire c t ly  re lated to both 
1 ipophi1i c i t y  and the type of substituent in the phenyl rings. 
Substitution a t the 4-posit ion  with metabolical ly stable and/or 
electron withdrawing groups reduces t r ia z o le  to x ic i ty  in v i t ro  
apparently by protecting the phenyl ring from metabolic attack (Table 
3). Compared to the 2 -pos it ion  the exposed 4-pos it ion  appears to be 
most vulnerable to metabolic attack, unless protected by a su itab le  
substituent (Table 4). The data suggest tha t to x ic i ty  in v i t r o  is  
mediated by the formation of a tox ic  intermediate ( quinone or arene 
oxide) possibly v ia  metabolic attack on the 4 pos it ion  in the phenyl 
r ing .
DISCUSSION AND CONCLUSIONS
In view of the potentia l fo r  embryonic xenobiotic metabolism during 
organogenesis resu lts  from in vivo studies in to  the mechanisms o f 
teratogenesis by co-adm inistration o f metabolic modulators w ith  the 
teratogen can often provide confusing re su lts .  Two factors  need to be 
determined: i )  the concentration of the compound in  the embryo and 
i i )  the d is t in c t io n  between the con tr ibu tion  of maternal and embryonic 
metabolism. The relevance of these two factors is  best studied under 
in v i t ro  conditions with e ith e r cultures of whole embryos or embryo 
c e l ls .
F l i n t  and Orton** found tha t 24 out of 25 teratogens screened in  v i t r o  
d ire c t ly  in h ib ite d  ra t  embryo ce ll  d i f fe re n t ia t io n  implying tha t most 
teratogens are d ire c t  acting and tha t metabolism is  not generally 
required fo r  teratogenic to x ic i t y .  This impression must in  a t le a s t 
some cases not be substantiated given the evidence o f the present study 
tha t embryo c e l ls  themselves have the potentia l to metabolise 
xenobiotics. Many teratogens (e .g. a ld r in ,  diazepam, 
d ie th y ls t i1boestro1) are in  fac t extensively metabolised in  v ivo. A l l  
of the possible drug metabolising enzymes cannot be provided in  v i t r o ,  
but in v i t r o  tes ts , p a r t ic u la r ly  the bacteria l tests fo r  detecting 
mutagens, have routine ley used supernatants prepared from homogenates 
of adult male ra t  l i v e r  plus the necessary cofactors (S9-mix). We 
found S9-mix to be tox ic  to eukaryotic mammalian c e l ls ,  ** pe rm itt ing  
two hours exposure to  50-100mu/S9 mix/ml cu lture medium or 5 days 
exposure to 3 ul S9 mix/ml cu ltu re  medium. C learly th is  is  an
inadequate model o f chronic drug exposure to pregnant female animals.
We are now inves tiga ting  routine transplacental induction of embryo 
cytochrome P450'by phenobarbitone, B-naphthoflavone or arochlor 1254 as 
an a lte rna t ive  method of ac t iva t ing  te s t  compounds. The p o s s ib i l i ty  
tha t the dam de tox if ies  the compound p r io r  to reaching the embryo may 
in  some cases l im i t  the p e d ic t iv i ty  of the wholly in v i t ro  te s t .  An ex 
vivo te s t ,  cu ltu r ing  embryo c e l ls  fo llow ing expoosure to te s t  compound 
in  vivo, *** has been proposed as a su itab le  method of accounting fo r  
th is  aspect of maternal metabolism.
The authors are grateful to Dr T C Orton fo r  his constructive advice 
during th is  p ro jec t.
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| ANTIBODY UNTREATED 3-METHYL­
CHOLANTHRENE
PHENO­
BARBITONE
B-NAPHTHO- | 
FLAVONE |
| Wolf/polyclonal Anti-3MC 
| raised P448 (3MCI) (levin 
| form d)
+ +( + ) NT ++ |
| Wolf/polyclonal 
| Anti-3MC raised P448 
| (3 MC2 ) (Levin form c)
+b ++ NT ++ |
| CTL/Hammersmith 
| monoclonal 3:4:2 Anti-f?NF 
| raised P448
+ + NTC +++ |
| Gibson/polyclonal 
| Anti-PB raised P450
++ ++ -H- -H- |
| Wolf/polyclonal Anti-PB 
| raised P450 (PB1)
. < + ) NT (+) NT |
| Wolf/polyclonal Anti-PB 
| raised P450 (PB2)
++ NT ++ NT |
| Wolf/polyclonal Anti-PB 
| raised P450 (PB3) (Levin 
| form b)
(+) NT (+) NT |
a. After five days of culture. Peroxidase stain was particularly associated 
with differentiating cells at the edges of chondrogenic foci.
b. 0 = absent, (+) = less than minimal, but present, + = minimal, ++ = moderate, 
-H-+ = very strong.
c . NT = not tested
TABLE I .  IMMUNOCYTOCHEMICAL IDENTIFICATION OF CYTOCHROME P450 IN CULTURES* 0 F 
RAT EMBRYO LIMB CELLS
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* Modulator Concentration3 
(ug/ml culture medium)
IC50^ of Diphenylhydantoin | 
(ug/ml culture medium) |
| None - 9 1 + 4  ug/ml |
| Cimetidine (mainly 
I P450 inhibitor
400 4 7 + 3 *  I
| Ranitidine (non P450 
| inhibiting analogue of 
| cimetidine
250 93 + 2 |
| Metyrapone (P450 
| inhibitor)
10 30 + 4 *  I
| Benziraidazole (broad 
| spectrum P450 
| inhibitor)
200 16 + 6* I
| Ellipticine (P448 
J inhibitor) 0.001 2 7 + 2 *  |
| Trichloropropene 
J oxide (Epoxide 
| hydratase inhibitor)
1 90 + 4 |
a. Highest concentration having no effect on limb cell growth or 
differentiation in vitro.
b. Concentration causing 50% reduction from control values in number of 
differentiated foci. *:Inhibition was significant with p < 0.5 (Student's 
t-test).
TABLE 2. EFFECT OF COINCUBATION WITH SOME CYTOCHROME P450 INHIBITORS AND OTHER 
COMPOUNDS ON TOXICITY OF DIPHENYLDANTOIN.
Monotriazole Bistriazole
Substituent
( R : R q)
IC50 
(nMoles/ ml)
Substituent
(R2)
IC50 
(nMoles /  ml)
4CI : 4Br 7.90 2,4CI 17.78
4CI : 4CI 14.79 4CI 114.82
4F : 4F 26.92 4F 173.78
4CF3 : 4CF3 34.67 4CF3 416.87
—  OH
! r
N ^ /R
OH
- r \
R
Table 3:
Effect of substitution in antifungal triazole compounds with groups of increasing 
metabolic stability and/or electron withdrawing character on inhibition of 
differentiation in cultures of rat embryo limb cells. Inhibition is measured as 
the IC50 (concentration inhibiting differentiation by 50% control value).
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Fig 1. D if fe re n t ia t io n  in cultures of ra t  embryo limb c e l ls  fo llow ing 
exposure to cyclophosphamide in the presence of metabolising enzymes 
( S9-mix) prepared from adult ra t l i v e r  homogenate. 3 ul of complete 
S9-mix was added to each ml of cu ltu re  medium. S9-mix was S9-fraction 
and phosphate bu ffe r (0.07 M, pH 7.4) in a ra t io  o f 3 : 7 v /v , with or 
w ithout 10 mM NADPH (prepared in the b u ffe r ) .
Fig 2. Activa tion  of cyclophosphamide to a tox ic  metabolite by 
cultured ra t  embryo limb c e l ls  fo llow ing transplacental induction of 
the embryos w ith  0-napthoflavone (see Methods).
Fig 3. In h ib i t io n  of d i f fe re n t ia t io n  in cu ltures of ra t embryo limb 
ce l ls  fo llow ing exposure to increasing concentrations o f 
diphenyl hydantoin in  the presence or absence of the cytochrome P450 
in h ib i to r  c im etid ine.
Fig 4. In h ib i t io n  o f d i f fe re n t ia t io n  in  cu ltures of ra t  embryo limb 
c e l ls  fo llow ing exposure to the major metabolite of diphenylhydantoin, 
p-hydroxydiphenyl hydantoin, in. the presence or absence o f the 
cytochrome P540 in h ib i to r  c im etid ine.
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INTRODUCTION
One significant problem in determining the mechanism of teratogenesis is 
the nature of the ultimate toxin; whether it is a metabolite or the 
compound itself.
Coadministration to the dam of the teratogen and various inhibitors or 
inducers of drug metabolism followed by examination of the fetuses for 
changes in the incidence of terata suggests that in some cases metabolic 
activation might be important. For example the epoxide hydratase 
inhibitor trichloropropene oxide (TCPO) doubles the incidence of cleft 
lip and palate in Swiss ICR mice following a single dose (50mg/kg) of 
diphenylhydantoin*. A toxic arene oxide intermediate appears to be the 
ultimate teratogen. On the other hand if the basal activity of maternal 
cytochrome P450 is enhanced by the inducer phenobarbitone^ or diminished 
by purified dietJ diphenylhydantoin related abnormalities are 
correspondingly reduced or increased. These experiments suggest that a 
metabolite is not involved; diphenylhydantoin appears to be the ultimate 
teratogen.
These conflicting conclusions result from an interpretation which assumes 
the dominance of maternal metabolism. The embryo is seen as inertly 
subject to maternally determined changes in the level of compound and 
metabolite. The embryo is not however metabolically inert, ^»5,6,7 aa(j 
metabolism of xenobiotics by the embryo cells themselves may be of 
profound importance in teratogenesis.
One way of separating the influence of maternal from embryo metabolism is 
to maintain the embryo or its component cells in culture. The micromass
O  Q  I Q
technique0* ’ is a method of culturing rat embryo limb or midbrain 
cells so that many aspects of cell differentiation related to normal 
embryogenesis are maintained in vitro. This paper describes preliminary 
experiments aimed at defining the cytochromes which are metabolically 
active in limb micromass cultures. Analysis of the in vitro toxicity of 
vitamin A and some related compounds, or of the glycol ethers suggests 
that there are limits to the ability of embryo cells to metabolise 
xenobiotics.
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METHODS
Compounds: Test compounds of the highest purity commercially available
were used. The glycol ethers and their metabolites (alkoxyacids) were a
gift of Dr Nigel Brown, MRC, Carshalton, Surrey.
Preparation of rat limb cell cultures: The technique has been previously
described in detail by Flint and co-workers. * *  Essentially, embryos 
of 34-36 somites are collected from pregnant female rats approximately 13 
days after conception. Forelimbs are dissected free and following 
enzymatic dissociation, single cell suspensions are prepared in culture 
medium (Ham's F12 plus 10% fetal calf serum). Cell suspensions are 
adjusted to give 2 X 10^ limb cells per ml. Ten or 20 ul drops are 
delivered to culture dishes (normally 5 drops per 35 mm diam. culture 
dish).
Sufficient replicate dishes are prepared for all subsequent treatments. 
The cells in each drop are allowed to settle and adhere to the dish over 
two hours at 37°C. The dish is then flooded with excess culture medium 
which may be supplemented with the test substance or vehicle control.
The adhering cells form separate micromass islands of from 6-8 mm 
diameter. These are cultured for 5 days at 37°C and 5% CO2 in air.
During the five days of culture a proportion of the cells in each
micromass island differentiates to form small foci of chondrocytes.
After fixation these foci are preferentially stained by alcian blue 
becoming regions of high contrast easily detectable with an automated 
image analyser. Counts of differentiated foci are compared in test 
substance exposed and control cultures. A concentration dependent 
inhibition profile is prepared and from this the concentration (IC50) 
inhibiting differentiation by 50% control values is estimated.
Cell survival is also estimated spectrophotometrically as the non 
specific uptake by all surviving cells of the dye neutral red. An IC50 
is also estimated from the concentration dependent survival curve.
Prediction of teratogenic hazard in vitro
We have found the following guidelines useful for the interpretation of
IC50 values whenever a concentration response curve indicates toxicity of 
the test compound.
1. Potent teratogens (e.g. aldrin, azaguanine, colchicine, cyloheximide, 
diethylstilbestrol, 5 flourouracil*®) all inhibit differentiation 
with an IC50 below 10 ug/ml. Weak or poorly substantiated 
teratogens (e.g. aspirin, diazepam, sulfisoxazole) have IC50’s 
greater than 50 ug/ml. As a general rule IC50fs less than 100 ug/ml 
are indicative of teratogenic hazard, becoming strongly indicative if 
less than 50 ug/ml.
2. The IC50 of the model teratogen vitamin A in limb cultures (Table 2) 
for cell survival (3.5 ug/ml) is 500 fold higher than the IC50 for 
cell differentiation (0.007 ug/ml) suggesting highly selective 
toxicity for cell differentiation. This sign of teratogenic hazard 
may be particularly indicative of those teratogens which will cause 
fetal abnormalities at doses which may not be significantly toxic to 
the mother, and is therefore considered to be an important 
criterion.
3. Teratogens are characterised by their selective toxicity for 
different organs (e.g. hydrocortisone and diphenylhydantoin - 
orofacial clefts; thalidomide - limb reduction). Therefore a 
difference of IC50 between midbrain and limb cultures may be taken as 
a further indication of teratogenic hazard.*®
Immunocytochemical staining of cytochrome P450 in limb cultures: The
peroxidase anti-peroxidase technique described by Wolf et al. was used. 
Fresh cultures were stained against a variety of anti-rat cytochrome P450 
antibodies. Polyclonal phenobarbitone raised P450, and -naphthoflavone
raised P448 were a gift from Dr Gibson, Biochemistry Department, 
University of Surrey. The monoclonal {3-napthflavone raised antibody 
3:4:2 was a gift from Central Toxicology, Alderley Park, Macclesfield, 
Cheshire and Hammersmith Hospital, London. The polyclonal 
3-methylcholanthrene raised P448 and phenobarbitone raised P450 
antibodies were a gift from Dr C R Wolf, Pharmacology Department, Western 
General Hospital, Edinburgh.
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Transplacental Induction of Embryo Metabolising Enzymes: Dams were dosed
with inducers in vivo and the embryos subsequently removed at day 13 of 
gestation. Cultures were prepared as described. The dosing schedules 
were: 3-methylcholanthrene (in arachis oil) 25 mg/kg, i.p., days 10-12 
gestation;^?-naphthoflavone (in arachis oil) 35 mg/kg, i.p. days 10 -12 
gestation; 0.1% sodium phenobarbitone was supplied ad libitum in the 
drinking water, days 6 - 1 3  gestation. These dosing regimes were known 
to raise hepatic cytochrome P450 levels in the dam.
RESULTS
Localisation of cytochromes P450/P448 by antibody staining: Staining of
5 day cultures of rat embryo midbrain and limb cells with antibodies to 
cytochromes P450 and P448 reveals constitutive levels of both 
isozymes**»^. Following transplacental exposure 3-methylcholanthrene 
(3MC) slightly induces the P448 isozyme.p  -napthoflavone (BNF) is a 
much stonger transplacental inducer of the embryo cytochrome P448. The 
cytochrome P450 isozyme is not inducible by any of the inducers to which 
the embryo was exposed. Isoenzymes which were inducible transplacentally 
were also directly inducible in vitro but to a lesser extent, as gauged 
by the intensity of anti-peroxidase stain.
Further studies with these antibodies now reveals that the cytochrome 
P450 antigen is present at constitutive levels from day 1-2 of culture 
but that cytochrome P448 only appears by day 3-4 of culture. Staining 
against the cytochrome P448 antigen is most intense around the periphery 
of the chondrogenic foci in limb cultures.
Drug metabolism in vitro by rat embryo cytochromes P450/P448: The
proteratogen cyclophosphamide is not toxic to induced cultured cells 
unless a preparation of rat liver metabolising enzymes is present*®. 
Transplacentally induced cells (BNF only, not 3MC or phenobarbitone-PB) 
are however able to metabolise cyclophosphamide to its toxic metabolite^ 
suggesting that the induction not only elevates the levels of cytochrome 
P448 but induces its synthesis at an earlier stage in culture than day 
3-4. Antibody staining of induced cultures is underway to demonstrate 
the precocious appearance of cytochrome P448. There appear to be 
differences between the enzyme antigenically defined as cytochrome P448 
in the embryo and that in the adult, because metabolism of
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cyclophosphamide is normally associated with cytochrome P450 isoenzymes. 
The toxicity of diphenylhydantoin (another teratogen) is also increased 
following transplacental exposure to 3MC and to BNF, but not to PB (Table 
! ) •
| Inducer Limb culture IC50 ug/ml Sa |
| None k 91 + 4 |
| Phenobarbitone c 90 + 17 |
| 3-methylcholanthrene 73 ± 6 * 1
| Beta naphthoflavane 64 + 14 * 1
a. Statistical significance (t test): * = p< 0.05.
b. Brown et al, 1986 (average of eight measurments)
c. IC50 for each inducer is the average of three experiments.
TABLE 1. IC50 of rat embryo limb cultures exposed to diphenylhydantoin 
following transplacental exposure to a variety of cytochrome P450/P448 
inducers.
This data strongly suggests that diphenylhydantoin toxicity in vitro may 
in part be mediated by a toxic metabolite following induction by 3MC/BNF 
but not PB. In fact the major p-hydroxy metabolite is at least equitoxic 
in vitro with the parent compound^. A toxic epoxide intermediate may not 
be involved, because the epoxide hydratase inhibitor TCPO added in vitro 
does not effect the IC50 of diphenylhydantoin even though covalent 
binding to limb*cell protein appears to increase substantially (10-20 
fold) in the presence of TCPO (unpublished results) indicating activity 
of the enzyme in the embryo. In addition glutathione and n-acetyl 
cysteine which would be expected to react non-enzymatically with a DPH 
epoxide do not affect toxicity in vitro (unpublished results).
A variety of inhibitors of cytochrome P450/P448 metabolism 
(benzimidazole, cimetidine, metyrapone, ellipticine) however, increase 
the toxicity of diphenylhydantoin when coincubated in vitro7 , suggesting 
that the parent compound is the ultimate toxin.
This apparently conflicting evidence may be resolved by the hypothesis 
(Fig 1) that both diphenylhydantoin and its major metabolite are
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responsible for toxicity in vitro but that toxicity is diminished because 
of the loss of intermediate reactive metabolites (probably epoxides) 
which bind to non essential proteins or form a non toxic dihydrodiol. 
Induction of cytochrome P450 increases the rate of production of the 
toxic p-hydroxy metabolite, whereas inhibition increases steady state 
levels of the toxic parent compound; thus in both cases toxicity will 
increase. TCPO causes more epoxide to be lost by binding to non 
essential proteins but does not effect an accumulation of 
diphenylhydantoin so that toxicity does not change.
The embryo itself may thus modulate the toxicity of diphenylhydantoin.
The degree of teratogenicity in vivo must in addition depend on maternal 
detoxification and elimination; i.e. the amount of either parent compound 
or unchanged p-hydroxy metabolite which reach the embryo. This may go 
some way to explaining the apparently contradictory outcome of 
experiments (outlined in the introduction) where diphenylhydantoin was 
coadministered with inhibitors or inducers of maternal cytochrome P450 
activity or the inhibitor of epoxide hydratase, TCPO. Clearly inhibiting
o o
the activity of cytochrome P450 * will lead to increased amounts of 
diphenylhydantoin reaching the embryo and thus increase the 
teratogenicity. Inducers, such as phenobarbitone essentially promote 
detoxification decreasing teratogenicity because less parent compound 
reaches the embryo. The increased incidence of the teratogenicity in the 
presence of TCPO^ suggests teratogenicity via a toxic arene oxide 
intermediate, but this intermediate has not been detected and must be so 
short lived that unless it is generated in the embryo its toxic effect 
will not be observed. An epoxide intermediate generated by the embryo 
cells themselves does not appear to lead to increased toxicity (see 
above, results with TCPO in vitro). It can only be speculated that the 
effect of TCPO in vivo is to inhibit maternal detoxification via 
dihydrodiol formation leading to increased toxicity because of increased 
levels of parent compound (or even possibly the p hydroxy metabolite 
following direct ring hydroxylation).
Limitations to xenobiotic metabolism with cultured rat embryo cells:
1. Synthetic retinoids, such as etretinate have recently been used with
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some success in the treatment of non-malignant dermatological disease 
in m a n ^ ‘^ .  Vitamin A itself is a model teratogen^ as is 
etretinate^ and therefore the teratogenicity of all compounds 
related to vitamin A has come into question. -carotene (Fig 2) a 
major dietary source of vitamin A, is a symmetrical molecule which is 
broken down in vivo from two molecules of vitamin A. J3 -carotene is 
without toxicity in vitro, though vitamin A itself is a potent 
inhibitor of limb cell differentiation in vitro at concentrations one 
thousand fold lower than those killing cells (Table 2). Thus the 
cells do not appear to possess the -carotene 15,15' oxygenase which 
in vivo would metabolise j3-carotene to the toxic vitamin A. This
1 o
enzyme is found in the adult only in the intestine and the liver■LO, 
and in agreement with our data, has not been reported in early 
embryonic tissue.
Vitamin A (acid or alcohol) consists of a cyclohexene ring attached 
to a polyene fatty acid or alchohol side chain (Fig 2).
Modifications to the side chain such as an amide rather than an acid 
or alcohol termination appear (at least in the hamster) to reduce or 
eliminate teratogenicity^^. It is thus pertinent to ask about the 
contribution of the fatty acid/alchohol side chain and the 
cyclohexene ring to the teratogenicity of the vitamin A molecule.
The ring itself with a greatly truncated side chain (|3- ionine, Fig 
2) is without teratogenic hazard in vitro (Table 2). Crocetin is a 
symmetrical polyene dicarboxylic fatty acid which is essentially 
^-carotene without the cyclohexene rings (Fig 2). Crocetin is toxic 
in vitro but at higher concentrations than vitamin A and with no 
specific toxicity for cell differentiation (Table 2). Thus specific 
inhibition of differentiation in vitamin A only arises when the fatty 
acid or alcohol is linked to the cyclohexene ring. Vitamin A alcohol 
or acid exert their physiological effects on the cell following
19binding to intracellular retinol or retinoic acid binding proteins . 
This binding is of course conformationally specific to the vitamin A 
molecule and would not be expected for a polyene fatty acid such as 
crocetin. Though the toxicity of vitamin A appears to be related to 
the structure of its side chain this toxicity does not appear to be 
revealed (at least as a specific teratogenic hazard in vitro) unless 
promoted by binding of the molecule to a retinol binding protein.
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This protein appears to ubiquitously present in*vivo and in many
I Q
cultured cell lines. J
IC50 (ug/ml)
CELL DIFFERENTIATION3 CYTOLETHALITYb
-Carotene No effectc No effect
Vitamin A, alcohol 0.007 3.5
J^-ionone No effect No effect
Crocetin 19 23
a. Number of differentiated chondrogenic foci per micromass island.
b. Neutral red spectrophotometric estimation of surviving cells.
c. No effect to maximum concentration on cell differentiation or cell 
survival.
Table 2. Effect of vitamin A and related compounds on cell 
differentiation and cell survival in rat embryo limb cells after five 
days in culture.
Methoxy ethanol (ME) is teratogenic in the rat^®. It is however 
without effect on the cultured rat embryo limb cells up to 5000 ug/ml 
(Table 3). Methoxyacetic acid (MA) which is generated in vivo by 
alcohol dehydrogenase from methoxy ethanol^*^ is toxic in vitro 
(Table 3) specifically inhibiting cell differentiation, confirming 
the observation that in vivo teratogenicity is probably mediated by
o 9
this metabolite . As the chain length of the principle metabolite
increases up to butyl (Table 3) so the concentration needed to
inhibit cell differentiation increases. This appears to be a
relationship that is limited to cell differentiation because evidence
93on the in vitro cytolethality J of the glycol ethers suggests that 
toxicity increases with chain length (ethoxyacetate is more cytotoxic 
than methoxyacetate, Table 3).
In other words the toxicity we observe in vitro is not simply the
result of cell killing but probably related specifically to the
teratogenicity of those compounds. Propoxyethanol^ and 
9 Abutoxyethanol^0 are not teratogenic in vivo. This is clearly
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supported by the lack of in vitro toxicity of the major acid 
metabolites (Table 3).
The in vitro toxicity of ethoxyethanol (Table 3) at first suggests 
the possible generation of its toxic metabolite by endogenous alcohol 
dehydrogenase. This however, is unlikely to be the case because 
there is no preferential inhibition of cell differentiation as with 
the acid metabolite. In addition the IC50 of the parent compound is 
three fold greater at 7.4 mM, a concentration which is unlikely to 
occur in vivo since serum concentrations appear to saturate around 
5 mM (P.Foster - Personal communication).
4
The in vitro data demonstrates that the embryo cells are not equipped 
with alcohol dehydrogenase. The acid metabolites are long lived 
(i.e. can be detected in the urine) and the teratogenicity of the 
glycol ethers in vivo may thus not be mediated by embryo metabolism. 
One final point arising out of this data is that though usually 
IC50's less than 100 ug/ml may be indicative of teratogenic hazard 
(see methods) this should not be taken as a hard and fast rule. With 
some compounds, such as, the glycol ethers, far greater concentrations 
are achievable in vivo. The most important criterion appears to be 
preferential inhibition of cell differentiation.
CONCLUSION
Rat embryo limb cells in vitro contain at least one if not more 
functional and inducible isozymes of cytochrome P448 which are capable of 
metabolisng xenobiotics to toxic metabolites. Experiments with both 
diphenylhydantoin and cyclophosphamide strongly suggest that rat embryo 
limb cytochromes P448 inducible by 3MC and BNF are functional xenobiotic 
metabolising enzymes. Flint and Orton^ found that of 27 teratogens most 
of which are actively metabolised in vitro 25 were directly toxic to the 
cultured cells, and thus metabolism did not appear to be a significant 
factor. This conclusion may have to be revised if the embryo cells 
themselves are potent sources of functional metabolising enzymes.
Not all teratogenicity appears to be mediated by cytochrome P450 
metabolism. Maternal enzymes responsible in vivo for metabolism of beta 
carotene or methoxyethanol to the teratogenic metabolites vitamin A or
methoxyacetic acid are absent from the embryo cells. The in vitro
Dr 0 P Flint 10
results with micromass cultures highlight the separation of non toxic 
parent compound from the toxic metabolite in a simple way which would be 
difficult to assess in vivo. It should be possible to use these cultures 
to investigate problems of metabolic activation of teratogens in a more 
systematic way.
The authors would like to thank Mrs K Jones for her technical assistance, 
Dr Nigel Brown for alkoxy alcohols and metabolites and Dr T C Orton for 
helpful discussions of the manuscript.
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FIG 1 In vitro metabolism of diphenylhydantoin
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1. INTRODUCTION
Several lines o f evidence substantiate the key role of metabolism in 
chemical teratogenesis. M etabolic studies w ith  inducers and inh ib itors o f the 
m aternal m ixed-function oxidase system (the cytochrome P-450 system) have 
shown that fo r some teratogens, metabolism plays a key role in the eventual 
teratogenic e ffe c t (1-3), and that inclusion o f a metabolic activa ting  system 
to in v itro  te ra togen ic ity  tests is very im portant in order to re fle c t the m 
vivo s ituation (4,3). In addition i t  is possible to demonstrate tha t rodent (and 
probably human) embryos possess low levels o f at least some o f the drug 
metabolising enzymes, and that some of these enzymes are inducible by 
xenobiotics (6,7).
In addition, the role o f maternal and embryonic activa ting  reactions on 
the teratogenic outcome in vivo depends on several factors including the ha lf 
li fe  o f the active m etabolite, the fe ta l genotype, and the m aternal genotype.
In this review, a b rie f outline o f the in vivo and iri v itro  teratogen tests 
is described, followed by examples of the key pieces o f evidence to 
demonstrate the role of metabolism in b ioactiva tion of teratogens.
1.1 TESTING METHODS FOR TERATOGENICITY
1.1.1 In V ivo:
The aim o f in vivo test procedures is to assess the e ffec ts  o f chemicals 
on reproduction using common laboratory species as models. Testing has a 
number o f common requirements:
(i) The chemical has to be tested fo r e ffects  on general reproductive 
performance as well as embryo development.
( ii)  Preferred species are the ra t, mouse and rabb it. O ther species may be 
used when differences in metabolism or tox icokine tics between the 
preferred species and man are known, or to c la r ify  an ambiguous 
result.
( iii)  S u ffic ien t numbers o f animals to perm it s ta tis tica l evaluation.
(iv) The route o f adm in istration should paralle l the route by which man is 
to be exposed.
(v) Chemicals administered at several dose levels (usually three).
(vi) The lowest dose should produce no observable e ffects  and the highest 
dose should be the maximum m aternal to lerated dose (MTD).
(v ii) Adequate concurrent contro l groups.
Detailed protocols from various countries and leading regulatory 
agencies can be found in references 8-13.
Chernoff and Kavlock (14) have proposed an jn vivo screen (in the 
mouse) in which compounds are administered throughout organogenesis at, or 
near MTD, and the newborn are examined for number and weight gain both at 
b irth  and three days a fte r pa rtu rition . The rationale is tha t prenatal insults
w ill m anifest themselves postnatally as reduced v ia b ility  and/or impaired 
growth upto 250 days post-partum  (15). There was a good corre la tion w ith  
known teratogens (100%, 15 out of 15), but also a high incidence o f false 
positive results w ith  non-teratogens (33%, 3 out o f 9). A recent report (16) 
suggests that maternal to x ic ity  its e lf may result in em bryotox ic ity , and since 
the C hernoff and Kaviock screen uses doses at or near the MTD this could 
account fo r the high percentage o f false positives reported. This la tte r test 
is more expensive and tim e consuming than the in v itro  screens described 
below, but is not necessarily more pred ictive .
1.1.2 In v itro  screens fo r teratogens and role o f m etabolism :-
In the quest for new, more pharm acologically active drugs, the need 
fo r early hazard assessment in the screening programme is essential. The 
answer would be an ideal in v itro  test system that would be simple, rapid, 
yie ld a large number o f in terpretabie and reproducible results (giving few 
'false negatives' and 'false positives') and reta in some relevance to 
mechanisms of teratogenesis. In v itro  teratogen tests have problems that are 
not found w ith  other [n v itro  to x ic ity  tests. F irs tly , the tox ico log ica l ta rge t 
is the embryo, a mass o f rapidly dividing cells, simultaneously d iffe re n tia tin g  
along divergent lines. As far as possible the test should reproduce these 
aspects o f embryogenesis. Secondly, both m aternal metabolism of xenobiotics 
and fe ta l-p lacenta l-m aterna l in teractions are usually not present in v it ro . 
Since some teratogens may require b ioactiva tion to the active form , the 
inclusion o f a reliable metabolising system or source of m etabolites in the 
screen would extend the u t il i ty  of the test procedure. This has been achieved 
as follows:
(i) Incorporation of serum from  chemical-exposed animals. Serum has 
been obtained from animals administered the test compound and then 
added to the culture medium for whole embryo cultures and lim b bud
6.
organ cultures. Whole rat embryo cultures were unaffected by the
d irec t addition o f cyclophosphamide (CPA) upto 800 pg/m l cu ltu re
medium, although serum from CPA pretreated (180 mg/kg) animals 
was em bryo-lethal a fte r only a 1 hr incubation period (17). S im ila rly
cu lture medium supplemented w ith  serum from  procarbazine 
pretreated rats (but not the compound added d irec tly  to the cu lture  
medium) showed a response to the drug (18). Serum from human 
patients receiving anticonvulsant therapy or chemotherapy has also 
been included in the culture medium of the whole ra t embryo cu lture  
system and the induced teratogenic responses compared to con tro l 
serum (19,20). These examples suggest that serum provides a 
sa tis factory method o f including m etabolites into in v itro  cu ltu re  
systems, however i t  is not routine ly used because o f the added expense 
in dosing and preparing heat inactivated serum.
(ii) Induction o f m aternal cytochrome P-450 isoenzymes. For example 
whole ra t embryos explanted from  dams pretreated w ith  
3-methylcholanthrene and subsequently cultured could b ioactiva te
2-acetylam inofluorene to a teratogenic m etabolite whereas uninduced 
controls could not (7,21). Limb bud organ cultures from  mice 
pretreated in utero w ith  A roclo r 1234 could b ioactivate CPA, whereas 
(non-treated) controls were re frac to ry  to the to x ic ity  (22). Results 
from our own laboratories have shown that cultures o f ra t embryo lim b 
bud cells from B-naphthoflavone pretreated dams could b ioactiva te  
CPA to a species which inhib ited d iffe ren tia tio n  (6), whereas 
phenobarbitone or 3-m ethylcholanthrene pre trea tm ent and contro l 
tissue showed no m etabolic activa tion  of the proteratogen.
( iii)  Tissues or target cells w ith  an m v itro  activa tion  system. CPA was 
activated to teratogenic m etabolites by both rabbit and hamster 
hepatocytes when co-cu ltu red  w ith  whole rat embryos (23). Hamster
embryo cells (capable of both phase I and II metabolism) were 
successful in activa ting  CPA to a tox ic m etabolite when co-incubated 
w ith  mouse lim b bud cultures (4).
Co-incubation w ith  hepatic microsomes or S9 live r fractions 
plus cofactors, usually from  A roc lo r 1254-induced male rodents, has 
been widely used, resulting in the successful activa tion o f various 
compounds including CPA, 2-acetylam inofluorene, 5 -flu rou rac il, 
diphenylhydantoin and thalidom ide in a number o f in v itro  screens 
including whole embryo cu lture  (24-28), embryonic lim b bud organ 
culture (29), d iffe re n tia tin g  embryo cells (30-33), inh ib ition  o f mouse 
ascite tumour ce ll attachm ent to lectin-coated surfaces (34-36) and 
d iffe ren tia tin g  human embryonic palatal mesenchymal cells (37).
The major disadvantages o f the use o f S9 fractions and 
cofactors as a source o f m etabolites are 1) the to x ic ity  o f the S9 m ix 
to embryo tissue/cells in v it ro ; 2) the lim ited  period o f a c tiv ity  o f the 
added activa tion system.
In addition we suggest the fo llow ing methods that m ight be 
experim entally relevant but which have not yet been reported in the 
lite ra tu re .
In v itro  exposure to inducers given that the embryo cells themselves 
contain inducible forms o f the b ioactiva tion enzymes (38).
Addition o f 59 fractions from  pregnant females, both contro l and 
preinduced.
Incubation o f the test compound w ith  an S9 fraction , then addition o f 
the f ilt ra te  to the i_n v itro  test system, thus c ircum venting the 
problem o f the to x ic ity  o f S9 fractions in v itro .
Addition o f purified enzyme components of the drug m etabolis ing
The most sa tis factory way of taking the fe ta l-m aterna i-p lacen ta l unit 
in to account is to dose the m other w ith  the test compound, p rio r to removing 
the embryos fo r cu lture (39-41). This would then constitute a combined in 
v ivo /in  v it ro , approach. Beaudoin and Fisher (41) dosed pregnant rats e ither 
24 hrs or 4 hrs p rio r to the recovery o f day 10 embryos for m v itro  cu lture  
and a ll compounds they tested inhib ited the rate o f development in v itro . 
Embryos from  the 24 hr (prior to explant) dosed dams were more severely 
a ffected  than those from  the 4 hr dosed dams. S im ilarly, F lin t et al. dosed 
pregnant rats 18 hrs prio r to the recovery o f day 13 embryos for the 
micromass ce ll culture assay and found that the 18 teratogens tested had 
s ign ifican tly  increased inh ib ition  of d iffe re n tia tio n  in v itro  compared to the 
13 non-teratogens tested (39).
Several reviews on the subject o f teratogen testing exist, covering the 
advantages, disadvantages and experim ental techniques o f a ll the m ajor 
categories o f in v itro  screens (29,32,42-31). In general i t  appears that in 
v itro  screens lack a reliable drug m etabo liz ing /activa ting  system. I t  has been 
suggested (30) that S9 hepatic fractions from  Arochlor-1254 induced male 
Sprague-Dauwley rats should be included in in v itro  tests to standardise the 
activa tion  system. Recently, the concensus workshop on jn  v itro  
te ra togen ic ity  testing recommended that test validation would be fa c ilita te d  
by testing specific xenobiotics w ith  defined te ra togen ic ity . Smith et al. (52) 
lis t 47 compounds which is intended to serve as a basis for m v itro  screens in 
the hope o f identify ing  systems which w ill contribu te  to a more e ffe c tive  test 
programme.
2. FACTORS INFLUENCING THE EXPRESSION OF A TERATOGENIC
INSULT:
The expression o f teratogenesis is influenced by several factors,
including genetic, sex and in te rspec ific  differences in m etabolic capability .
(i) Genetic: The Ah locus is a cluster of genes thought to be the centre 
o f the genetic regulation o f some o f the hepatic cytochrome P450 
dependent mono-oxygenases (33,34), metabolising aryl hydrocarbons. 
Benzo(a)pyrene is m etabolized by cytochrome P450 mono-oxygenases 
under the contro l o f the Ah locus and the degree o f 
responsiveness/susceptibility to both benzo(a)pyrene teratogenesis and 
enzyme induction d iffe rs  in two mice strains (C57/BL6 = responsive 
strain, AKR = non-responsive strain) (55,56). Responsive m ice were 
found to have 50 tim es more hepatic cytosolic receptor (a pro te in  
contro lling induction) than the non-responsive strain (57). Teratogens 
that show a corre la tion between stra in  sensitiv ity  and increased Ah 
receptors in mice include 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
(54,58,59), diazepam (60), g lucocorticoids (58,61-64) diphenylhydantoin 
(58,65-70) and acetazolamide (71-73). However, caution is required in 
the in te rpre ta tion  o f the apparent corre la tion between tera togenic 
susceptib ility and Ah responsiveness, as the strains involved vary at 
innumerable loci in addition to the Ah locus. A fu rthe r example o f 
genetic va riab ility  was the case study of the discordant expression o f 
the fe ta l hydantoin syndrome in heteropaternal d izygotic  tw ins (74). 
The m other, was an ep ileptic  receiving diphenylhydantoin therapy, the 
heteropaternal twins despite the same in utero exposure discordantly 
expressed the fe ta l hydantoin syndrome.
( ii)  Sex: The sex o f the animal also has an influence on suscep tib ility  to 
teratogenesis. M ethylm ercury is an established in vivo teratogen, and 
additionally decreases hepatic mono-oxygenase a c tiv ity  in the male
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offspring only (75). In contrast, acetazolamide-induced te ra togen ic ity  
seems to a ffe c t a greater percentage o f female offspring (76). 
S im ilarly the synthetic oestrogen, d ie thy ls tilbestro l, therapeutica lly 
used between 1950-1970 in order to prevent threatened m iscarriage
during the f irs t trim ester, caused the female o ff-spring to develop 
vaginal adenocarcinomas (77,78), during sexual m aturation (14-22 yrs 
old). In addition, male offspring s im ila rly  exposed pre-nata lly , have 
been reported to have reduced sperm counts and a high incidence o f 
s te r ility  (79), but no e ffe c t on hormonally sensitive tissue.
( iii)  Species differences in teratogenesis and metabolism: Table 1 shows
the inter-species variations between the minimum teratogenic doses o f 
some selected compounds. There are clear differences fo r example, 
between the mouse and ra t in that the mouse appears more sensitive 
to the teratogenic e ffects  o f diazepam, 2,5-diaminotoluene, ca ffe ine , 
diphenylhydantoin and aspirin. In contrast, the ra t is more sensitive to 
the e ffects  o f L-dopa. The interspecies variations are not en tire ly  due 
to differences in p lacentation (because the mouse and rat are s im ilar) 
but may well be due to differences in e ither xenobiotic 
biotransform ation or the pharm acokinetic p ro file  o f the chem ical.
3. PHARMACOKINETIC PHENOMENA IN PREGNANT ANIMALS
During pregnancy there are increases in the clearance o f ora lly  
administered drugs whose excretion is predominently renal and related to 
creatin ine clearance, but no change in the clearance o f oral drugs that are
extensively metabolized by the live r, i.e. have a high hepatic extraction 
ra tio  (120). Processes which a ffe c t the kinetics o f clearance (renal plasma 
flow  and glomerular f ilt ra tio n  rate) are usually increased during pregnancy
(121). The apparent volume o f d is tribu tion is also altered due to increased 
plasma volume, an increase in body fa t and a decrease in the concentration of 
plasma proteins. The net result is a tendency towards prolonged drug h a lf- life
(122). In addition, delayed gastric emptying has been noted during pregnancy 
(approxim ately tw ice as long as compared to non-pregnant women, 123).
Most drugs are p a rtia lly  bound to plasma proteins, predom inantly 
albumin. The albumin concentration fa lls  in the f irs t  4 months o f pregnancy 
which reduces the binding capacity o f a given volume o f plasma, but since the 
plasma volume increases during pregnancy the to ta l mass o f albumin 
e ffe c tive ly  remains constant. For highly bound drugs, the hypoalbuminaemia 
o f pregnancy w ill produce a lower to ta l plasma concentration, associated 
w ith  a decrease o f the bound drug fraction  and a corresponding increase o f 
the free drug fraction  in the plasma (124,125). In contrast to albumin, the 
concentration o f most globulin fractions rise during pregnancy. The to ta l 
e ffe c t o f changing patterns o f plasma proteins and o f physiological 
com petitors for the ir binding sites is complex and varies from  compound to 
compound (123). A lte red pharmacokinetics during pregnancy is therefo re  a 
well documented area in both humans and laboratory animals (121,126-131).
In humans there is l i t t le  evidence o f changes in drug m etabo lite  p ro files  
during pregnancy, or liver s ize/w eight changes (129). However, the liv e r o f
the pregnant ra t has been reported to increase by up to 40% o f the normal 
weight and it  has been suggested that this increase is an adaptive response to 
accommodate hydroxylation of the rising tide o f sex hormones (132). 
In teresting ly, the same group also noted a decrease (53-73%) in cytochrome 
P450-mediated reactions accompanied by live r weight changes p rio r to 
pa rtu rition  (132).
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4. ENZYMOLOGY OF TERATOGEN ACTIVATION
Studies o f the in te rac tion  of chemicals w ith  biological systems have 
shown that in many cases, the parent compound is not the chemical species 
responsible fo r the observed toxic e ffects . Rather, the parent compound is
biotransform ed and converted to a tox ic reactive in term ediate or m etabolite. 
These reactions have been studied in maternal hepatic tissue and in tissues o f 
importance to teratogenesis, including the placenta and fe ta l live r.
4.1 Drug metabolism by the placenta:
The main role o f placental cytochrome P450 appears to be in 
cholesterol side chain cleavage and biosynthesis o f estrogens from  C19 
endogenous steroids (133-138). Most o f the drug biotransform ation reactions 
present in the live r have also been reported in the placenta (133). Examples 
are cytochrome P450 dependent reactions (134), glucuronidation, sulphation, 
glutathione conjugation, epoxide hydratase, catechol-O -m ethyltransferase 
and monoamine oxidase (133). Human placental cytochrome P430 
concentration is approxim ately 20% of that found in m aternal live r (135,136), 
w ith  the placental m itochondrial cytochrome P450 concentration being 
several times greater than in the microsomal frac tion  (137).
There is some evidence for the m u ltip lic ity  of cytochrom e P450 
isoenzymes in the placenta (137-139) and placental cytochrome P450 appears 
to be inducible only by 3-methylcholanthrene (3MC) and related inducers 
(137). The aryl hydrocarbon hydroxylase system (i.e. the po lycyc lic  
hydrocarbon metabolising system) in the placenta appears to have a na tura lly  
high basal a c tiv ity  compared to other types o f MFO reactions (140) and is 
highly inducible, especially by benzo(a)pyrene or c igare tte  smoking 
(138,139,141,142). However, the detoxication o f benzo(a)pyrene m etabolites 
by phase II glutathione conjugation does not appear to be s im ila rly  induced 
(143).
4.2. Drug metabolism by the fetus:
The fe ta l live r o f prim ates possess a well-developed complement of 
xenobiotic metabolising enzymes (a lbe it less active than the adult), in 
contrast to the fetuses o f many laboratory animals (ra t, mouse, guinea pig, 
rabbit and hamster) which are de fic ien t in the microsomal cytochrome P450 
system. The la tte r  appears to be due to the la te development o f the smooth 
endoplasmic reticu lum  (144) and hence the associated development o f 
cytochrome P-450 (145,146).
a) Tissue sub-fractions:
Studies on the stum pta il monkey (147) and marmoset (148) have shown 
tha t the ir xenobiotic m etabolizing capacity at m id-gestation resembles 
closely the human fe ta l capacity (147). Human fe ta l microsomes as early as 
the 13th week o f gestation have the capability  o f m etabolizing the teratogens 
aldrin, benzo(a)pyrene, diphenylhydantoin and diazepam (134,145,149,150).
Classical metabolism studies using model substrate have shown that the 
live r o f laboratory animals, w ith  few exceptions, have a low capacity to 
oxidise xenobiotics un til a fte r b irth . The appearance o f oxidative enzymes in 
the live r are f irs t detectable close to b irth , and the adult levels are atta ined 
in a few days (as in the guinea pig) or a few weeks (as in the ra t) (151). There 
also appears to be a sex d ifference in tim e of a tta inm ent o f adult levels in 
the ra t; the female requires 30 days and the male 40 days (152). For a more 
comprehensive analysis of the above aspect o f developmental pharmacology 
than is possible here, the numerous reviews and artic les on the subject should 
be consulted (145-157).
b) Isolated cells and organs:
Human fe ta l hepatocytes do have phase I m etabolizing enzyme a c tiv ity  
a lbe it less than adult levels. For example, the cytochrome P-450 content o f 
fe ta l livers (gestational ages 9-15 weeks) was 50% tha t o f the adult 
(0.2-0.4 nmol/mg microsomal prote in compared to 0.4-0.8 nmol/mg 
microsomal prote in in the adult live r, 145). In fe ta l livers o f gestational age 
range 15-24 weeks, epoxide hydrolase a c tiv ity  was 25% of adult livers (158) 
and glutathione-S-transferase a c tiv ity  40% o f adult livers (158). Table 2 
shows the metabolism of some teratogens in the fetus re la tive  to the adult.
Recently using molecular biology techniques, the work o f Nebert et al. 
(161), has shown the presence o f mRNA for cytochrome P-450-^/P-448 as 
early as day 13 o f gestation in the mouse. Such evidence fo r the presence o f 
the enzyme at so early a stage in development contrasts sharply w ith  the lack 
o f m etabolic capability (except fo r benzo(a)pyrene epoxidation and 
hydroxylation (57,162)). It may be tha t the use o f model drug substrates is 
too insensitive to detect metabolism which may be confined to specific cells 
(e.g. those of the d iffe ren tia tin g  embryo).
In v itro  studies w ith cultured fe ta l ra t hepatocytes have shown that 
the ir ab ility  to metabolize certa in  xenobiotics only appeared a fte r day 18 o f 
gestation (163,164). Other studies w ith  cultured mouse embryos (during early 
development) have however indicated that the onset o f po lycyclic  arom atic 
hydrocarbon activation occurs very early coinciding w ith  blastocyte 
form ation (162), and that by day 12 o f gestation, benzo(a)pyrene 
hydroxylation is easily detectable (57). In vivo pre trea tm ent o f the mothers, 
or in v itro  exposure to inducers have shown tha t certa in  cytochrome P-450 
isoenzymes in fe ta l hepatocytes can be induced (6,161-166). Mouse limb bud 
organ cultures for example can activa te  the proteratogen cyclophosphamide
fo llow ing 3 days o f A roclor 1234 induction in utero (22), w ithout the need for 
an external activa ting  source. In utero or i_n v itro  exposure to e ither 
3-m ethylcholanthrene or 3-naphthoflavone can induce a form  o f cytochrome 
P-448 detected im m unocytochem ically, in limb bud cultures from rat
embryos (167). I t  appears that fe ta l/em bryo cytochrome P-450 is only 
inducible by certa in  inducers (6,7,21,164-168).
5. BIOACTIVATION OF TERATOGENS
5.1 Compounds that require b ioactiva tion:
a) Cyclophosphamide
The bioactivation o f cyclophosphamide (CPA) has been most extensively 
studied. In 1961, Foley et al. (169) demonstrated that CPA required hepatic 
activa tion  before (growth) inh ib ition  o f tumour cells could be observed, and i t  
is now w idely accepted that CPA-induced teratogenesis involves m etabolic 
ac tiva tion . The maternal live r is the site o f b ioactiva tion (170-172) via the
cytochrome P450 dependent monooxygenases (14,28,173-176). This has been
fu rthe r confirm ed - by in v itro  studies w ith  inducers and inhib itors o f 
cytochrome P450-mediated metabolism (Table 3).
In vivo studies: In the ra t, phenobarbitone pre trea tm ent o f the
pregnant female increased CPA te ra togen ic ity ; p re trea tm ent w ith  $- 
naphthoflavone however, had e ithe r no e ffe c t or decreased the te ra togen ic ity  
(171). In the mouse, phenobarbitone again increased te ra togen ic ity  and SKF 
525A decreased the response; in these animals, phenobarbitone decreased and 
SKF 5225A increased the frac tion  o f unchanged drug in m aternal plasma and 
the embryos (1,2), indicating that a CPA m etabolite  is the u ltim a te  
teratogen. In contrast, acute or chronic adm in istra tion o f A roc lo r 1254 (a 
polychlorinated biphenyl m ixture ) attenuated CPA em bryo tox ic ity  and 
te ra togen ic ity ; the kinetics and placental transfer o f to ta l rad io ac tiv ity  
fo llow ing ^ C -C P A  adm in istration was unaffected by A roc lo r 1254 
p re trea tm en t (177).
In v itro  studies: Incubation o f whole ra t embryos in v itro  w ith  CPA had 
no e ffe c t on em bryotoxic ity  or te ra togen ic ity  (178,179); a 5 hr exposure in 
the cu lture  medium w ith a metabolising system (S9 m ix) is however su ffic ie n t 
to e lic it  the teratogenic e ffe c t (180). The em bryotoxic and tera togenic
e ffe c t o f CPA was increased in ra t embryo culture w ith  liver S9 fraction  
from  phenobarbitone (7) or A roc lo r 1254 pretreated male rats (7,181); 
3-naphthoflavone or 3-m ethylcholanthrene pretreatm ent had no e ffe c t 
(7,181). In teresting ly, i t  was not possible to induce m alform ations in embryos
transplacentally pretreated w ith  phenobarbitone (or 3 methycholanthrene) 
and then exposed to CPA in v itro  (6,7), however 8-naphthoflavone could 
activa te  CPA in v itro  w ith  lim b bud cells from  d iffe ren tia tin g  ra t embryos 
(6).
The major reactive (teratogenic) m etabolites o f CPA are acrolein and 
phosphoramide mustard (Figure 1). Phosphoramide mustard is a potent 
a lky la ting  agent (172,182), and is presumed to be the u ltim a te  teratogen o f 
CPA (170,183). In v ivo , acrole in, has been reported to be em bryolethal but 
not teratogenic (170,184). However, embryonic abnormalities are observed in 
cultured whole ra t embryos exposed to acrolein in serum free medium (185), 
suggesting that its  extensive binding to prote in may play an im portant role in 
reducing the teratogenic e ffe c t in v ivo . Co-adm in istration o f CPA w ith  th io l 
compounds (cysteine, glutathione and S-m ethylg lu tath ione) in vivo to rats 
causes a decrease in CPA te ra togen ic ity , whereas co-adm in istra tion w ith  
d ie thyl maleate (DEM, a th io l depleting agent), causes an increase in 
teratogenic e ffec ts  (186). 4-Hydroperoxy CPA, which decomposes to 
phosphoramide mustard and acrole in (170,182,184), causes dysmorphogenesis 
in mouse limb-bud cultures (187) s im ila r to tha t observed w ith  CPA in v ivo .
b) 2-AcetyIam inofiourene
In v itro  studies: 2-acetylam inofluorene (2AAF) is tera togenic to whole 
ra t embryos in v itro  only in the presence o f a hepatic S9 m ix from  A roc lo r or 
3-m ethylcholanthrene pretreated male rat (188). N -hydroxy A A F , a 
m etabo lite  o f 2AAF, was found to be d ire c tly  teratogenic in v itro  (188) g iving
the prosencephalic defects observed w ith  2AAF following in v itro  activa tion. 
Embryos transplacentally exposed to 3-methylcholanthrene and subsequently 
trea ted during cu lture w ith  2AAF in the absence of S9 m ix showed increases 
in m alform ation incidence; transplacental exposure to phenobarbitone had no
e ffe c t (7). Oxidative m etabolites o f 2AAF were detected during incubation 
o f 2AAF w ith  homogenates o f day 10 embryos transplacentally exposed to
3-m ethylcholanthrene (7).
c) Benzhydryipiperazine derivatives
The benzhydryipiperazine antih istam in ic drugs, ch lo rcyc liz ine , 
cyc liz ine , bucyclizine, m ecliz ine, hydroxyzine and norcycliz ine are 
tera togenic in rats and m ice (189-191). Cytochrome P450 mediated N- 
dea lkylation o f ch lo rcycliz ine and m eclizine forms a common m etabolite , 
norch lo rcyc liz ine  (192), In the ra t, the incidence o f c le ft  palate induced by 
ch lo rcyc liz ine , but not norchlorocycliz ine, was reduced by SKF 525A 
adm in istra tion. This response was associated w ith  an increased fe ta l 
concentration o f chlorcycline (6-12 fold) and a decrease in norch lorcycliz ine, 
ind ica ting tha t norchlorcycliz ine is the u ltim a te  teratogen (3).
d) Benzo(a)pyrene
The Ah locus encodes fo r a cytosolic receptor which regulates the 
expression o f pa rticu la r isozymes o f cytochrome P-450 (161,193-197). This 
cytoso lic  receptor is highly inducible by po lycyclic  arom atic compounds in 
some mouse strains; Ah^ denotes the responsive and dominant a lle le  and Ah^ 
the non-responsive and recessive allele (161,193-197). The work o f Nebert et 
al. (161,193-197) illustrates that benzo(a)pyrene (BP) teratogenesis is due to a 
m etabo lite  and that several other factors govern the tera togenic 
suscep tib ility  to BP including the m aternal genotype, fe ta l genotype and 
route o f BP adm in istration.
When BP is adm inistrated in traperitoneally to pregnant female 
non-responsive m ice (e.g. C57BL strain Ah^/Ah^) that had been mated w ith  
responsive (A h^/A h13 DBA) male m ice, the embryos w ith  Ah^/Ah^ phenotype 
were more susceptible to in trau te rine  to x ic ity  than embryos o f the phenotype
A h^/Ah^ (196). This was due to induction of cytochrome P-450 isoenzymes
and aryl hydrocarbon hydroxylase a c tiv ity  in the embryo and presumably a
higher steady state o f tox ic  BP m etabolites. A ll o ff-sp ring  from  responsive 
b dAh /A h  mothers regardless o f the paternal genotype did not exh ib it genetic 
differences in em bryo -tox ic ity  because o f the higher amounts o f P-450 
isoenzymes in the m other and hence m etabolites available fo r placental 
transfer.
d dHowever, when BP was given ora lly  to Ah /Ah mothers mated to
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responsive males the homozygous (Ah /A h  ) o ff-sp ring  were more a ffec ted  
than the heterozygous o ff-sp ring . The explanation is the heterozygous
o ff-sp rin g  appear to de tox ify  BP more rapidly and presumably transfer
d dm etabolites in to the ammotic sac or back across the placenta while Ah /A h  
o ff-sp ring  have higher levels o f BP and m etabolites trapped w ith in  proxim al 
embryonic tissues (197). I f  BP is given ora lly  to pregnant A h^/A h^ responsive 
females then the result is a reduction in embryotoxic e ffec ts . G enetic 
d ifferences in susceptib ility  between the embryos are ob lite ra ted  due to high 
m aternal P-448 levels and hence high levels o f c ircu la ting  tox ic  m etabolites 
fo r placental transfer.
e) R ifam pin
Rifam pin, an an tib io itc , causes neural defects in the ra t (198), however, 
in v itro  i t  causes ra t embryo grow th re tardation but no increases in neural 
tube defects. The addition o f a live r microsomal preparation and co factors  
to embryos cultured in the presence o f rifam pin  resulted in an increased
neural tube defect which could be related to the abnormalities observed in 
fetuses exposed in utero (199). These results indicate that an unidentified 
m etabolite, probably produced by a cytochrome P450-mediated reaction, is 
the u ltim a te  teratogen.
f) Procarbazine
Procarbazine is teratogenic in rats (200) however i t  is not teratogenic 
to whole cultured ra t embryos in v itro  unless the serum from  pretreated 
animals or an S9 m ix is added to the cu lture  medium (18), again emphasising 
the importance o f metabolism in teratogen bioactivation.
5.2 Compounds tha t may or may not require b ioactivation:
a) Aldrin
In vivo studies: L ite ra tu re  reports indicate that both a ldrin and its  
m ajor m etabolite  d ie ldrin are tera togenic, but induce d iffe re n t types o f 
m alform ation (201-202). Studies on the teratogenic e ffects  o f a ldrin and its  
m ajor m etabolites at equimolar doses did not elucidate whether or not the 
parent compound was the more teratogenic e n tity  (203).
In v itro  studies: A ld rin  (33) and d ie ldrin  (39) inh ib it d iffe re n tia tio n  o f 
ra t embryo limb bud and CNS cells in the absence of a metabolising system.
b) D iethylstilbestrol
In vivo studies: D ie thy ls tilbes tro l (DES) is a transplacental carcinogen 
and teratogen. The e ffe c t o f this compound appears to be dependent on the 
amount o f unchanged drug reaching the fetus (204,205) although i t  has been 
recently reported that a m etabo lite  may be the active species (204-208).
c) Thalidomide
The main transform ation o f thalidomide in the body is generally 
considered to be spontaneous non-enzymic hydrolysis (112-113). However in 
tissues o f a varie ty o f experim ental animals, the turnover rates in plasma and 
muscle tissue are surprisingly constant, whereas the rates in the live r vary 
considerably. A t present, i t  has never been clearly defined i f  thalidomide 
does or does not require m etabolic activation to express its  te ra togen ic ity .
In v itro  studies: D iffe re n tia tio n  o f ra t lim b bud cells, cultured at low 
density was inhib ited by thalidom ide in the absence o f a metabolising system 
(33). Metabolism has been shown however to play a role in thalidom ide 
cy to to x ic ity . Gordon et al. (209) reported that only microsomes from  a 
thalidom ide sensitive species were capable o f producing tox ic  m etabolites 
(arene oxide?) in an in v itro  lymphocyte system. Braun et al measured 
adhesion o f mouse ovarian ascites tumour cells and showed tha t thalidom ide 
to x ic ity  requires activa tion  by hepatic microsomes, an NADPH-generating 
system and molecular oxygen (36,210).
d) Diphenylhydantoin
Diphenylhydantoin (DPH) is used in the trea tm ent o f epilepsy despite a 
syndrome o f drug related teratogenic e ffec ts  described in humans (91,92,211). 
A dichotomy exists between the be lie f that DPH its e lf (93,212-216) or a 
m etabolica lly  derived arene oxide in term ediate is the u ltim ate  teratogen. 
(217-226) (Figure 2).
I) Evidence tha t an arene oxide in term ediate o f DPH m etabolism  is
the u ltim ate  teratogen.
1. In common w ith  other arom atic hydroxylations (222,224) i t  
has been proposed that the hydroxylation of DPH to 4-(4-
hydroxyphenyl)-5-phenylhydantoin, observed in ra t and
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man, proceeds via an arene oxide interm ediate. In v itro  
studies have shown that an oxidative m etabolite of DPH (ie
NADPH/O2 dependent) irreversib ly binds to ra t liver 
microsomes; this binding could be increased by co­
incubation w ith  trichloropropene oxide, an epoxide 
hydratase inh ib ito r, and reduced by glutathione (220-222), 
suggestive o f form ation o f a reactive arene oxide. Sim ilar 
findings were reported using a human leucocyte system 
(223).
2. There is a corre la tion between the teratogenic e ffe c t and
amount o f covalently bound m ate ria l in fe ta l tissue o f the
14mouse fo llow ing adm in istration o f C-DPH.
Coadm inistration o f trichloropropene oxide and DPH to the 
mouse doubled the incidence o f c le ft  palate and the extent 
o f covalent binding (220). This experiment can not be 
regarded as conclusive evidence o f the role o f the reactive 
m etabolite , as the dihydrodiol m etabolite  was detected in 
maternal flu id  samples indicating in e ffec tive  inh ib ition  o f 
epoxide hydratase.
II) Evidence that DPH is teratogenic per se.
1. Studies on the teratogenic response induced by the m ajor 
m etabolites o f DPH at equimolar doses in mouse embryos 
in v itro  show tha t the maximum response of any o f the 
m etabolites was only 10% o f that caused by DPH its e lf 
(212). However this evidence cannot be regarded as 
conclusive as the dihydrodiol m etabo lite  (or the arene 
oxide in term ediate) have not been tested.
2. DPH is d irec tly  inh ib ito ry  in the rat micromass cell culture 
system (33).
3. DPH to x ic ity  in jn  v itro  micromass cell culture was 
increased by between 13-80% above contro l levels by co­
incubation w ith  a variety o f cytochrome P45Q inhib itors 
(6).
4. DPH te ra togen ic ity  was increased over 3-fo ld  in A /J  mice 
fed a purified  d iet compared to standard rodent chow. This 
d iffe rence is associated w ith  an increased concentration o f 
DPH in m aternal blood (227).
5. SKF 323A pre-trea tm ent increased DPH te ra togen ic ity  in 
the mouse. In this experiment, metaobolism o f DPH was 
inhib ited as indicated by a raised concentration o f DPH and 
a lowered concentration p-hydroxy DPH in m aternal 
plasma, but parent and m etabolite concentrations in 
(whole) fetuses were however unaffected. In contrast, 
phenobarbitone pre trea tm ent of the mother decreased DPH 
tera togen ic ity  and this was associated w ith  lowered 
concentration of DPH and raised concentration o f p- 
hydroxy DPH in the fetus (215).
O ther theories as to the u ltim ate  teratogenic species o f DPH include a 
D PH-prote in com plex/m odified serum prote in  (20,228) or the catechol 
m etabolite  (229,230).
e) Chloram bucil
Chloram bucil is a b ifunctional a lky la ting  agent (231) and is tera togenic 
when added d irec tly  to cultures o f whole rat embryos (232). The addition o f
an S9 m ix enhances the e ffects , although cytochrome P450 was shown not to 
be involved by selective inh ib ito r studies (232). It has been postulated tha t 
chlorambucil and/or its phenylacetic acid m etabolite are responsible fo r the 
teratogenic e ffec ts  (232).
f) Adriamycin
Adriam ycin is a glycosidic anthracycline an tib io tic  commonly used in 
the trea tm ent o f a varie ty o f tumours. The compound is teratogenic in the 
ra t (233) but not in the rabb it. Em bryotoxic ity  was observed when cultured 
ra t embryos were d irec tly  exposed to adriam ycin. This response was 
enhanced when cultures were incubated w ith  live r S9 frac tion  prepared from  
rats p re-treated w ith  3 methylcholanthrene or A roc lo r 1234; the addition o f 
S9 from  contro l or phenobarbitone treated rats had no e ffe c t (234). The data 
suggests adriamycin is m etabolica lly activated, although the fa ilu re  o f carbon 
monoxide to inh ib it the response w ith  an 59 frac tion  from  3- 
m ethylcholanthrene pretreated animals argues against the involvement o f a 
cytochrom e P448-dependent oxygenation, leading to activa tion.
5.3 Compounds not requiring b ioactiva tion:
D irec t acting teratogens include:
a) the metals which form  prote in  complexes tha t d ire c tly  
in te rfe re  w ith  ce ll p ro life ra tion  and organogenesis (235).
b) androgens, estrogens, glucocorticoids and synthetic  
steroids which bind to cytosolic receptors and are 
translocated as complexes into the nucleus where the 
complex binds to chrom atin and u ltim a te ly  disrupts p ro te in  
biosynthesis (53,58,65,204,236).
c) D-oxo-norleucine which is thought to act through binding 
to a prote in receptor (65).
vitam in A which is more teratogenic than any o f its 
m etabolites (35,237). When vitam in A was given at both 
teratogenic and non teratogenic doses, the amount o f 
retinol-b inding prote in transferred to mice fetuses was 
found to be d irec tly  proportional to the maternal dose o f 
vitam in A (238), strongly suggesting a role for receptors 
rather than b ioactiva tion.
Ethylenethiourea is teratogenic both ora lly  and 
subcutaneously in rats and hamsters (239-241). In both 
species, m etabolic modulation studies showed tha t 
phenobarbitone pre trea tm ent had no e ffe c t on the 
te ra togen ic ity  while SKF525A increased the incidence o f 
the m alform ations. The increased te ra togen ic ity  w ith  
SKF525A suggests the parent compound is the u ltim a te  
teragen.
Salicyclic acid and none of its putative m etabolites cause 
dysmorphogenesis in cultured ra t embryos (242,243). In the 
same series o f experiments, pre-incubation o f sa licyc lic  acid 
w ith  a varie ty  o f b iotransform ing systems fa iled to generate 
a more tox ic m etabolite .
Cytochalasin D is d irec tly  em bryotoxic in the ra t embryo 
cu lture  system but the e ffe c t is greatly reduced by 
incubation w ith  an Arochlor 1254 pretreated ra t liv e r 
enzyme preparation (39,244), presumably due to m etabolism  
(and hence inactiva tion ) o f the active parent compound.
Ethanol but not its princip le  m etabolite , acetaldehyde, 
causes fe ta l m alform ations iri vivo in the mouse (106). 
Further, co-adm in istra tion o f ethanol w ith  the alcohol
dehydrogenase inh ib itor, 4-methylpyrazole, causes an 
increase in m alform ations (106). M alformations in the 
cultured ra t embryo are found on d irect exposure to ethanol, 
confirm ing tha t the alcohol is very like ly  the u ltim a te
teratogen (245,246).
i) Acetazolam ide is probably a d irect acting teratogen as
e ither in tra -am n io tic  or in tra-u terine in jection o f the
compound give rise to the typical pattern o f limb
abnormalities observed fo llow ing oral adm inistration (247- 
248). However, this conclusion assumes tha t the developing 
em bryo/fetus lacks the activa tion enzymes.
j)  Caffe ine is a d irec t acting teratogen as pre trea tm ent w ith
8-naphthoflavone to cytochrome P450 -inducible and non­
inducible strains o f mice showed that increased drug 
metabolism was concom itant w ith  a decrease in caffe ine 
te ra togen ic ity  (249).
k) OTHER COMPOUNDS 
There remain a group o f compounds which are teratogenic because of 
the ir e ffec ts  on the mother or the extra-em bryonic tissues rather than the 
embryo its e lf. One example is M irex which causes a s ign ificant decrease in 
blood flow  to the uterus and placenta and this is related to its em bryo tox ic ity
(250). Trypan blue which does not cross into the embryo (251) inh ib its
visceral yolk sac lysosomal enzymes, e ffe c tive ly  starving the embryo o f 
essential nutrien ts (252).
The teratogenic a c tiv ity  o f several compounds can be accounted fo r by 
the m aternal to x ic ity  caused at doses where te ra togen ic ity  was observed 
(16,253,254). When these compounds (insulin, to lbutam ide, 6-am ino- 
n icotinam ide, morphine sulphate, dinoseb, zinc-1, 10-phenanthroline com plex,
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maytansine, v incris tine, nickdl chloride, indole-3-acetic acid, d i-(2- 
ethylhexyD-phthalate, phencyclidine, 2-nitro-p-phenylenediamine, ethylene 
glycol rnonomethyl ether and N -phtha loyl-L-g lu tam ic acid) were administered 
at non m aterna lly toxic doses, no te ra togen ic ity  was observed.
6. BIOACTIVATION OF TERATOGENS BY RAT EMBRYO CELLS IN
VITRO
6.1. Preparation o f micromass cultures:
The preparation and use o f rat limb cell cultures in te ra togen ic ity  
studies has been previously described in detail by F lin t and co-workers 
(6,32,33,38). Essentially, embryos o f 34-36 somites are collected from  
pregnant female rats approxim ately 13 days post conception. Forelimbs are 
dissected free and fo llow ing enzymatic dissociation, single cell suspensions 
are prepared in cu lture  medium (Ham's F12 plus 10% fe ta l ca lf serum). C e ll 
suspensions are adjusted to give 2 x 10^ lim b cells per m l. 10 or 20 pi Drops 
are delivered to cu lture  dishes and the cells in each drop are allowed to se ttle  
and adhere to the dish over 2 hrs at 37°C. The dish is then flooded w ith  
excess cu lture medium which may be supplemented w ith  the test substance or 
vehicle contro l. The adhering cells form  separate micromass islands o f 
6-8 mm diameter, and are continuously cultured fo r 3 days at 37°C, 5% CC^ 
in a ir. During the five days o f cu lture a proportion o f the cells in each 
micromass island d iffe re n tia te  to form small foci o f chondrocytes. A fte r  
fixa tion  these foci are p re fe ren tia lly  stained by alcian blue, becoming regions 
o f high contrast easily detectable w ith  an automated image analyser. Counts 
o f d iffe ren tia ted  foci are compared in test substance-exposed and con tro l 
cultures. A concentration dependent inh ib ition p ro file  is prepared and from  
this the concentration (IC^g) inh ib iting  d iffe ren tia tio n  by 30% of the con tro l 
values is estimated. Thus, the lower the IC ^q value, then the more potent is- 
the chemical.
This is a highly p red ictive  test. In a validation study 24 out o f 25 
(> 93%) teratogens tested d ire c tly  inhib ited d iffe re n tia tio n  (33), w ith  very 
few false positive or false negative results.
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6.2. Evidence for functional cytochrome P-45U's in rat embryo cells:
Inh ib ito r studies:
(i) Co-incubation w ith  a varie ty o f P-450 inhib itors (at concentrations that 
were non-cytotoxic) increased the to x ic ity  o f diphenylhydantoin (DPH) 
in v itro  by between 13-80% compared to control values. SKF525A 
was the least e ffe c tive  and e llip tic ine  and benzimidazole the most 
e ffe c tive  (6,38,235). No modulation o f the to x ic ity  o f the p-hydroxy 
m etabolite  iri v itro  was observed when co-incubated w ith  any o f the 
inh ib itors. C im etid ine increased DPH to x ic ity  by 47%, however a 
s truc tu ra lly  and pharm acologically s im ilar compound, ran itid ine , which 
is not a cytochrome P-450 inh ib ito r, had no e ffe c t on DPH to x ic ity  
when co-incubated in v itro .
These results imply tha t the increase in to x ic ity  appeared to be 
specifica lly  caused by inh ib ition  o f the cytochrome P-450 mediated 
metabolism of DPH.
S tru c tu re /A c tiv ity  Relationships:
( ii)  S truc tu re -ac tiv ity  relationships among triazo le  antifungals showed tha t 
to x ic ity  appears to be d ire c tly  re lated to both hydrophobicity and the 
type o f substituent in the phenyl rings. Substitution at the 4-position 
w ith  m etabolica lly stable and/or e lectron w ithdraw ing groups reduces 
triazo le  to x ic ity  in v itro  apparently by protecting the phenyl ring from  
m etabolic a ttack. Compared to the 2-position, the exposed 4-pos ition  
appears to be most vulnerable to m etabolic a ttack, unless pro tected by 
a suitable substituent (255). The data suggests that to x ic ity  in v itro  is 
mediated by the form ation o f a tox ic  in term ediate (a quinone or arene 
oxide) possibly via m etabolic a ttack on the 4-position on the phenyl 
ring.
Induction and f- unctional A c t iv ity  o f Embryonic Cytochrome P-450:
( iii)  Transplacental induction of embryo xenobiotic metabolising enzymes 
was achieved by dosing the dams in vivo and subsequently removing the 
embryos at day 13 o f gestation.
Cyclophosphamide (CPA) has no inh ib itory e ffe c t on limb cell 
d iffe ren tia tio n  (number o f d iffe ren tia ted  foci) unless a preparation o f 
A roc lo r 1254 induced, active ly metabolising adult ra t live r enzymes (S9 
plus NADPH) is present (33). Thus CPA is an excellent positive contro l 
fo r b ioactiva tion studies. Follow ing transplacental induction by 
B-naphthoflavone, d iffe ren tia tio n  was inhib ited by CPA suggesting the 
presence o f a functional and inducible cytochrome P-450 isoenzyme. 
Neither transplacental exposure to 3-m ethylcholanthrene nor 
phenobarbital induced s ign ifican t CPA teratogenesis (6,38,255).
Imm unocytochemical Iden tifica tion  o f Cytochrome P-450:
(iv ) Immunocytochemical staining o f cytochrome P-450 by the an ti- 
peroxidase technique described by W olf et al. (256) was used on the 
cultures a fte r 5 days incubation. Fresh cultures were stained against a 
varie ty o f cytochrome P-450 antibodies.
Our recent results showed a constitu tive  level o f cytochrome P-450 (a 
phenobarbitone-inducible form) and P-448 (a 3-m ethylcholanthrene- 
inducible form ) were detected in 5 day old cultures (6,38,167,255). 
However, trans-placental induction was only observed w ith  
8-naphthoflavone w ith  phenobarbitone having no e ffe c t. These 
observations are in close agreement w ith  the a b ility  o f the inducers to 
induce CPA metabolism.
The evidence presented here indicates strongly that ra t embryo ce lls  m 
v itro  not only have constitu tive  levels o f cytochrome P-450's but tha t 
some are inducible and ca ta ly tica lly  com petent. Most teratogens tha t
are well metabolised in vivo (33) were d irect acting in v itro . In the 
ligh t of evidence presented in this section we should now consider the 
possib ility  tha t the embryo cells themselves metabolise these 
teratogens, form ing tox ic reactive interm ediates. The cultures thus 
open up the possibility o f investigating the role o f embryo metabolism 
as opposed to the m aternal metabolism in teratogenesis.
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7. EPILOGUE
Like all new sciences, the study o f teratology has, un til recently, been 
largely phenomenological. The re la tive  importance of the role of maternal 
and embryonic metabolism has yet to be fu lly  established, but we have tried  
to illu s tra te  some of the pharmacokinetic and metabolic influences in the 
action o f teratogens which should, in the future, receive more attention. 
Problems o f metabolism in tera to logy are almost certa in ly  more easily 
approachable w ith  current techniques than the far more in tractable problems 
surrounding the actual mechanisms o f dysmorphogenesis. This la tte r  problem 
w ill have to aw ait a more comprehensive understanding o f the molecular 
basis o f developmental ce ll biology.
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TABLE 1: INTERSPECIES DIFFERENCES BETWEEN THE LOWEST
TERATOGENIC DOSE
The fo llow ing compounds have been given for between 3 and 6 days o f the most sensitive 
phase o f organogenesis for each species. The minimum teratogenic dose is the lowest 
m aternal dose at which te ra ta  are observed.
Compound Species
Route o f 
adm inistration
Minimum
teratogenic
dose
(mg/kg)
Reference
Chlorocholine Hamster Oral 300-400 (80)
chloride Rat Oral 500 (81)
C affe ine Human Oral 7 (82)
Rat Oral 300 (83)
Mouse Oral 50-75 (83)
Phenobarbital Rabbit Oral 450 (84)
Rat Oral 10 (85)
Mouse Oral 10 (86)
Dichlorophen- Hamster Oral 100 (87)
oxyacetic acid R at Oral 25,50-100 (88,89)
Mouse Oral 177-221 (90)
Diphenylhydantoin Human Oral ? (91-93)
Rat Oral 100 (94)
Mouse Oral 45 (95)
Diazepam Human Oral ? (96-98)
Rat Oral 200 (99)
Mouse Oral 100 (95)
Guinea pig Oral 280 (100)
Asp irin  Rat Oral 400 (101)
Mouse Oral 15 (102)
Cat Oral 25 (103)
Dog Oral 400 (104)
Rabbit Oral 250 (105)
L-Dopa Rat Oral 10 (106)
Mouse Oral 500 (107)
TABLE 1: (CONT'D)
Route o f M inimum
Compound Species adm inistration teratogenic
dose
(mg/kg)
Reference
2,5-D iam ino- Rat Sub-cutaneous (108)
toluene Mouse Sub-cutaneous 50 (109)
Thalidomide Human Oral ? (110,111)
aRat Oral 150 (111-115)
Mouse Oral 200 (115)
Hamster Oral 200 (116)
Rabbit Oral 25-200 (112,117)
Monkey Oral 10 (118)
(a) Thalidomide may produce a teratogenic e ffe c t i f  given a t a high dose by 
intravenous adm in istra tion (See References 114,119).
TABLE 2: TERATOGENS METABOLISED IN VITRO BY 
CULTURED FETAL HEPATOCYTES
T eratogen Species M etabolic
Reaction
% o f A du lt 
L ive r 
A c tiv ity
Reference
Benzo(a)pyrene rat'*’ hydroxylation 0.7 159
2human hydroxylation 2-4 134
A ld rin ra t^ epoxidation 30-40 134
Diphenylhydantoin 2human hydroxylation detectable 145
epoxidation detectable 145
Diazepam rat"* m etabolite
production
10% 160
1. - fetuses gestational age o f 17-20 days.
2. - fetuses gestational age o f 10-15 weeks.
3. - fetuses gestational age o f 21 days.
5U.
TABLE 3:
EFFECT OF MODULATING METABOLIC PATHWAYS 
INVOLVED IN TERATOGEN ACTIVATION
Teratogen Test System E ffe c t o f Modulators 
on the Teratogenic 
E ffe c t
Reference
Cyclophosphamide
(CPA)
In vivo, mouse PB increased and SKF 323 A 
reduced tera togenic ity
(1,2)
In vivo, ra t PB caused an increase and 
$NF had no e ffe c t
Thiol compounds reduced 
and th io l-depleting 
compounds increased 
tera togenic ity
(171)
(186)
In v itro , whole 
ra t embryo 
cultures
Co-incubation w ith  e ither 
PB or A roclor 1254 induced 
microsomes enhanced the 
teratogenic e ffe c t; $NF and 
3MC induced microsomes had 
no e ffe c t.
(7,
181)
In v itro , mouse 
lim b bud 
cultures.
A fte r  in utero pre trea tm ent 
o f the mothers w ith  A roc lo r 
1254 the limb buds could 
activa te  CPA, to a 
teratogenic m etabolite .
(22)
In v itro , ra t 
embryo m ic ro ­
mass
$NF in utero exposure 
perm itted  limb bud cells 
to activate CPA to a tox ic  
m etabolite . PB and 3MC 
had no e ffe c t.
(6)
2-Acety lam ino- 
fluorene (AAF)
In v itro , whole 
ra t embryos
3MC and A roclo r 1254 induced 
microsomes enhanced the 
teratogenic e ffe c t. In utero 
exposure to 3MC allowed AAF 
activa tion  by cultures; PB had 
no e ffe c t.
(7,
118)
C h lorcycliz ine In vivo, ra t SKF 525 A reduced the 
incidences of m a lfo rm ation
(3)
(Cont.)
TABLE 3: (CONPD)
Diphenylhydantoin
(DPH)
In vivo, mouse PB decreased and SKF 525 A 
increased tera togenic ity
Co-adm inistration w ith  a 
th io l-depleting agent 
(diethylmaleate) increased 
tera togenic ity.
(215)
(222)
Co-adm inistration w ith  1,2- 
expoxy- 3j3,3-trichloropropane 
(an epoxide hydratase 
inh ib itor) increased the 
e ffects.
(222)
In v itro , ra t 
embryo m icro- 
mass
Co-incubation w ith  a varie ty  
o f cytochrome P450 inh ib itors 
increased the to x ic ity .
(6)
Adriam ycin
In v itro , whole 
ra t embryo
Co-incubation w ith  e ither 
3MC or A roclor 1254 induced 
microsomes enhanced the 
e ffects ; PB induced or contro l 
microsomes had no e ffe c t.
(23 4)
Ethylenethiourea In vivo, ra t 
In vivo, hamster
PB had no e ffe c t, and SKF 525 A 
increased te ra togen ic ity . (239-241)
Ethanol In vivo, mouse Co-adm instration w ith  an 
alcohol dehydrogenase inh ib ito r 
(4-m ethylpyrazole) increased 
te ra togen ic ity .
(106)
C affe ine In vivo, mouse 8NF co-trea tm ent decreased 
the e ffects.
(249)
Abbreviations used are: PB
8NF
3MC
phenobarbitone
3-naphthoflavone
3-methylcholanthrene
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Role o f metabolism in the teratogenic b ioactiva tion 
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